WO2023146897A1 - 2-substituted thiazole hsd17b13 inhibitors and uses thereof - Google Patents
2-substituted thiazole hsd17b13 inhibitors and uses thereof Download PDFInfo
- Publication number
- WO2023146897A1 WO2023146897A1 PCT/US2023/011520 US2023011520W WO2023146897A1 WO 2023146897 A1 WO2023146897 A1 WO 2023146897A1 US 2023011520 W US2023011520 W US 2023011520W WO 2023146897 A1 WO2023146897 A1 WO 2023146897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- aryl
- heterocycloalkyl
- cycloalkyl
- cgalkylene
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 22
- -1 2-substituted thiazole Chemical class 0.000 title description 263
- 150000001875 compounds Chemical class 0.000 claims abstract description 400
- 101000806241 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 claims abstract description 80
- 102100037429 17-beta-hydroxysteroid dehydrogenase 13 Human genes 0.000 claims abstract description 79
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 50
- 208000019423 liver disease Diseases 0.000 claims abstract description 36
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 24
- 208000016097 disease of metabolism Diseases 0.000 claims abstract description 14
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 14
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims abstract description 8
- 206010072268 Drug-induced liver injury Diseases 0.000 claims abstract description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 260
- 125000003118 aryl group Chemical group 0.000 claims description 237
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 234
- 125000001072 heteroaryl group Chemical group 0.000 claims description 210
- 229910052736 halogen Inorganic materials 0.000 claims description 146
- 150000002367 halogens Chemical group 0.000 claims description 146
- 150000003839 salts Chemical class 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 107
- 229910052739 hydrogen Inorganic materials 0.000 claims description 99
- 239000001257 hydrogen Substances 0.000 claims description 99
- 239000012453 solvate Substances 0.000 claims description 99
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 78
- 201000010099 disease Diseases 0.000 claims description 74
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 73
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 64
- 125000002947 alkylene group Chemical group 0.000 claims description 64
- 125000004429 atom Chemical group 0.000 claims description 64
- 229910052805 deuterium Inorganic materials 0.000 claims description 64
- 150000002431 hydrogen Chemical group 0.000 claims description 57
- 125000003342 alkenyl group Chemical group 0.000 claims description 50
- 125000000304 alkynyl group Chemical group 0.000 claims description 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 102100022586 17-beta-hydroxysteroid dehydrogenase type 2 Human genes 0.000 claims description 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 6
- 101001045223 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 206010008635 Cholestasis Diseases 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 102100037425 17-beta-hydroxysteroid dehydrogenase 14 Human genes 0.000 claims description 4
- 101000806245 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 14 Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000007232 portal hypertension Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 35
- 238000011282 treatment Methods 0.000 abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 227
- 239000011541 reaction mixture Substances 0.000 description 167
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 137
- 239000007787 solid Substances 0.000 description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 127
- 239000000243 solution Substances 0.000 description 123
- 230000015572 biosynthetic process Effects 0.000 description 121
- 238000003786 synthesis reaction Methods 0.000 description 120
- 238000006243 chemical reaction Methods 0.000 description 100
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 99
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 95
- 235000019439 ethyl acetate Nutrition 0.000 description 76
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 70
- 239000012267 brine Substances 0.000 description 58
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 58
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 52
- 230000002829 reductive effect Effects 0.000 description 51
- 238000003818 flash chromatography Methods 0.000 description 50
- 229910052938 sodium sulfate Inorganic materials 0.000 description 50
- 235000011152 sodium sulphate Nutrition 0.000 description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 46
- 125000004432 carbon atom Chemical group C* 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 38
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 29
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 229960004132 diethyl ether Drugs 0.000 description 23
- 206010067125 Liver injury Diseases 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 22
- 239000012043 crude product Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 21
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- 231100000753 hepatic injury Toxicity 0.000 description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
- 125000004404 heteroalkyl group Chemical group 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 125000004043 oxo group Chemical group O=* 0.000 description 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 230000001587 cholestatic effect Effects 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000013058 crude material Substances 0.000 description 13
- AULKDLUOQCUNOK-UHFFFAOYSA-N 3,5-dichloro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(Cl)=C(O)C(Cl)=C1 AULKDLUOQCUNOK-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 12
- 208000025721 COVID-19 Diseases 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000004900 autophagic degradation Effects 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- 150000002825 nitriles Chemical class 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 208000018565 Hemochromatosis Diseases 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 9
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 9
- 125000005605 benzo group Chemical group 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 9
- NRCHLPNRCUKSAX-UHFFFAOYSA-N methyl 2-bromo-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=C(Br)SC=1NC(=O)OC(C)(C)C NRCHLPNRCUKSAX-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 108090000340 Transaminases Proteins 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 230000036210 malignancy Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WCEBOMLMQRLPPH-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]cyclobutan-1-amine Chemical compound NC1CCC1C1=CC=CC=C1C(F)(F)F WCEBOMLMQRLPPH-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011343 solid material Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 description 5
- SVQUGDTXNDKUMC-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]cyclobutan-1-one Chemical compound FC(F)(F)c1ccccc1C1CCC1=O SVQUGDTXNDKUMC-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- ZSKQIFWUTUZAGF-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC=C1C(F)(F)F ZSKQIFWUTUZAGF-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 210000003445 biliary tract Anatomy 0.000 description 5
- 208000003167 cholangitis Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 102000014898 transaminase activity proteins Human genes 0.000 description 5
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 description 4
- CFYMUCDDZDMONG-UHFFFAOYSA-N 2-amino-6-bromo-3-methylbenzoic acid Chemical compound CC1=CC=C(Br)C(C(O)=O)=C1N CFYMUCDDZDMONG-UHFFFAOYSA-N 0.000 description 4
- XSYZTYQXKIXPRC-UHFFFAOYSA-N 3,5-dichloro-4-methoxybenzoic acid Chemical compound COC1=C(Cl)C=C(C(O)=O)C=C1Cl XSYZTYQXKIXPRC-UHFFFAOYSA-N 0.000 description 4
- 201000011374 Alagille syndrome Diseases 0.000 description 4
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 201000005271 biliary atresia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- ZUZZOMNVTBAESU-UHFFFAOYSA-N methyl 5-amino-2-bromo-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=C(Br)SC=1N ZUZZOMNVTBAESU-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 4
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
- VZFVWAWYEGYHJI-UHFFFAOYSA-N 2-amino-6-bromo-3-fluorobenzoic acid Chemical compound NC1=C(F)C=CC(Br)=C1C(O)=O VZFVWAWYEGYHJI-UHFFFAOYSA-N 0.000 description 3
- XIDBELOIUFHQAW-UHFFFAOYSA-N 3,5-dichloro-4-hydroxybenzamide Chemical compound NC(=O)C1=CC(Cl)=C(O)C(Cl)=C1 XIDBELOIUFHQAW-UHFFFAOYSA-N 0.000 description 3
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- XEFAEKVTHRJTKM-KUHUBIRLSA-N CC(N([C@@H](CC1)[C@H]1C1=CC=CC=C1)C(C1=C(C=C2)NC(C(C=C3Cl)=NC(Cl)=C3O)=O)=O)=NC1=C2F Chemical compound CC(N([C@@H](CC1)[C@H]1C1=CC=CC=C1)C(C1=C(C=C2)NC(C(C=C3Cl)=NC(Cl)=C3O)=O)=O)=NC1=C2F XEFAEKVTHRJTKM-KUHUBIRLSA-N 0.000 description 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 3
- 206010008592 Cholangioadenoma Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KWMWWQHSLDSPCD-UHFFFAOYSA-N N-[2-[2-(trifluoromethyl)phenyl]cyclobutylidene]hydroxylamine Chemical compound ON=C1CCC1c1ccccc1C(F)(F)F KWMWWQHSLDSPCD-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000005345 deuteroalkyl group Chemical group 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- JYGRVMQGWVVHJE-UHFFFAOYSA-N ethyl 2-amino-2-cyanoacetate Chemical compound CCOC(=O)C(N)C#N JYGRVMQGWVVHJE-UHFFFAOYSA-N 0.000 description 3
- BWZGULCGNJTQMK-UHFFFAOYSA-N ethyl 2-benzamido-2-cyanoacetate Chemical compound CCOC(=O)C(C#N)NC(=O)C1=CC=CC=C1 BWZGULCGNJTQMK-UHFFFAOYSA-N 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000031169 hemorrhagic disease Diseases 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- UBOGPSNFKMAOPP-UHFFFAOYSA-N methyl 4-amino-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1N UBOGPSNFKMAOPP-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- IDQREVFITBUVSD-UHFFFAOYSA-N tert-butyl n-[[2-(trifluoromethyl)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1C(F)(F)F IDQREVFITBUVSD-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 229940123774 Hydroxysteroid 17-beta dehydrogenase 13 inhibitor Drugs 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 101150091094 lipA gene Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- RGPWKLUCJYFFHE-UHFFFAOYSA-N methyl 3-amino-1-phenylpyrazole-4-carboxylate Chemical compound N1=C(N)C(C(=O)OC)=CN1C1=CC=CC=C1 RGPWKLUCJYFFHE-UHFFFAOYSA-N 0.000 description 2
- UTGQTDLLIDYCAB-UHFFFAOYSA-N methyl 5-amino-1-methylpyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NN(C)C=1N UTGQTDLLIDYCAB-UHFFFAOYSA-N 0.000 description 2
- KGQFAPZUQKYADG-UHFFFAOYSA-N methyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NNC=1N KGQFAPZUQKYADG-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- SQSWYWCEKCVQEA-UHFFFAOYSA-N (2-fluoro-5-formylphenyl)boronic acid Chemical compound OB(O)C1=CC(C=O)=CC=C1F SQSWYWCEKCVQEA-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006748 (C2-C10) heterocycloalkenyl group Chemical group 0.000 description 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- KVUXYQHEESDGIJ-UHFFFAOYSA-N 10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2CC(O)CCC2(C)C2C1C1CC(O)CC1(C)CC2 KVUXYQHEESDGIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
- SOZGHDCEWOLLHV-UHFFFAOYSA-N 2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC=C1C#N SOZGHDCEWOLLHV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- 102000009878 3-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010020420 3-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZEMWKDVVCDPCKT-UHFFFAOYSA-N 3-benzyl-5-(4-fluoroanilino)-5-(trifluoromethyl)imidazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1NC1(C(F)(F)F)C(=O)N(CC=2C=CC=CC=2)C(=O)N1 ZEMWKDVVCDPCKT-UHFFFAOYSA-N 0.000 description 1
- ZAHUZZUGJRPGKW-UHFFFAOYSA-M 3-bromopropyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCBr)C1=CC=CC=C1 ZAHUZZUGJRPGKW-UHFFFAOYSA-M 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- USZABUOLFPZBEV-UHFFFAOYSA-N 5-amino-2-methyl-1,3-thiazole-4-carboxylic acid Chemical compound CC1=NC(C(O)=O)=C(N)S1 USZABUOLFPZBEV-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 206010067092 AIDS cholangiopathy Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FYXMMFFZMQMXCQ-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OC(F)(F)F FYXMMFFZMQMXCQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000013564 activation of immune response Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 1
- 229950010157 aleglitazar Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000004653 anthracenylene group Chemical group 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000841 delta opiate receptor agonist Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- LCFXLZAXGXOXAP-DAXSKMNVSA-N ethyl (2z)-2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N/O)\C#N LCFXLZAXGXOXAP-DAXSKMNVSA-N 0.000 description 1
- KDZLTNORBKZJKE-UHFFFAOYSA-N ethyl 5-bromo-1,3,4-thiadiazole-2-carboxylate Chemical compound CCOC(=O)C1=NN=C(Br)S1 KDZLTNORBKZJKE-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229950003707 farglitazar Drugs 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- ANWHCLPGJQUYRX-UHFFFAOYSA-N methyl 2-methyl-4-nitropyrazole-3-carboxylate Chemical compound COC(=O)C1=C([N+]([O-])=O)C=NN1C ANWHCLPGJQUYRX-UHFFFAOYSA-N 0.000 description 1
- BQKHGDZEUNUQCP-UHFFFAOYSA-N methyl 3-amino-1-methylpyrazole-4-carboxylate Chemical compound COC(=O)C1=CN(C)N=C1N BQKHGDZEUNUQCP-UHFFFAOYSA-N 0.000 description 1
- ARAFBUCGMOKZMI-UHFFFAOYSA-N methyl 4-nitro-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1NN=CC=1[N+]([O-])=O ARAFBUCGMOKZMI-UHFFFAOYSA-N 0.000 description 1
- OTNJGCAOEGZZMM-UHFFFAOYSA-N methyl 5-amino-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C=1N=CSC=1N OTNJGCAOEGZZMM-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- CFUHHJFKOONWBM-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-fluoro-n-methylsulfonylanilino)acetamide Chemical compound C=1C=C2OCCOC2=CC=1NC(=O)CN(S(=O)(=O)C)C1=CC=CC(F)=C1 CFUHHJFKOONWBM-UHFFFAOYSA-N 0.000 description 1
- YCWDKWLFWCWKDG-UHFFFAOYSA-N n-[5-[(2,3-dimethylphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2,2,2-trifluoroacetamide Chemical compound CC1=CC=CC(OCC=2SC(NC(=O)C(F)(F)F)=NN=2)=C1C YCWDKWLFWCWKDG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GKOKBYDWCYRBGB-UHFFFAOYSA-N n-methyl-1-[2-(trifluoromethyl)phenyl]methanamine Chemical compound CNCC1=CC=CC=C1C(F)(F)F GKOKBYDWCYRBGB-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical group N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
- 229960000989 perhexiline Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000005562 phenanthrylene group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 102220150679 rs200318261 Human genes 0.000 description 1
- 102220060482 rs786201985 Human genes 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940057739 vivitrol Drugs 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- Nonalcoholic fatty liver diseases including NASH (nonalcoholic steatohepatitis) are considered to be hepatic manifestations of the metabolic syndrome and are characterized by the accumulation of triglycerides in the liver of patients without a history of excessive alcohol consumption.
- NAFLD nonalcoholic steatohepatitis
- the majority of patients with NAFLD are obese or morbidly obese and have accompanying insulin resistance.
- the incidence of NAFLD/NASH has been rapidly increasing worldwide consistent with the increased prevalence of obesity, and it is currently the most common chronic liver disease.
- NAFLD is classified into simple steatosis, in which only hepatic steatosis is observed, and NASH, in which intralobular inflammation and ballooning degeneration of hepatocytes is observed along with hepatic steatosis.
- the proportion of patients with NAFLD who have NASH is still not clear but might range from 20-40%.
- NASH is a progressive disease and may lead to liver cirrhosis and hepatocellular carcinoma. Twenty percent of NASH patients are reported to develop cirrhosis, and 30- 40% of patients with NASH cirrhosis experience liver-related death. Recently, NASH has become the third most common indication for liver transplantation in the United States.
- the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise.
- pharmacological therapy is indispensable because obese patients with NAFLD often have difficulty maintaining improved lifestyles.
- HSD17Bs 17[3-Hydroxysteroid dehydrogenases (HSD17Bs) comprise a large family of 15 members some of which involved in sex hormone metabolism. Some HSD17Bs enzymes also play key roles in cholesterol and fatty acid metabolism.
- HSD17B13 hydroxysteroid 17[3-dehydrogenase 13 (HSD17B13), an enzyme with unknown biological function, is a novel liver-specific lipid droplet (LD)- associated protein in mouse and humans.
- HSD17B13 expression is markedly upregulated in patients and mice with non-alcoholic fatty liver disease (NAFLD). Hepatic overexpression of HSD17B13 promotes lipid accumulation in the liver.
- HSD17B13 could also have potential as a biomarker of chronic liver disease, such as alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) (for example: steatosis, nonalcoholic steatohepatitis (NASH), NASH-fibrosis, or cirrhosis), steatohepatitis, and liver cancer.
- ALD alcoholic liver disease
- NAFLD non-alcoholic fatty liver disease
- NASH-fibrosis for example: steatosis, nonalcoholic steatohepatitis (NASH), NASH-fibrosis, or cirrhosis
- steatohepatitis and liver cancer.
- kits for reducing expression or activity of HSD17B13 in a subject in need thereof are provided herein. Also, provided herein are methods, compounds, and compositions comprising HSD17B13 specific inhibitors, which can be useful in reducing the morbidity of HSD17B 13 -related diseases or conditions in a subject in need thereof. Such methods, compounds, and compositions can be useful, for example, to treat, prevent, delay, or ameliorate liver disease, metabolic disease, or cardiovascular disease.
- Ring A is thiazolyl
- R 1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl
- R 2 is hydrogen or Ci-Cgalkyl
- X is N or CR X ;
- R x is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- R 5 is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R 6 is independently a halogen; each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkyny
- the compound is of Formula (la):
- the compound is of Formula (lb):
- composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
- Also disclosed herein is a method of treating a disease in a subject in need thereof, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a pharmaceutical composition disclosed herein.
- the disease is a liver disease, a metabolic disease, or a cardiovascular disease.
- the disease is NAFLD.
- the disease is NASH.
- the disease is drug induced liver injury (DILI).
- the disease is associated with HSD 17B 13.
- the diseases is alcoholic liver disease.
- the disease is cirrhosis.
- the disease is decompensated portal hypertension.
- the disease is cholestatic liver disease.
- Also disclosed herein is a method for selectively inhibiting HSD17B13, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound selectively inhibit HSD17B13 over HSD17B2, HSD17B14, or any combination thereof.
- Carboxyl refers to -COOH.
- Alkyl refers to a straight-chain, or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2 -methyl- 1 -propyl, 2 -methyl -2 -propyl, 2- methyl-1 -butyl, 3 -methyl- 1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-methyl- 1 -pentyl, 4-methyl-l -pentyl, 2 -methyl -2 -pentyl, 3-methyl-2-pentyl, 4-methyl -2 -pentyl, 2,2-dimethyl-l- butyl, 3,3 -dimethyl- 1 -butyl, 2-ethyl-l -but
- a numerical range such as “Ci-Ce alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
- the alkyl is a Ci-Cio alkyl. In some embodiments, the alkyl is a Ci-
- the alkyl is a C1-C5 alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a C1-C3 alkyl. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
- Alkenyl refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms.
- C2-C6 alkenyl means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
- an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, - OMe, -NH2, or -NO2. In some embodiments, the alkenyl is optionally substituted with halogen, -CN, - OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.
- Alkynyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like.
- a numerical range such as “C2-C6 alkynyl”, means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated.
- an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen. [0021] “Alkylene” refers to a straight or branched divalent hydrocarbon chain.
- an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkylene is optionally
- the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
- Alkoxy refers to a radical of the formula -Oalkyl where alkyl is defined as above. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.
- Aryl refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring.
- the aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems.
- the aryl is a 6- to 10-membered aryl.
- the aryl is a 6-membered aryl (phenyl).
- Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
- an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, - CF3, -OH, -OMe, -NH2, or -NO2.
- the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
- Cycloalkyl refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated.
- Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3-C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl).
- the cycloalkyl is a 3 - to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6- membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl.
- Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Polycyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- ⁇ cycloalkyls include, for example, adamantyl, norbomyl, decalinyl, bicyclo [3.3.0] octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo [3.3.2] decane, and 7,7-dimethyl- bicyclo[2.2.1]heptanyl.
- Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
- a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, - COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe.
- the cycloalkyl is optionally substituted with halogen.
- Halo or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
- Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, 3 -bromo-2 -fluoropropyl, 1,2-dibromoethyl, and the like.
- Hydroxyalkyl refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.
- Aminoalkyl refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
- Deuteroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuteriums. Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3.
- Heteroalkyl refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
- a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
- a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or two atoms selected from the group consisting of oxygen, nitrogen, and sulfur wherein
- heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
- heteroalkyl are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, - CH(CH 3 )OCH 3 , -CH2NHCH3, -CH 2 N(CH 3 )2, -CH2CH2NHCH3, or -CHjCHjNCOE .
- a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2.
- a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
- Heterocycloalkyl refers to a 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens.
- the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen.
- the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
- heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl or C2-C15 heterocycloalkenyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl or C2-C10 heterocycloalkenyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl or C2-C8 heterocycloalkenyl), from two to seven carbon atoms (C2-C7 heterocycloalkyl or C2-C7 heterocycloalkenyl), from two to six carbon atoms (C2-C6 heterocycloalkyl or C2-C6 heterocycloalkenyl), from two to five carbon atoms (C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl), or two to four carbon atoms (C2-C4 heterocycloalkyl or C2-C4 heterocycloalkenyl).
- the heterocycloalkyl is a 3- to 8-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. In some embodiments, the heterocycloalkyl is a 3 - to 6- membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. In some embodiments, the heterocycloalkyl is a 5 - to 6-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur.
- heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
- heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl.
- the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8- membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl.
- the heterocycloalkyl is a 3 - to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl.
- a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -C00H, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.
- Heteroaryl refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur, and at least one aromatic ring.
- the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen.
- the heteroaryl comprises one to three nitrogens.
- the heteroaryl comprises one or two nitrogens.
- the heteroaryl comprises one nitrogen.
- the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
- the heteroaryl is a 5- to 10-membered heteroaryl.
- the heteroaryl is a 5 - to 6-membered heteroaryl.
- the heteroaryl is a
- the heteroaryl is a 5-membered heteroaryl. In some embodiments, the heteroaryl is a 5 - to 6-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur.
- Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
- a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or - OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
- an optionally substituted group may be un-substituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), mono-substituted (e.g., -CH2CH2F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH2CHF2, - CH2CF3, -CF2CH3, -CFHCHF2, etc.).
- any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.
- the term “one or more” when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject
- ⁇ group is optionally substituted with one substituent.
- the subject group is optionally substituted with two substituents.
- an “effective amount” or “therapeutically effective amount” refers to an amount of a compound administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
- treatment includes administration of a pharmaceutical composition, subsequent to the initiation of a pathologic event or contact with an etiologic agent and includes stabilization of the condition (e.g., condition does not worsen) or alleviation of the condition.
- treatment also includes prophylactic treatment (e.g., administration of a composition described herein when an individual is suspected to be suffering from a liver disease, e.g., NAFLD).
- “Synergy” or “synergize” refers to an effect of a combination that is greater than additive of the effects of each component alone at the same doses.
- HSD17B13 means hydroxysteroid 17-beta dehydrogenase 13 and refers to any nucleic acid of HSD17B13.
- HSD17B13 includes a DNA sequence encoding HSD17B13, an RNA sequence transcribed from DNA encoding HSD17B13 (including genomic DNA comprising introns and exons).
- HSD17B13 can also refer to any amino acid sequence ofHSD17B13 (may include secondary or tertiary structures of the protein molecule), encoded by a DNA sequence and/or RNA sequence. The target may be referred to in either upper or lower case.
- Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof useful in the treatment of liver diseases.
- the liver disease is NAFLD.
- the compounds disclosed herein are selective HSD17B13 inhibitors.
- Disclosed herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- Ring A is thiazolyl
- R 1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl
- R 2 is hydrogen or Ci-Cgalkyl
- X is N or CR X ;
- R x is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- R 5 is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R 6 is independently a halogen;
- each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyal
- Ring A is thiazolyl
- R 1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl
- R 2 is hydrogen or Ci-Cgalkyl
- X is N or CR X ;
- R x is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- R 5 is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R 6 is independently a halogen; each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl,
- each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgal
- the compound is of Formula (la):
- the compound is of Formula (lb): Formula (lb).
- R 1 is hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 1 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 1 is hydrogen.
- R 2 is Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 2 is hydrogen.
- R 3 is Ci-Cioalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 3a .
- R 3 is C-rCioalkyl, Ci-Ciohaloalkyl, Ci-Cwdeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 3a .
- R 3 is Ci-Cioalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 3a .
- R 3 is C4-Cioalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 3a .
- R 3 is Ci-Cioalkyl or Ci-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R 3a .
- R 3 is C4-Cioalkyl or C2-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R 3a .
- R 3 is Ci-Cioalkyl optionally and independently substituted with one or more R 3a . In some embodiments of a compound of Formula (I), (la), or (lb), R 3 is C4-Cioalkyl optionally and independently substituted with one or more R 3a . In some embodiments of a compound of Formula (I), (la), or (lb), R 3 is C4-Cioalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 3 is Ci-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R 3a .
- R 3 is C2-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R 3a .
- R 3 is C2-Cgalkylene(aryl); wherein the aryl is optionally and independently substituted with one or more R 3a .
- each R 3a is independently deuterium, halogen, -OH, -OR a , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; or two R 3a on the same atom are taken together to form an oxo.
- each R 3a is independently halogen, -OR a , or Ci-Cghaloalkyl.
- each R 3a is independently Ci-Cghaloalkyl.
- X is N. In some embodiments of a compound of Formula (I), (la), or (lb), X is CR X .
- R x is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R x is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R x is hydrogen.
- R 5 is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 5 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R 5 is hydrogen.
- each R 6 is chloro. In some embodiments of a compound of Formula (I), (la), or (lb), each R 6 is fluoro. In some embodiments of a compound of Formula (I), (la), or (lb), one R 6 is fluoro and the other R 6 is chloro. embodiments of a compound of Formula (I), (la), or (lb), embodiments of a compound of Formula (I), (la), or (lb),
- R 4 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl),
- R 4 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R 4a .
- R 4 is cycloalkyl optionally substituted with one or more with one or more R 4a .
- R 4 is heterocycloalkyl optionally substituted with one or more with one or more R 4a .
- R 4 is aryl or heteroaryl; wherein the aryl and heteroaryl is optionally substituted with one or more with one or more R 4a .
- R 4 is aryl optionally substituted with one or more with one or more R 4a .
- R 4 is heteroaryl optionally substituted with one or more with one or more R 4a .
- each R 4a is independently halogen.
- two R 4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R.
- two R 4a on the same carbon are taken together to form a cycloalkyl optionally substituted with one or more R.
- two R 4a on the same carbon are taken together to form a heterocycloalkyl; each optionally substituted with one or more R.
- two R 4a on the different atoms are taken together to form a cycloalkyl optionally substituted with one or more R.
- two R 4a on the different atoms are taken together to form a heterocycloalkyl optionally substituted with one or more R.
- two R 4a on the different atoms are taken together to form a aryl optionally substituted with one or more R.
- two R 4a on the different atoms are taken together to form a heteroaryl optionally substituted with one or more R.
- R 1 is halogen
- R 2 is halogen
- X is N or CR X ;
- R x is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- Y is N or CR Y ;
- R Y is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- R 3 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- Ring A is a pyrazole; each R 4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; n is 0-2;
- R 5 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- the compound is of Formula (Ila), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- R 4a is hydrogen or R 4 ;
- R 4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- the compound is of Formula (lib), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- R 4a is hydrogen or R 4 ;
- R 4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- the compound is of Formula (lie), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- R 4a is hydrogen or R 4 ;
- R 4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- the compound is of Formula (lid), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- R 4a is hydrogen or R 4 ;
- R 4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- R 4a is hydrogen, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Ila)-(IId), R 4a is hydrogen.
- R 1 is fluoro or chloro. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R 1 is chloro.
- R 2 is fluoro or chloro. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R 2 is chloro.
- X is CR X . In some embodiments of a compound of Formula (II) or (Ila)-(IId), X is N.
- R x is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R x is hydrogen or halogen. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R x is hydrogen. [0085] In some embodiments of a compound of Formula (II) or (Ila)-(IId), Y is CR Y . In some embodiments of a compound of Formula (II) or (Ila)-(IId), Y is N.
- R Y is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R Y is hydrogen or halogen. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R Y is hydrogen. [0087] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R 3 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R 3 is hydrogen.
- each R 4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- each R 4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- each R 4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- each R 4 is independently Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl; wherein each alkyl, cycloalkyl, and aryl is optionally and independently substituted with one or more R.
- each R 4 is independently Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl.
- each R 4 is independently Ci-Cgalkyl or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R 4 is independently aryl.
- n is 0 or 1. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 0. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 1. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 2.
- R 4b is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- R 4b is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- R 4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- R 4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl; wherein each alkyl, cycloalkyl, and aryl is optionally and independently substituted with one or more R.
- R 4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl. In some embodiments of a compound of Formula (Ila)-(IId), R 4b is Ci-Cgalkyl or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (Ila)-(IId), R 4b is aryl.
- R 5 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R 5 is hydrogen.
- R 6 is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R 6a .
- R 6 is Ci-Cgalkyl optionally substituted with
- R 6 is Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R 6a .
- R 6 is Ci-Cgalkylene(aryl) or Ci-Cgalkylene(heteroaryl); wherein the alkylene, aryl, and heteroaryl is optionally substituted with one or more R 6a .
- R 6 is Ci-Cgalkylene(aryl); wherein the alkylene and aryl is optionally substituted with one or more R 6a .
- each R 6a is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; wherein each alkyl is optionally and independently substituted with one or more R 6b .
- each R 6a is independently -OR a , Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R 6b is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R 6b is independently deuterium, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl.
- R 12 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R 13 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; p is 0-3;
- Ring B is aryl or heteroaryl. In some embodiments of a compound of Formula (II), Ring B is aryl. In some embodiments of a compound of Formula (II), Ring B is heteroaryl. In some embodiments of a compound of Formula (II), Ring B is 5- or 6-membered heteroaryl. In some embodiments of a compound of Formula (II), Ring B is phenyl or pyridyl. In some embodiments of a compound of Formula (II), Ring B is phenyl. In some embodiments of a compound of Formula (II), Ring B is pyridyl.
- each R 11 is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R 11 is independently halogen, -OH, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (II), each R 11 is independently halogen or -OH.
- m is 1-3. In some embodiments of a compound of Formula (III), m is 2 or 3. In some embodiments of a compound of Formula (III), m is 2. In some embodiments of a compound of Formula (III), m is 3.
- the compound is of Formula (Illa), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- R 15 is halogen
- R 16 is halogen
- W is N or CR W ;
- R w is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
- Z is N or CR Z ;
- R z is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or
- R 15 is fluoro or chloro. In some embodiments of a compound of Formula (Illa), R 15 is chloro.
- R 16 is fluoro or chloro. In some embodiments of a compound of Formula (Illa), R 16 is chloro.
- W is CR W . In some embodiments of a compound of Formula (Illa), W is N.
- R w is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Illa), R w is hydrogen or halogen. In some embodiments of a compound of Formula (Illa), R w is hydrogen.
- Z is CR Z . In some embodiments of a compound of Formula (Illa), Z is N.
- R z is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Illa), R z is hydrogen or halogen. In some embodiments of a compound of Formula (Illa), R z is hydrogen.
- R 12 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (III) or (Illa), R 12 is hydrogen.
- each R 13 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
- each R 13 is independently halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R 13 is independently halogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R 13 is independently halogen. In some embodiments of a compound of Formula (III) or (Illa), each R 13 is independently Ci-Cgalkyl.
- p is 0-2. In some embodiments of a compound of Formula (III) or (Illa), p is 0 or 1. In some embodiments of a compound of Formula (III) or (Illa), p is 0. In some embodiments of a compound of Formula (III) or (Illa), p is 1. In some embodiments of a compound of Formula (III) or (Illa), p is 2.
- R 14 is Ci-Cgalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 14a .
- R 14a is Ci-Cgalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 14a .
- R 14 is Ci-Cgalkyl optionally substituted with one or more R 14a .
- R 14 is Ci-Cgalkylene(aryl) or Ci-Cgalkylene(heteroaryl); wherein each alkylene, aryl, and heteroaryl is optionally and independently substituted with one or more R 14a .
- R 14 is Ci-Cgalkylene(aryl); wherein each alkylene and aryl is optionally and independently substituted with one or more R 14a .
- each R 14a is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; wherein each alkyl is optionally and independently substituted with one or more R 14b .
- each R 14a is independently - OR a , Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R 14a is independently Ci-Cghaloalkyl.
- each R 14b is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R 14b is independently deuterium, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl.
- each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R.
- each R a is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl.
- each R a is independently Ci-Cgalkyl or Ci-Cghaloalkyl.
- each R a is independently Ci-Cgalkyl.
- each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein
- each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl.
- each R b is independently hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen or Ci-Cgalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen. In some embodiments of a compound disclosed herein, each R b is independently Ci-Cgalkyl.
- each R c and R d are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl.
- each R c and R d are independently hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen or Ci-Cgalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen. In some embodiments of a compound disclosed herein, each R c and R d are independently Ci-Cgalkyl.
- R c and R d are taken together with the atom to which they are attached to form a 5 - or 6-membered heterocycloalkyl optionally substituted with one or more R. In some embodiments of a compound disclosed herein, R c and R d are taken together with the atom to which they are attached to form a 5 -membered heterocycloalkyl optionally substituted with one or more R. In some embodiments of a compound disclosed herein, R c and R d are taken together with
- each R is independently halogen, -CN, -OH, -OCi-C 3 alkyl, -OCi-C 3 haloalkyl, -NH 2 , -NHCi- C 3 alkyl, -N(Ci-C 3 alkyl) 2 , Ci-C 3 alkyl, Ci-C 3 haloalkyl, Ci-C 3 deuteroalkyl, Ci-C 3 hydroxyalkyl, Ci- C 3 aminoalkyl, Ci-C 3 heteroalkyl, or C 3 -Cgcycloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, -CN, -OH, -OCi- C 3 alkyl, -OCi-C 3 haloalkyl, -NH 2 , Ci-C 3 alkyl, Ci-C 3 haloalkyl, Ci-C 3 deuteroalkyl, or C 3 -Cgcycloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, Ci-C 3 alkyl, or Ci-C 3 haloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, Ci-C 3 alkyl, or Ci- C 3 haloalkyl. In some embodiments of a compound disclosed herein, each R is independently halogen or Ci-C 3 alkyl. In some embodiments of a compound disclosed herein, each R is independently halogen. [00121] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
- Described herein is a compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from a compound in Table la.
- Described herein is a compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from a compound in Table lb. TABLE lb.
- the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti,
- Z isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
- the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
- dissociable complexes are preferred.
- the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
- the compounds described herein exist in their isotopically -labeled forms.
- the methods disclosed herein include methods of treating diseases by administering such isotopically -labeled compounds.
- the methods disclosed herein include methods of treating diseases by administering such isotopically -labeled compounds as pharmaceutical compositions.
- the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes examples include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
- Compounds described herein, and the pharmaceutically acceptable salts, solvates, or stereoisomers thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
- Certain isotopically-labeled compounds for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays.
- Tritiated, i.e., 3 H and carbon-14, i.e., 14 C, isotopes are particularly preferred fortheir ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e., 2 H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
- the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
- the labeled compounds described herein are used for measuring in vitro and in vivo binding of unlabeled HSD17B13 inhibitors.
- the compounds described herein exist as their pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or a solvate, or stereoisomer thereof, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid or inorganic base, such salts including, acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-l,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne- 1,6-dio
- the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane sulfonic acid, ethane sulfonic acid,
- other acids such as oxalic, while not in themselves pharmaceutically acceptable, are employed in the preparation of salts useful as intermediates in obtaining the compounds disclosed herein, solvate, or stereoisomer thereof and their pharmaceutically acceptable acid addition salts.
- those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- a suitable base such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
- bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (CI-4 alkyl)4, and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It
- the compounds described herein also include the quatemization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quatemization.
- the compounds described herein exist as solvates.
- the invention provides for methods of treating diseases by administering such solvates.
- the invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
- the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
- HSD17B13 expression or activity which can be useful for treating, preventing, or ameliorating a disease associated with HSD17B13 in a subject in need thereof, such as NAFLD or NASH, by administration of a compound that targets HSD 17B 13, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the cell is a hepatocyte cell.
- the cell is in the liver.
- the cell is in the liver of a subject who has, or is at risk of having a disease, disorder, condition, symptom, or physiological marker associated with a liver disease, metabolic disease, or cardiovascular disease or disorder.
- the cells are the adipocytes or monocytes from a subject who has or is at risk of having a disease. In some embodiments, the cells are the lymphocytes from a subject who has or is at risk of having a disease. In some embodiments, the liver disease,
- ⁇ metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, nonalcoholic steatohepatitis (NASH), fulminant Wilson’s disease, rapidly fibrosing hepatitis C viral injury, and decompensated portal vein hypertension.
- the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH.
- the liver disease, metabolic disease, or cardiovascular disease or disorder is cholestatic liver disease.
- the liver disease is primary biliary cirrhosis or primary sclerosing cholangitis
- kits for treating, preventing, delaying the onset, slowing the progression, or ameliorating one or more diseases, disorders, conditions, symptoms, or physiological markers associated with HSD17B13 comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the subject in need thereof is identified as having, or at risk of having, the disease, disorder, condition, symptom, or physiological marker.
- the liver disease, metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).
- the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH.
- hepatic steatosis a subject in need thereof comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is provided for use in reducing, improving, or regulating hepatic steatosis in the individual.
- the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is provided for use in reducing, improving, or regulating liver fibrosis in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating triglyceride synthesis in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating lipid levels in the individual.
- the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is provided for use in reducing, improving, or regulating hepatic lipids in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating ALT levels in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating NAFLD
- the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is provided for use in reducing, improving, or regulating cholesterol levels in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating triglyceride levels in the individual. In some embodiments, the subject is identified as having, or at risk of having a disease, disorder, condition, symptom, or physiological marker associated with a liver disease, metabolic disease, or cardiovascular disease or disorder.
- the liver disease, metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).
- the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH.
- kits for treating, preventing, or delaying onset drug induced liver injury comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the liver injury is steatohepatitis.
- methods for treating, preventing, or delaying onset drug induced steatohepatitis (DISH) in a subject in need thereof.
- the subject in need thereof is receiving chemotherapy for treating cancer.
- the subject in need thereof is receiving a treatment for a cardiovascular disease.
- the subject in need thereof is receiving treatment for a psychiatric disease/condition. In some embodiments, the subject in need thereof is receiving treatment for pain. In some embodiments, the subject in need thereof is receiving treatment for arthritis.
- the chemotherapy is tamoxifen, toremifene, irinotecan, methotrexate, fluorouracil (5-FU), or any combination thereof.
- the subject in need thereof is receiving amiodarone, perhexiline, propranolol, or any combination thereof. In some embodiments, the subject in need thereof is receiving amitriptyline, clozapine, or any combination thereof. In some embodiments, the subject in need thereof is receiving methotrexate, pirprofen, or any combinations thereof.
- a method of treating a cholestatic disease in a subject in need thereof comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- HSD17B13 hydroxysteroid 17-beta dehydrogenase 13
- inhibiting HSD17B13 improves bile flow.
- inhibition of HSD17B13 is used to treat a cholestatic disease.
- Cholestatic diseases include primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in cystic fibrosis patients and progressive familial intrahepatic cholestasis (PFIC).
- PSC primary sclerosis cholangitis
- PBC primary biliary cholangitis
- Alagille Syndrome biliary atresia
- liver injury in cystic fibrosis patients and progressive familial intrahepatic cholestasis (PFIC).
- PFIC progressive familial intrahepatic cholestasis
- Inactive HSD17B13 has been associated with increases in liver and plasma phosphatidylcholine. Phosphatidylcholine is essential for bile flow. Hepatic phosphatidylcholine is secreted into the bile at a rate equivalent to the total liver levels of phosphatidylcholine being secreted within a day along with bile acids (BAs) and cholesterol. In some embodiments, inactive HSD17B13 is associated with increased plasma levels of VLDL-cholesterol. Meaning that there is a greater secretion of cholesterol out of the liver and not catabolized to bile acids for secretion in bile.
- inhibition of HSD17B13 improves bile flow through increased phosphatidylcholine.
- HSD17B13 is protecting the biliary tree by preventing inflammation.
- HSD17B13 is protecting the biliary tree by preventing the cytotoxic bile acids from injuring the biliary tree.
- the cholestatic disease is primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in a cystic fibrosis patient, progressive familial intrahepatic cholestasis (PFIC), intrahepatic cholestasis of pregnancy; drug-induced cholestasis, AIDS cholangiopathy, IG4-associated cholangitis, biliary stricture, or low phospholipid- associated cholestasis.
- PSC primary sclerosis cholangitis
- PBC primary biliary cholangitis
- Alagille Syndrome biliary atresia
- liver injury in a cystic fibrosis patient progressive familial intrahepatic cholestasis (PFIC), intrahepatic cholestasis of pregnancy
- drug-induced cholestasis AIDS cholangiopathy
- the cholestatic disease is primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in a cystic fibrosis patient, or progressive familial intrahepatic cholestasis (PFIC).
- PSC primary sclerosis cholangitis
- PBC primary biliary cholangitis
- Alagille Syndrome biliary atresia
- liver injury in a cystic fibrosis patient or progressive familial intrahepatic cholestasis (PFIC).
- PFIC progressive familial intrahepatic cholestasis
- the cholestatic disease is primary sclerosis cholangitis (PSC).
- the PSC is accompanied by inflammatory bowel disease (IBD). In some embodiments, the PSC is accompanied by elevated levels of lipopolysaccharide (LPS) (endotoxemia). In some embodiments, the elevated levels of LPS is in the blood. In some embodiments, the elevated levels of LPS is in the liver. In some embodiments, the elevated levels of LPS is in the biliary tree. In some embodiments, the cholestatic disease is primary biliary cholangitis (PBC). In some embodiments, the cholestatic disease is Alagille Syndrome. In some embodiments, the cholestatic disease is biliary atresia.
- IBD inflammatory bowel disease
- LPS lipopolysaccharide
- LPS lipopolysaccharide
- the elevated levels of LPS is in the blood. In some embodiments, the elevated levels of LPS is in the liver. In some embodiments, the elevated levels of LPS is in the biliary tree.
- the cholestatic disease is liver injury in a cystic fibrosis patient. In some embodiments, the cholestatic disease is progressive familial intrahepatic cholestasis (PFIC). In some embodiments, the PFIC is PFIC-3 type. In some embodiments, the PFIC-3 type is due to a mutation in ABCB4 which requires phosphatidylcholine for bile acid transport.
- PFIC progressive familial intrahepatic cholestasis
- the cholestatic disease is treated by improving bile flow in the subject in need thereof. In some embodiments, the cholestatic disease is treated by improving cholesterol secretion out of the liver in the subject in need thereof.
- inactive HSD17B13 is associated to lower cytokines and inflammatory gene expression. In some embodiments, there is an improvement in the hepatocyte response to LPS in hepatocytes with inactive HSD17B13. In some embodiments, inactive HSD17B13 is associated with improved autophagy in response to LPS (see FIG. 1A, FIG. IB, and FIG. 1C). In some embodiment,
- ⁇ increases in LC3B-11 combined with increases in p62 indicate accumulation of autophagosomes and defective autophagy.
- a method of treating liver injury due to protein accumulation in a subject in need thereof comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the protein that accumulates is alpha 1 -antitrypsin.
- Alpha 1 -antitrypsin is encoded by the gene SERPINA1.
- the normal allele is referred to as M
- SERPINA1 alleles that have been associated with liver disease have amino acid changes Glu264Val, referred to as S and Glu342Lys, referred to as Z.
- Individuals that are homozygotes for the Z (designated PiZZ) allele have pulmonary manifestations of their Al AT deficiency and can be treated by supplementation of the enzyme.
- individuals that are heterozygotes for the Z allele either with the M (designated PiMZ) or with the S allele (designated PiSZ) have liver disease manifestations.
- the protein resulting from translation of the Z and S alleles is a misfolded protein. This misfolded protein has been found to polymerize and lead to cellular injury due to accumulation of misfolded and polymerized protein. Protection against the injury due to accumulated misfolded protein has been observed by increasing autophagy.
- HSD17B13 plays a role in autophagy.
- autophagy is important for eliminating misfolded proteins and has been implicated in liver injury due to alpha 1 -antitrypsin deficiency.
- inhibition of HSD17B13 improves autophagy and thus improve clearance of misfolded proteins and thus, improve liver health.
- liver disease associated with alpha 1-antitrypsin deficiency include inflammation and decreases in platelets.
- inactive HSD17B13 is associated with lower inflammation, decreased inflammatory genes including NF-kB and TGF-J3 as well as increases in platelets.
- the protein accumulation is cleared via autophagy.
- the protein is a misfolded protein.
- the liver injury is due to alpha 1- antitrypsin deficiency.
- the alpha 1-antitrypsin deficiency results in a protein that does not get fully processed and accumulates as a mis-folded protein in the liver.
- the liver disease associated with alpha 1-antitrypsin deficiency include inflammation.
- the liver disease associated with alpha 1-antitrypsin deficiency include decreases in platelets.
- Disclosed herein is a method of treating a viral infection-induced liver injury in a subject in need thereof, the method comprising administering a therapeutically effective amount of a
- Also disclosed herein is a method of decreasing the severity of inflammation in a subject with a viral infection, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor to the subject.
- HSD17B13 hydroxysteroid 17-beta dehydrogenase 13
- Also disclosed herein is a method of decreasing the severity of acute immune response in a subject with a viral infection, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- inactive HSD17B13 is associated with lower levels of genes of activation of immune response including innate immune response, cytokines. Inflammation is a key component of viral-driven injury. In some embodiments, inactive HSD17B13 protects against rapidly progressing fibrosis in HCV patients.
- AAV-driven gene therapies are aided by autophagy for incorporating into liver cells so an HSD17B13 inhibitor that improves autophagy and decreases inflammation can both enhance efficacy and decrease side effects.
- the viral infection is hepatitis A. In some embodiments, the viral infection is hepatitis B. In some embodiments, the viral infection is hepatitis C.
- the viral infection is SARS-Cov-2.
- liver transaminases are a common feature in patients with severe SARS-Cov-2 infection. There is no apparent increased risk of COVID- 19 associated with liver disease, therefore, 2-11% of patients with COVID-19 have underlying liver comorbidities. In contrast, a much larger portion of patients (14-53%) have elevated liver transaminases. Patients suspected of having COVID-19 that test positive for the SARS-CoV-2 RNA had elevations in ALT, AST and decreases in albumin when compared to patients that tested negative for the viral RNA consistent with liver injury. In patients that died from COVID-19, 58% and 78% of patients had liver transaminase elevations.
- liver transaminase elevations have been especially notable in patients in intensive care units at 62% compared to 25% of patients not requiring ICU care.
- Patients with a CT-scan confirmed diagnosis of COVID-19 in the subclinical stage have a lower incidence of liver transaminase elevations when compared to patients diagnosed after the onset of symptoms.
- ⁇ cytokine storm would therefore be important to treating the patients with the most severe disease.
- Analysis of COVID- 19 patient’s blood has shown in general decreases in CD4 and CD8 cells but an increase in Thl7 cells.
- IL-6, IL-10, IL-2 and IFNy there was an increase in IL-6, IL-10, IL-2 and IFNy.
- liver injury is seen in COVID-19 patients who are experiencing a broader and more severe disease where multiple organs, beyond the lungs, have become involved.
- the liver then is exposed to the virus and as a critical mediator for inflammatory responses, could thus mediate either a resolving inflammatory process or mediate an accelerating inflammatory process that leads to increased cytokine release and further organ damage.
- the genetic evidence for the gene for the enzyme HSD17B13 association with liver transaminase levels and liver diseases has grown rapidly. At this writing, the genetic evidence includes many studies with genetic and disease information from more than 200,000 individuals.
- the lack of HSD 17B 13 activity has been shown to be protective against liver disease caused by over nutrition, excess and chronic alcohol intake, toxins such as copper and viruses such as HCV.
- the highly reproducible association of HSD17B13 with liver disease, liver transaminase elevations and liver injury in multiple forms has inspired efforts to develop inhibitors of this enzyme to protect against and reverse liver damage.
- the variety of toxicants and injuries against which HSD17B13 loss of function protects is such that it is proposed here to protect against liver injury in severe COVID-19.
- HSD17B13 activity has been shown to be involved in inflammation and inflammatory response. HSD17B13 loss of function has recently been associated with decreased gene expression and protein levels of immune response genes involved in adverse outcomes including IL-6, IL- 10 and IL-1J3. Enzymatically inactive polymorphs of HSD17B13 are associated with lower severity of histopathological endpoints of inflammation in addition to lower ALT levels in patients with nonalcoholic fatty liver disease.
- HSD17B13 inhibitors prevent and treat liver injury and decrease the severity of inflammation and acute immune response in patients with COVID-19.
- the viral infection is associated with a dysregulated liver inflammatory response.
- the administration results in lowering the levels of immune response activation genes.
- the administration results in decreased inflammation.
- the subject in need thereof has elevated levels of alanine aminotransferase (ALT).
- the subject in need thereof has elevated levels of aspartate aminotransferase (AST).
- the subject in need thereof has decreased levels of albumin.
- HCC hepatocellular carcinoma
- cholangioadenoma cholangiocarcinoma
- gallbladder adenocarcinoma a malignancy of bile duct
- Inactive HSD17B13 is associated with lower rates of HCC.
- HSD17B13 expression is low in tumor tissue but normal in the peritumoral space.
- High protein levels in the peritumoral space is associated with improved survival and tumor free survival.
- This apparent contradiction supports the use of small molecules to inhibit HSD17B13 but keep the protein available to support autophagic activity.
- Autophagy is important to maintaining a killer T cell response and use the body’s own immune system to fight the tumor. By inhibiting HSD17B13, the surrounding tissue will be capable of killer T cell response due to effective autophagy.
- HSD17B13 is highly expressed in normal gallbladder. Inactive HSD17B13 is associated with increased phospotidylcholine which is essential for sequestering cytotoxic bile acids for excretion and bile flow. For these reasons and the additional improved killer T cell response and decreased inflammation and fibrosis are the mechanism by which an inhibitor of HSD17B13 can be used to treat cholangioadenoma and gallbladder adenocarcinoma.
- the malignancy is hepatocellular carcinoma (HCC). In some embodiments, the malignancy is cholangioadenoma. In some embodiments, the malignancy is cholangiocarcinoma. In some embodiments, the malignancy is gallbladder adenocarcinoma. In some embodiments, the HSD17B13 receptor is expressed in the peritumoral space.
- HCC hepatocellular carcinoma
- the malignancy is cholangioadenoma.
- the malignancy is cholangiocarcinoma.
- the malignancy is gallbladder adenocarcinoma.
- the HSD17B13 receptor is expressed in the peritumoral space.
- a method of treating hemochromatosis in a subject in need thereof comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the hemochromatosis is primary hemochromatosis.
- the hemochromatosis is secondary hemochromatosis.
- the hemochromatosis is caused by a liver disease.
- the hemochromatosis is drug- induced hemochromatosis.
- Lysosomal acid lipase deficiency (LAL-D)
- lysosomal acid lipase deficiency (LAL-D) in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the lysosomal acid lipase deficiency (LAL-D) is caused by mutations in the LIPA gene.
- the lysosomal acid lipase deficiency (LAL-D) causes Wolman disease.
- the lysosomal acid lipase deficiency causes Cholesteryl ester storage disease. In some embodiments, the lysosomal acid lipase deficiency (LAL-D) is caused by mutations in the LIPA gene. In some embodiments, the
- LAL-D ⁇ lysosomal acid lipase deficiency
- a method of treating a bleeding disorder in a subject in need thereof comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the bleeding disorder is hemophilia A or hemophilia B.
- a method of treating a coagulation factor disorder in a subject in need thereof comprising administering a therapeutically effective amount of a hydroxysteroid 17- beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the coagulation factor disorder is Von Willebrand disease.
- the disease to be treated by inhibition of hydroxy steroid 17-beta dehydrogenase 13 (HSD17B13) is listed in the table below.
- Also disclosed herein is a method for selectively inhibiting HSD17B13, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the compound selectively inhibit HSD17B13 over HSD17B2, HSD17B14, or any combination thereof.
- inhibition of HSD17B2 is associated with disruption of normal endocrine function in multiple tissues.
- inhibition of HSD17B2 is associated with weight loss.
- inhibition of HSD17B2 is associated with muscle loss.
- inhibition of HSD17B14 is associated with disruption of normal endocrine function in multiple tissues.
- compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments.
- the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient’s health status, weight, and response to the drugs, and the judgment of the treating physician.
- Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation and/or dose ranging clinical trial.
- compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder, or condition. Such an amount is defined to be a “prophylactically effective amount or dose.”
- a patient susceptible to or otherwise at risk of a particular disease, disorder, or condition is defined to be a “prophylactically effective amount or dose.”
- the precise amounts also depend on the patient’s state of health, weight, and the like.
- effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient’s health status and response to the drugs, and the judgment of the treating physician.
- prophylactic treatments include administering to a mammal, who previously experienced at least one symptom of or risk factor for the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent a return of the symptoms of the disease or condition.
- prophylactic treatments include administering to a mammal having patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent liver damages.
- PNPLA3 patatin-like phospholipase domain-containing 3
- I148M variant predisposes towards the full spectrum of liver damage associated with fatty liver: from simple steatosis to steatohepatitis and progressive fibrosis.
- the I148M variant represents a major determinant of progression of alcohol related steatohepatitis to cirrhosis, and to influence fibrogenesis and related clinical outcomes in chronic hepatitis C virus hepatitis, and possibly chronic hepatitis B virus hepatitis, hereditary hemochromatosis and primary sclerosing cholangitis.
- PNPLA3 polymorphism is used to predict liver disease progression.
- a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage, or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent or daily treatment on a long-term basis upon any recurrence of symptoms.
- the amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, but nevertheless is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
- doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day. In one aspect, doses employed for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously or at appropriate intervals, for example as two, three, four or more sub-doses per day.
- the daily dosages appropriate for the compound described herein, or a pharmaceutically acceptable salt thereof are from about 0.01 to about 50 mg/kg per body weight. In some embodiments, the daily dosage, or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
- Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LDw and the ED ⁇ )(I .
- the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50.
- the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans.
- the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED 50 with minimal toxicity.
- the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
- any of the aforementioned aspects are further embodiments in which the effective amount of the compound described herein, or a pharmaceutically acceptable salt thereof, is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously
- any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once a day; or (ii) the compound is administered to the mammal multiple times over the span of one day.
- Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration.
- parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
- a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation.
- long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ specific antibody.
- the liposomes are targeted to and taken up selectively by the organ.
- the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation.
- the compound described herein is administered topically.
- the compounds described herein are administered to a subject in need thereof, either alone or in combination with pharmaceutically acceptable carriers, excipients, or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice.
- the compounds of this invention may be administered to animals.
- the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal, and topical routes of administration.
- compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and at least one pharmaceutically acceptable excipient.
- Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- a summary of pharmaceutical compositions described herein can be
- the pharmaceutically acceptable excipient is selected from carriers, binders, fdling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, and any combinations thereof.
- compositions described herein are administered to a subject by appropriate administration routes, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
- parenteral e.g., intravenous, subcutaneous, intramuscular
- intranasal e.g., buccal
- topical e.g., rectal, or transdermal administration routes.
- the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- compositions including compounds described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
- compositions for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.
- disintegrating agents are added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions that are administered orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- a plasticizer such as glycerol or sorbitol.
- ⁇ push-fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added.
- compositions for parental use are formulated as infusions or injections.
- the pharmaceutical composition suitable for injection or infusion includes sterile aqueous solutions, or dispersions, or sterile powders comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- the pharmaceutical composition comprises a liquid carrier.
- the liquid carrier is a solvent or liquid dispersion medium comprising, for example, water, saline, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and any combinations thereof.
- the pharmaceutical compositions further comprise a preservative to prevent growth of microorganisms.
- Disclosed herein are method of treating a liver disease, metabolic disease, or cardiovascular disease using a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an additional therapeutic agent.
- the additional therapeutic agent is used for the treatment of diabetes or diabetes related disorder or conditions.
- the additional therapeutic agent comprises a statin, an insulin sensitizing drug, an insulin secretagogue, an alpha-glucosidase inhibitor, a GLP agonist, a GIP agonist, a THR beta agonist, a PDE inhibitor, a DPP -4 inhibitor (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, gemigliptin, or dutogliptin), a catecholamine (such as epinephrine, norepinephrine, or dopamine), peroxisome proliferator-activated receptor (PPAR)-gamma agonist (e.g., a thiazolidinedione (TZD) [such as pioglitazone, rosiglitazone, rivoglitazone, or troglitazone], aleglit
- a statin such
- statin is a HMG-CoA reductase inhibitor.
- additional therapeutic agents include fish oil, fibrate, vitamins such as niacin, retinoic acid (e.g., 9 cis-retinoic acid), nicotinamide ribonucleoside or its analogs thereof, or combinations thereof.
- additional therapeutic agents include ACC inhibitors, FGF19 and FGF21 mimics, CCR2/CCR5 antagonists, or combinations thereof.
- the additional therapeutic agent is vivitrol.
- the additional therapeutic agent is a statin such as a HMG-CoA reductase inhibitor, fish oil, fibrate, niacin, or a combination thereof.
- the additional therapeutic agent is a dyslipidemia drug that prevent lipid absorption such as orlistat.
- the additional therapeutic agent is a vitamin such as retinoic acid or tocopheryl acetate for the treatment of diabetes and diabetes related disorder or condition such as lowering elevated body weight and/or lowering elevated blood glucose from food intake.
- the additional therapeutic agent is a glucose-lowering agent. In some embodiments, the additional therapeutic agent is an anti-obesity agent. In some embodiments, the additional therapeutic agent is selected from among a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon -like peptide- 1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a glucophage, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, and sulfonylurea.
- PPAR peroxisome proliferator activated receptor
- IV dipeptidyl peptidase
- GLP-I glucagon -like peptide- 1
- the additional therapeutic agent is metformin, sitagliptin, saxaglitpin, repaglinide, nateglinide, exenatide, liraglutide, insulin lispro, insulin aspart, insulin glargine, insulin detemir, insulin isophane, and glucagon -like peptide 1, or any combination thereof.
- the additional therapeutic agent is a lipid-lowering agent.
- the additional therapeutic agent is an antioxidant, corticosteroid such as budesonide, anti-tumor necrosis factor (TNF), or a combination thereof.
- corticosteroid such as budesonide, anti-tumor necrosis factor (TNF), or a combination thereof.
- the additional therapeutic agent is administered at the same time as the compound disclosed herein. In some embodiments, the additional therapeutic agent and the compound disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered prior than the administration of the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered after the administration of the compound disclosed herein.
- Step 2 Synthesis of 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl) carbamoyl)-lH- pyrazol-3-yl)picolinamide:
- Step 1 Synthesis of 3-amino-l-methyl-N-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide: [00210] To a stirred solution of methyl 3-amino-l-methyl-lH-pyrazole-4-carboxylate (0.4 g, 2.58 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (0.45 g, 2.58 mmol) in toluene (4 mL) was added 2 M trimethylaluminium in toluene (2.47 mL, 25.8 mmol) at 0 °C. The resulting reaction mixture was stirred at 100°C for 32 h.
- the resulting reaction mixture was stirred at 100 °C for 2 h.
- the reaction mixture was cooled to ambient temperature and quenched with ice-cold water (20 mL).
- the precipitated solid was fdtered and dried under reduced pressure to afford crude.
- the resulting crude product was purified by reverse phase prep-HPLC to afford 4,6-dichloro-5-hydroxy-N-[l-methyl-4-( ⁇ [2- (trifluoromethyl)phenyl]methyl ⁇ carbamoyl)-lH-pyrazol-3-yl]pyridine-2-carboxamide (0.073 g, 9 %) as a pale yellow solid.
- reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL), obtained solid was collected through fdtration, washed with diethyl ether (5 mL) and dried under reduced vacuum to afford crude as off white solid.
- Step 1 Synthesis of methyl l-methyl-4-nitro-lH-pyrazole-3-carboxylate
- Step 2 Synthesis of methyl 4-amino-l-methyl-lH-pyrazole-3-carboxylate
- Step 3 Synthesis of 4-amino-l-methyl-N-(2-(trifluoromethoxy)benzyl)-lH-pyrazole-3-carboxamide
- methyl 4-amino-l-methyl-lH-pyrazole-3-carboxylate (0.25 g, 1.61 mmol) and l-[2-(trifluoromethoxy)phenyl]methanamine (0.30 g, 1.61 mmol)
- Toluene 5 mL
- 2A7 trimethylaluminium in toluene (0.46 mL, 4.83 mmol
- Step 1 Synthesis of 3-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
- Step 2 Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
- Step 1 Synthesis of 5-amino-l-methyl-N-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide
- methyl 5-amino-l-methyl-lH-pyrazole-4-carboxylate 0.4 g, 2.58 mmol
- l-[2-(trifluoromethyl)phenyl]methanamine 0.358 mb, 2.58 mmol
- 2M trimethylaluminium in toluene 0.741 mb, 3 eq., 7.73 mmol
- Step 2 Synthesis of 5-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
- 3,5-dichloro-4-methoxybenzoic acid 0.0593 g, 0.268 mmol
- pyridine a stirred solution of 3,5-dichloro-4-methoxybenzoic acid (0.0593 g, 0.268 mmol) in pyridine (1 mL) was added phosphoroyl trichloride (0.025 mL, 0.268 mmol) at 0 °C and allowed to stirred at room temperature for 10 minutes.
- phosphoroyl trichloride 0.025 mL, 0.268 mmol
- Step 3 Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
- Example 8 Synthesis of 4,6-dichloro-5-hydroxy-2V-(l-phenyl-4-((2-(trifluoromethyl) benzyl (carbamoyl)-! //-pyrazol-3-yl)picolinamide
- Step 1 Synthesis of methyl 3-amino- l-phenyl- l//-pyrazole-4-carboxylate
- reaction mass was quenched with water (20mL) and extracted with ethyl acetate (20 mL), organic layer was collected and washed with water (20 mL), brine solution (20 mL), organic layer was dried over sodium sulphate and filtered and evaporated to get crude product which was purified by flash column chromatography to get pure methyl 3 -amino- 1 -phenyl- lH-pyrazole-4-carboxylate (0.3 g, 65%) as off-white solid.
- LCMS (ES) m/z calculated for Cl 1H11N3O2, 217; found, 218 (M+H) .
- Step 2 Synthesis of methyl 3-(4,6-dichloro-5-hydroxypicolinamido)-l-phenyl-LH-pyrazole-4- carboxylate
- Step 3 Synthesis of 4,6-dichloro-5-hydroxy-2V-(l-phenyl-4-((2-(trifluoromethyl) benzyl)carbamoyl)-LH-pyrazol-3-yl)picolinamide
- Step 1 Synthesis of 5-amino-l-methyl-JV-(2-(trifluoromethyl)benzyl)-LH-pyrazole-4-carboxamide
- Step 1 Synthesis of 5-amino-l-methyl-JV-(2-(trifluoromethyl)benzyl)-LH-pyrazole-4-carboxamide
- Step 2 Synthesis of 4,6-dichloro-5-hydroxy-JV-(l-methyl-4-((2-(trifluoromethyl)benzyl) carbamoyl)-LH-pyrazol-5-yl)picolinamide
- reaction mass was quenched with ice-cold water, extracted with ethyl acetate (5 mL x 2). The combined organic layer was washed with water (3 mL x 2), brine (4 mL x 2), dried over sodium sulfate to afford crude compound which was purified by Combi flash chromatography. Pure fractions were collected and concentrated to afford title compound which was further purified by reverse phase prep-HPLC.
- reaction mixture was stirred for 20 minutes and then adjust the pH to about 2 with concentrated hydrochloric acid, and continued stirring for another 20 min.
- the precipitated solid was filtered and washed with hexane (25 mL), dried to obtain 5-bromo-8-methyl-3-(2- (trifluoromethyl)benzyl)benzo[d][l,2,3] triazin-4(3H)-one (3.4 g, 61 %) as orange solid.
- Step 3 Synthesis of tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[ ⁇ /] [l,2,3]triazin-5-yl)carbamate
- Step 4 Synthesis of 5-amino-8-methyl-3-(2-(trifluoromethyl) benzyl) benzo[d] [1,2,3] triazin-4(3H)- one.
- Step 5 Synthesis of 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[ ⁇ /] [l,2,3]triazin-5-yl)benzamide
- Step 1 Synthesis of 2-amino-6-bromo-3-fluoro-JV-(2-(trifluoromethyl)benzyl) benzamide
- Step 2 Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) benzo[d] [1,2,3] triazin-4(3/7)- one
- Step 3 Preparation of tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4- dihydrobenzo[ ⁇ Z] [1,2,3] triazin-5-yl)carbamate
- Step 4 Synthesis of 5-amino-8-fluoro-3-(2-(trifluoromethyl) benzyl) benzo [ ⁇ /] [1,2,3] triazin-4(3/7)- one
- Step 5 Synthesis of 4,6-dichloro-5-hydroxy-JV-(8-methyl-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4- dihydrobenzo[ ⁇ /
- Step 1 Synthesis of 2-amino-6-bromo-3-fluoro-N-((lS,2R)-2-phenylcyclobutyl) benzamide
- Step 3 Synthesis of tert-butyl (8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4- dihydroquinazolin-5-yl)carbamate
- Step 4 Synthesis of 5-amino-8-fluoro-2-methyl-3-((lS,2R)-2-phenylcyclobutyl) quinazolin-4(3H)- one
- Step 5 Synthesis of 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4- dihydroquinazolin-5-yl)-5-hydroxypicolinamide
- Step 1 Preparation of l-(cyclopropylidenemethyl)-2-(trifluoromethyl) benzene
- Step 2 Synthesis of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one
- Step 4 Synthesis of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-amine
- Step 5 Synthesis of 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) benzamide
- Step 6 Synthesis of 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) quinazolin- 4(3H)-one
- Step 7 Preparation 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl) phenyl)cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
- Step 2 Synthesis of 5-bromo-l-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2, 4(1/7, 3/7)-dione
- 5-bromo-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4( lH,327)-dione 0.5 g, 1.25 mmol
- potassium carbonate 0.26 g, 1.88 mmol
- potassium iodide 0.05 g, 0.301 mmol
- bromoethane 0.13 g, 1.25 mmol
- Step 3 Synthesis of tert-butyl (l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate
- Step 4 Synthesis of 5-amino-l-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(l//,3//)-dione [00257]
- tert-butyl (l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate 0.6 g, 1.29 mmol
- dichloromethane 5 mL
- HC1 dioxane
- reaction mixture was diluted with ethyl acetate (10 mL) and washed with water (10 mL x 2), aqueous bicarbonate solution (10 mL) and the combined organic layer was concentrated to get residue which was purified by reverse phase prep-HPLC. Pure fractions were collected and concentrated to afford 4,6- dichloro-A-(l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l,2,3,4-tetrahydroquinazolin -5-yl)-5- hydroxypicolinamide (54 mg, 18 % yield) as white solid.
- Step 1 Synthesis of 5-bromo-8-fluoro-2/f-benzo[rZ
- Step 2 Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) quinazoline-2, 4(1/7, 3//)-dione
- 5-bromo-8-fluoro-2H-benzo[d][l,3] oxazine-2, 4( l//)-dionc 0.4 g, 1.54 mmol
- tetrahydrofuran 10 mL
- l-[2-(trifluoromethyl)phenyl]methanamine (0.21 mL, 1.54 mmol
- triethylamine (0.24 mL
- reaction mixture was heated at 80 °C for 2 h. After completion, reaction mixture was cooled to room temperature and quenched with water (50 mL) and extracted into ethyl acetate (3x50 mL). The combined organics were washed with water (10 mL) and brine solution (10 mL) dried over Na2SC>4, filtered, and concentrated under reduced vacuum to afford a brown oil. The oil was dissolved in Tetrahydrofuran (10 mL) cooled to 0°C, then Triphosgene (0.22 g, 0.76 mmol) was added. The reaction mixture was stirred at room temperature for 30 min then was added with triethylamine (0.24 mL).
- Step 3 Synthesis of 5-bromo-8-fluoro-l-methyl-3-(2-(trifluoromethyl) benzyl) quinazoline- 2, 4(1/7, 3/0-dione
- Step 4 Synthesis of tert-butyl (8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate
- reaction mixture was heated to 100 °C for 12 h.
- the reaction mixture was filtered through celite pad, washed with ethyl acetate (2 x 50 mL), the filtrate was evaporated under reduced pressure to afford crude tert-butyl (8 -fluoro- l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)- 1,2,3, 4-tetrahydroquinazolin-5-
- Step 5 Synthesis of 5-amino-8-fluoro-l-methyl-3-(2 (trifluoromethyl) benzyl) quinazoline- 2,4(1 //,3//)-dione
- Step 6 Synthesis of 4,6-dichloro-N-(8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl) benzyl)-
- Example 21 Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide
- Step 1 Synthesis of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide
- HATU 2.4 g, 6.32 mmol
- triethylamine 2.2 mL, 15.8 mmol
- (2- (trifluoromethoxy)phenyl)methanamine 0.6 g, 3.16 mmol
- Step 2 Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide:
- Step3 Synthesis of ethyl 5-amino-2-phenyl-l,3-thiazole-4-carboxylate
- Step 5 Synthesis of 5-amino-2-phenyl-N- ⁇ [2-(trifluoromethyl)phenyl]methyl ⁇ -l,3-thiazole-4- carboxamide
- Step 6 Synthesis of Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-phenyl-N-(2 (trifluoromethyl)benzyl)thiazole-4-carboxamide
- Step 1 Synthesis of l-(2-(trifluoromethyl)phenyl)cyclopropan-l-amine
- Step 2 Synthesis of 5-amino-N-(l-(2-(trifluoromethyl)phenyl)cyclopropyl)thiazole-4-carboxamide
- 5-amino-l,3-thiazole-4-carboxylic acid 0.2 g, 1.39 mmol
- l-[2- (trifluoromethyl)phenyl]cyclopropan-l-amine 279 mg, 1.39 mmol
- triethylamine 0.5 mL 4.16 mmol
- HATU 0.5 mL 4.16 mmol
- the reaction mixture was stirred at ambient temperature for 3 h.
- reaction mixture was diluted with Ethyl acetate (50 mL), washed with water (2x20 mL) and brine solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, fdtered, and evaporated to get crude product.
- Step 3 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-(l-(2-(trifluoromethyl) phenyl)cyclopropyl)thiazole-4-carboxamide
- reaction mixture was diluted with Ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (20 mL), water (20 mL) and brine solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to get crude product. Purification by prep HPLC afforded 4,6-dichloro-5-hydroxy-N-[4-( ⁇ l-[2-(trifluoromethyl) phenyl] cyclopropyl (carbamoyl) -1,3- thiazol-5-yl]pyridine-2-carboxamide (0.05 g, 31%) as white solid.
- Step 1 Synthesis of tert-butyl (2-(trifluoromethyl)benzyl)carbamate
- Step 3 Synthesis of 5-amino-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
- methyl 5-amino-l,3-thiazole-4-carboxylate (0.25 g, 1.58 mmol)
- methyl( ⁇ [2-(trifluoromethyl)phenyl]methyl ⁇ )amine hydrochloride (0.28 g, 1.9 mmol)
- triethylamine (0.22 mL, 1.58 mmol
- toluene 2 mL, 16.9 mmol
- the mixture was cooled to 0 °C and added trimethylalumane (0.455 mL, 4.74 mmol).
- Step 4 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- reaction mixture was cooled to ambient temperature and quenched into ice-cold water (10 mL) and resulting mixture was extracted into ethyl acetate (5 mL x 2). The combined organic layer was washed with brine (3 mL x 2), dried over sodium sulfate, and evaporated under reduced pressure to result in crude.
- the resulting crude product was purified by prep-HPLC to afford 5-(4,6-dichloro-5- hydroxypicolinamido)-JV-methyl-JV-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.048 g, 13 %) as white solid.
- Step 1 Synthesis of methyl 5-((/e/7-butoxycarbonyl)amino)-2-cyclopropylthiazole-4-carboxylate [00282] To a stirred solution of methyl 5-bromo-2-cyclopropylthiazole-4-carboxylate (0.5 g, 1.91 mmol) and tert-butyl carbamate (0.223 g, 1.91 mmol) in 1,4-dioxane (10 mL) was added cesium carbonate (1.24 g, 3.82 mmol) and degassed with nitrogen for 10 min, followed by Pd(dba)2 (0.054 g, 0.095 mmol), Xanthphos (0.11 g, 0.19 mmol) were added and stirred at 100°C for 16 h.
- Step 3 Synthesis of 5-amino-2-cyclopropyl-2V-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
- tert-butyl N-[2-cyclopropyl-4-( ⁇ [2- (trifluoromethyl)phenyl]methyl ⁇ carbamoyl)-l,3-thiazol-5-yl]carbamate (0.120 g, 0.272 mmol) in dichloromethane (2 mL) was cooled to 0°C and then added 4 M HC1 in 1,4 dioxane (2 mL). The resulting reaction mixture was stirred at ambient temperature for 2 h.
- Step 4 Synthesis of 2-cyclopropyl-5-(4,6-dichloro-5-hydroxypicolinamido)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- Step 1 Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate [00286] To a stirred solution of methyl 5-amino-2-bromothiazole-4-carboxylate (1 g, 4.22 mmol) in tetrahydrofuran (20 mL, 246 mmol) was added di-tert-butyldicarbonate (1.45 mL, 6.33 mmol), DIPEA (2.2 mL, 12.7 mmol) and DMAP (0.520 g, 4.22 mmol) at ambient temperature and then stirred at same temperature for another 2 h.
- Step 2 Preparation of methyl 5-((ter/-butoxycarbonyl) amino)-2-(2-fluorophenyl) thiazole-4- carboxylate
- Step 4 Preparation of 5-amino-2-(2-fluorophenyl)-2V-(2-(trifluoromethyl) benzyl) thiazole-4- carboxamide
- Step 5 Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-2V-(2- (trifluoromethyl) benzyl) thiazole-4-carboxamide
- Step-1 Step-2 p p
- Step 1 Synthesis of methyl 5-amino-2-bromothiazole-4-carboxylate
- Step 3 Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(l,l-dioxidothiomorpholino)thiazole- 4-carboxylate
- Step 4 Synthesis of tert-butyl (2-(l,l-dioxidothiomorpholino)-4-((2-(trifluoromethyl) benzyl)carbamoyl)thiazol-5-yl)carbamate
- Step 5 Synthesis of 5-amino-2-(l,l-dioxidothiomorpholino)-N-(2-(trifluoromethyl) benzyl)thiazole- 4-carboxamide
- Step 6 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l,l-dioxidothiomorpholino)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- reaction mixture was poured into ice-cold water (20 ml), precipitated solid was filtered and purified by flash column chromatography to afford brown color solid, which was further purified by Prep-HPLC to afford 5 -(4,6- dichloro-5-hydroxypicolinamido)-2-(l,l-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole- 4-carboxamide as a yellow solid (0.153 g, 17 %).
- Step 1 Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate [00299] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (1.65 g, 4.89 mmol) and Morpholine (0.633 mL, 7.34 mmol) in 1,4-dioxane (8 mL) was added cesium carbonate (4.78 g, 14.7 mmol) and degassed with nitrogen for 10 min, followed by Pd(dba)2 (0.14 g, 0.244 mmol), Xanthphos (0.27 g, 0.48 mmol) were added and stirred at 100°C for 12 h.
- Step 2 Synthesis of tert-butyl (2-morpholino-4-((2-(trifluoromethyl)benzyl)carbamoyl) thiazol-5- yl)carbamate
- Step 3 Synthesis of 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
- tert-butyl (2-morpholino-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate 430 mg, 0.884 mmol
- HC1 in dioxane 15 mL, 60 mmol
- Step 4 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- Step 1 Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(3,6-dihydro-2H-pyran-4-yl)thiazole- 4-carboxylate
- Step 2 Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(tetrahydro-2/7-pyran-4-yl)thiazole- 4-carboxylate
- Step 3 Synthesis of tert-butyl (2-(tetrahydro-2H-pyran-4-yl)-4-((2-(trifluoromethyl) benzyl)carbamoyl)thiazol-5-yl)carbamate
- Step 4 Synthesis of 5-amino-2-(tetrahydro-2/f-pyran-4-yl)-JV-(2-(trifluoromethyl) benzyl)thiazole- 4-carboxamide
- Step 5 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- Step 1 Preparation of methyl 5-((tert-butoxycarbonyl) amino)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl) thiazole-4-carboxylate
- reaction mixture was purged with nitrogen for 15 minutes followed by [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.177 g, 0.216 mmol) was added and stirred at 100°C for 16 h.
- the reaction mixture was monitored by TLC.
- the reaction mixture was poured into water (40 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with water (10 ml), brine (5mL) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
- Step 2 Preparation of tert-butyl (2-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-4-((2- (trifluoromethyl) benzyl) carbamoyl) thiazol-5-yl) carbamate
- Step 3 Preparation of 5-amino-2-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4-carboxamide
- Step 4 Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4-carboxamide [00313] To a suspension of 5-amino-2-( 1 -methyl- 1,2,3, 6-tctrahydropyridin-4-yl)-A- ⁇ [ 2- (trifluoromethyl) phenyl] methyl ⁇ -l,3-thiazole-4-carboxamide (0.150 mg, 0.378 mmol) in chlorobenzene (5 mL) was added 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.0866 g, 0.416 mmol) and phosphorus trichloride (0.0331 mL, 0.378 mmol) at ambient temperature, the resulting reaction mixture was stirred at 130°C for 3 h.
- reaction was monitored by TLC.
- the reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 mL), brine (3 mL) and dried over anhydrous sodium sulfate, fdtered, and concentrated in vacuo.
- Step 1 Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(l-methylpiperidin-4-yl)thiazole-4- carboxylate
- Step 2 Synthesis of tert-butyl (2-(l-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl) carbamoyl)thiazol-5-yl)carbamate.
- Step 4 Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methylpiperidin-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide.
- Example 105 Synthesis of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
- Step 2 Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)thiazole-4-carboxylate
- Step 3 Preparation of tert-butyl (2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate [00321] To a stirred solution of methyl 5- ⁇ [(tert-butoxy)carbonyl]amino ⁇ -2- ⁇ 2-fluoro-4-[(pyrrolidin-l- yl)methyl]phenyl ⁇ -l,3-thiazole-4-carboxylate (0.205 g, 0.471 mmol) in Toluene (2 mb, 16.9 mmol) was added l-[2-(trifluoromethyl)phenyl]methanamine (0.066 mb, 0.471 mmol) and cooled to 0°C.
- Step 4 Preparation of 5-amino-2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- reaction mixture was basified with sodium bicarbonate (10 mL) and extracted into Ethyl acetate (25 mL x 2).
- the combined organic layer was washed with water (10 mL), brine solution (10 ml) dried over sodium sulfate and evaporated under reduced pressure to get 5-amino-2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-N- (2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (95 mg, 29%) as a light yellow solid.
- Step-5 Preparation of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
- reaction mixture was poured into ice cold water (20mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (lOmL), brine solution (5mL) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
- the crude material was purified by Prep HPLC, using 0.1% TFA in Water: Acetonitrile gradient.
- Step 4 Preparation of JV-(bicyclo[l.l.l]pentan-l-ylmethyl)-5-bromo-2-(2-fluorophenyl)thiazole-4- carboxamide.
- Step-5 Preparation of JV-(bicyclo[l.l.l]pentan-l-ylmethyl)-5-(3-chloro-5-fluoro-4- hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide
- Step-1 Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate [00329] To a stirred solution of methyl 5-amino-2-bromothiazole-4-carboxylate (1 g, 4.22 mmol) in Tetrahydrofuran (20 mL, 246 mmol) was added di-tert-butyl dicarbonate (1.45 mL, 6.33 mmol), DIPEA (2.2 mL, 12.7 mmol) and DMAP (0.520 g, 4.22 mmol) at ambient temperature and then stirred at same temperature for another 2 h.
- Step-2 Preparation of methyl 5-((ter/-butoxycarbonyl) amino)-2-(2-fluorophenyl) thiazole-4- carboxylate
- Step-3 Preparation of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl) benzyl) carbamoyl) thiazol-5-yl) carbamate
- Step-4 Preparation of 5-amino-2-(2-fluorophenyl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4- carboxamide
- Step-5 Preparation of 5-(4-chloro-6-fluoro-5-methoxypicolinamido)-2-(2-fluorophenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- reaction mixture was cooled to ambient temperature and reaction mixture was quenched with ice-cold water (10 mL), solid was collected by filtration to get crude residue which was purified by flash column chromatography using 30% Ethyl acetate in Hexane as an eluent to afford 5-(4-)
- Step-6 Preparation of 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
- Example A Estrone detection assay for evaluation of HSD17B13 activity and identification of inhibitors
- the liquid chromatography/mass spectrometry (LC/MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B13.
- This assay was undertaken in a 96wp format (Eppendorf deep well Plate 96/500) in an 80pl reaction volume containing: 4pM of Estradiol (E2; Cayman; #10006315), 6mM NAD + (Sigma; #N0623) and 30 nM HSD17B13 enzyme (in-house; E. coli expressed His-tagged, purified, soluble protein) in a reaction containing IM potassium phosphate buffer pH 7.4, with 0.5% vehicle (DMSO).
- DMSO liquid chromatography/mass spectrometry
- Example B Estrone detection assay for Evaluation of HSD17B14 activity and identification of inhibitors via detection of estrone product
- the liquid chromatography/mass spectrometry (LC/MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B14.
- This assay was undertaken in a 96 well plates (Eppendorf deep well), in an 80 pl reaction volume containing: 8 pM of estradiol (E2; Cayman); 4 mM NAD+ (Sigma); 120 nM HSD17B14 enzyme (in-house E. coli expressed His-tagged, purified, soluble protein); IM potassium phosphate buffer pH 7.4, and 1.2% vehicle (DMSO). Reactions were incubated for 2 hours at 37° C.
- Estradiol (E2) conversion to estrone (El) was quantitated by LC-MS/MS based analyte detection for El using LCMS grade reagents.
- Non-linear regression was performed using a four-parameter logistic model and GraphPad Prism software. All assessments were undertaken in duplicate evaluations, which were pooled during the extraction process and subsequently injected as duplicates for LC-MS/MS analysis.
- Example C Evaluation of HSD17B2 activity and identification of inhibitors via detection of reduced nicotinamide adenine dinucleotide (NADH) product
- the fluorescence based detection assay monitors the conversion of the co-factor NAD + to NADH, which occurs coincident with the conversion of estradiol to estrone by HSD17B2.
- These assays were performed in 384 well plates (Greiner V-shape PP -microplate).
- the 20 pl reaction volume contained: 0.7 pM estradiol (E2); 6 mM NAD + (Sigma); 250 nM HSD17B2 enzyme (Origene; Cat# TP303293); 0.25 M potassium phosphate buffer pH 7.4, 0.75% vehicle (DMSO). Reactions were incubated for 2 hours at 37° C, and the reaction was stopped by freezing the reaction plates at -80° C. Zero time samples were frozen immediately.
- NAD + to NADH was quantitated using NAD-Glo kits (Promega; Cat#G9062) according to the manufacturers’ instructions.
- a volume of 15 pL of enzyme reaction mixture was added to 15 pL of reconstituted Gio reagent, and the plates were incubated for 30 minutes at room temperature. Luminescence was quantitated on a Tecan Spark Reader®.
- a standard curve of NADH (0.1- 50 pL) in potassium phosphate buffer pH 7.4/1% DMSO was run on each plate.
- A is less than or equal to 0.1 pM
- B is more than 0.1 pM and less than or equal to 0.5 pM
- C is more than 0.5 pM and less than or equal to 1.0 pM
- D is more than 1.0 pM and less than or equal to 10 pM
- E is more than 10 pM
- A is less than or equal to 50 nM
- B is more than 50 nM and less than or equal to 100 nM
- C is more than 100 nM and less than or equal to 500 nM
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Description
2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF
CROSS-REFERENCE
[0001] This application claims the benefit of Indian Application No. 202211004338 filed January 26, 2022; U. S. Provisional Application Serial No. 63/342,786 filed May 17, 2022; and U. S. Provisional Application Serial No. 63/377,421 filed September 28, 2022; which are hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] Nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) are considered to be hepatic manifestations of the metabolic syndrome and are characterized by the accumulation of triglycerides in the liver of patients without a history of excessive alcohol consumption. The majority of patients with NAFLD are obese or morbidly obese and have accompanying insulin resistance. The incidence of NAFLD/NASH has been rapidly increasing worldwide consistent with the increased prevalence of obesity, and it is currently the most common chronic liver disease.
[0003] NAFLD is classified into simple steatosis, in which only hepatic steatosis is observed, and NASH, in which intralobular inflammation and ballooning degeneration of hepatocytes is observed along with hepatic steatosis. The proportion of patients with NAFLD who have NASH is still not clear but might range from 20-40%. NASH is a progressive disease and may lead to liver cirrhosis and hepatocellular carcinoma. Twenty percent of NASH patients are reported to develop cirrhosis, and 30- 40% of patients with NASH cirrhosis experience liver-related death. Recently, NASH has become the third most common indication for liver transplantation in the United States. Currently, the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise. However, pharmacological therapy is indispensable because obese patients with NAFLD often have difficulty maintaining improved lifestyles.
[0004] 17[3-Hydroxysteroid dehydrogenases (HSD17Bs) comprise a large family of 15 members some of which involved in sex hormone metabolism. Some HSD17Bs enzymes also play key roles in cholesterol and fatty acid metabolism. A recent study showed that hydroxysteroid 17[3-dehydrogenase 13 (HSD17B13), an enzyme with unknown biological function, is a novel liver-specific lipid droplet (LD)- associated protein in mouse and humans. HSD17B13 expression is markedly upregulated in patients and mice with non-alcoholic fatty liver disease (NAFLD). Hepatic overexpression of HSD17B13 promotes lipid accumulation in the liver. HSD17B13 could also have potential as a biomarker of chronic liver disease, such as alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) (for example: steatosis, nonalcoholic steatohepatitis (NASH), NASH-fibrosis, or cirrhosis), steatohepatitis, and liver cancer.
SUMMARY OF THE INVENTION
[0005] Provided herein are methods, compounds, and compositions useful for reducing expression or activity of HSD17B13 in a subject in need thereof. Also, provided herein are methods, compounds, and compositions comprising HSD17B13 specific inhibitors, which can be useful in reducing the morbidity
of HSD17B 13 -related diseases or conditions in a subject in need thereof. Such methods, compounds, and compositions can be useful, for example, to treat, prevent, delay, or ameliorate liver disease, metabolic disease, or cardiovascular disease.
[0006] Disclosed herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (I), wherein:
Ring A is thiazolyl;
R1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl; R2 is hydrogen or Ci-Cgalkyl;
R3 is Ci-Cwalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, C2-Cioalkenyl, C2-Cioalkynyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a; each R3a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R3a on the same atom are taken together to form an oxo;
R4 is deuterium, halogen, Ci-Cgalkyl, C2-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a; each R4a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=0)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl,
Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo; or two R4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R; or two R4a on the different atoms are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R;
X is N or CRX;
Rx is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R5 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R6 is independently a halogen; each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more with one or more R; and each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -SCi-C3alkyl, -S(=O)Ci- C3alkyl, -S(=O)2Ci-C3alkyl, -S(=O)2NH2, -S(=O)2NHCi-C3alkyl, -S(=O)2N(Ci-C3alkyl)2, -NH2, - NHCi-C3alkyl, -N(Ci-C3alkyl)2, -C(=O)Ci-C3alkyl, -C(=O)OH, -C(=O)OCi-C3alkyl, -C(=O)NH2, -
- 3 -
\
C(=O)NHCi-C3alkyl, -C(=O)N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci- C3hydroxyalkyl, Ci-C3aminoalkyl, Ci-C3heteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo.
[0009] Also disclosed herein is a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0010] Also disclosed herein is a method of treating a disease in a subject in need thereof, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a pharmaceutical composition disclosed herein. In some embodiments of a method of treating a disease, the disease is a liver disease, a metabolic disease, or a cardiovascular disease. In some embodiments of a method of treating a disease, the disease is NAFLD. In some embodiments of a method of treating a disease, the disease is NASH. In some embodiments of a method of treating a disease, the disease is drug induced liver injury (DILI). In some embodiments of a method of treating a disease, the disease is associated with HSD 17B 13. In some embodiments of a method of treating a disease, the diseases is alcoholic liver disease. In some embodiments of a method of treating a disease, the disease is cirrhosis. In some embodiments of a method of treating a disease, the disease is decompensated portal hypertension. In some embodiments of a method of treating a disease, the disease is cholestatic liver disease.
[0011] Also disclosed herein is a method for selectively inhibiting HSD17B13, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound selectively inhibit HSD17B13 over HSD17B2, HSD17B14, or any combination thereof.
INCORPORATION BY REFERENCE
[0012] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0013] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
[0014] Reference throughout this specification to “some embodiments” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
[0015] The terms below, as used herein, have the following meanings, unless indicated otherwise: [0016] ‘ ‘oxo” refers to =0.
[0017] “Carboxyl” refers to -COOH.
[0018] “Alkyl” refers to a straight-chain, or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2 -methyl- 1 -propyl, 2 -methyl -2 -propyl, 2- methyl-1 -butyl, 3 -methyl- 1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3-methyl- 1 -pentyl, 4-methyl-l -pentyl, 2 -methyl -2 -pentyl, 3-methyl-2-pentyl, 4-methyl -2 -pentyl, 2,2-dimethyl-l- butyl, 3,3 -dimethyl- 1 -butyl, 2-ethyl-l -butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl and the like. Whenever it appears herein, a numerical range such as “Ci-Ce alkyl”, means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a Ci-Cio alkyl. In some embodiments, the alkyl is a Ci-
- 5 -
\
Cg alkyl. In some embodiments, the alkyl is a C1-C5 alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a C1-C3 alkyl. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
[0019] “Alkenyl” refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated. Unless stated otherwise specifically in the specification, an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, - OMe, -NH2, or -NO2. In some embodiments, the alkenyl is optionally substituted with halogen, -CN, - OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.
[0020] “Alkynyl” refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkynyl”, means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated. Unless stated otherwise specifically in the specification, an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen. [0021] “Alkylene” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkylene is optionally
- 6 -
\
substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
[0022] “Alkoxy” refers to a radical of the formula -Oalkyl where alkyl is defined as above. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.
[0023] “Aryl” refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl (phenyl). Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, - CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
[0024] “Cycloalkyl” refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3-C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl). In some embodiments, the cycloalkyl is a 3 - to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6- membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic
- 7 -
\
cycloalkyls include, for example, adamantyl, norbomyl, decalinyl, bicyclo [3.3.0] octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo [3.3.2] decane, and 7,7-dimethyl- bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, - COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally substituted with halogen.
[0025] “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
[0026] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, 3 -bromo-2 -fluoropropyl, 1,2-dibromoethyl, and the like.
[0027] “Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.
[0028] “Aminoalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
[0029] “Deuteroalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuteriums. Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3. [0030] “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or two atoms selected from the group consisting of oxygen, nitrogen, and sulfur wherein
- 8 -
\
the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, - CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or -CHjCHjNCOE . Unless stated otherwise specifically in the specification, a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
[0031] “Heterocycloalkyl” refers to a 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens. In some embodiments, the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl or C2-C15 heterocycloalkenyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl or C2-C10 heterocycloalkenyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl or C2-C8 heterocycloalkenyl), from two to seven carbon atoms (C2-C7 heterocycloalkyl or C2-C7 heterocycloalkenyl), from two to six carbon atoms (C2-C6 heterocycloalkyl or C2-C6 heterocycloalkenyl), from two to five carbon atoms (C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl), or two to four carbon atoms (C2-C4 heterocycloalkyl or C2-C4 heterocycloalkenyl). In some embodiments, the heterocycloalkyl is a 3- to 8-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. In some embodiments, the heterocycloalkyl is a 3 - to 6- membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. In some embodiments, the heterocycloalkyl is a 5 - to 6-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
- 9 -
\
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1 -oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-l-yl, 3- oxo-1, 3-dihydroisobenzofuran-l-yl, methyl-2-oxo-l,3-dioxol-4-yl, and 2-oxo-l,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8- membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3 - to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless stated otherwise specifically in the specification, a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -C00H, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.
[0032] “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5 - to 6-membered heteroaryl. In some embodiments, the heteroaryl is a
- 10 -
\
6-membered heteroaryl. In some embodiments, the heteroaryl is a 5-membered heteroaryl. In some embodiments, the heteroaryl is a 5 - to 6-membered ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1 -oxidopyridinyl, 1-oxidopyrimidinyl, 1 -oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- IH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or - OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
[0033] The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl” as defined above. Further, an optionally substituted group may be un-substituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), mono-substituted (e.g., -CH2CH2F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH2CHF2, - CH2CF3, -CF2CH3, -CFHCHF2, etc.). It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are sterically impractical and/or synthetically non-feasible. Thus, any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.
[0034] The term “one or more” when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject
- 11 -
\
group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents.
[0035] An “effective amount” or “therapeutically effective amount” refers to an amount of a compound administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
[0036] ‘ ‘Treatment” of an individual (e.g. a mammal, such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. In some embodiments, treatment includes administration of a pharmaceutical composition, subsequent to the initiation of a pathologic event or contact with an etiologic agent and includes stabilization of the condition (e.g., condition does not worsen) or alleviation of the condition. In some embodiments, treatment also includes prophylactic treatment (e.g., administration of a composition described herein when an individual is suspected to be suffering from a liver disease, e.g., NAFLD).
[0037] “Synergy” or “synergize” refers to an effect of a combination that is greater than additive of the effects of each component alone at the same doses.
[0038] “HSD17B13” means hydroxysteroid 17-beta dehydrogenase 13 and refers to any nucleic acid of HSD17B13. For example, in some embodiments, HSD17B13 includes a DNA sequence encoding HSD17B13, an RNA sequence transcribed from DNA encoding HSD17B13 (including genomic DNA comprising introns and exons). HSD17B13 can also refer to any amino acid sequence ofHSD17B13 (may include secondary or tertiary structures of the protein molecule), encoded by a DNA sequence and/or RNA sequence. The target may be referred to in either upper or lower case.
Compounds
[0039] Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof useful in the treatment of liver diseases. In some embodiments, the liver disease is NAFLD. In some embodiments, the compounds disclosed herein are selective HSD17B13 inhibitors. [0040] Disclosed herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (I), wherein:
Ring A is thiazolyl;
R1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl;
R2 is hydrogen or Ci-Cgalkyl;
R3 is Ci-Cwalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, C2-Cioalkenyl, C2-Cioalkynyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a; each R3a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6deuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R3a on the same atom are taken together to form an oxo;
R4 is deuterium, halogen, Ci-Cgalkyl, C2-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a; each R4a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo; or two R4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R; or two R4a on the different atoms are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R;
X is N or CRX;
Rx is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R5 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R6 is independently a halogen;
- 13 -
\
each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more with one or more R; and each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -SCi-C3alkyl, -S(=O)Ci- C3alkyl, -S(=O)2Ci-C3alkyl, -S(=O)2NH2, -S(=O)2NHCi-C3alkyl, -S(=O)2N(Ci-C3alkyl)2, -NH2, - NHCi-C3alkyl, -N(Ci-C3alkyl)2, -C(=O)Ci-C3alkyl, -C(=O)OH, -C(=O)OCi-C3alkyl, -C(=0)NH2, - C(=O)NHCi-C3alkyl, -C(=O)N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci- C3hydroxyalkyl, Ci-C3aminoalkyl, Ci-C3heteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo.
[0041] Disclosed herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (I), wherein:
Ring A is thiazolyl;
R1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl;
R2 is hydrogen or Ci-Cgalkyl;
R3 is Ci-Cwalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, C2-Cioalkenyl, C2-Cioalkynyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a; each R3a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6deuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R3a on the same atom are taken together to form an oxo;
R4 is deuterium, halogen, Ci-Cgalkyl, C2-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a; each R4a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo; or two R4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R; or two R4a on the different atoms are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R;
X is N or CRX;
Rx is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R5 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R6 is independently a halogen; each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl,
- 15 -
\
heteroaryl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more with one or more R; and each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -SCi-C3alkyl, -S(=O)Ci- C3alkyl, -S(=O)2Ci-C3alkyl, -S(=O)2NH2, -S(=O)2NHCi-C3alkyl, -S(=O)2N(Ci-C3alkyl)2, -NH2, - NHCi-C3alkyl, -N(Ci-C3alkyl)2, -C(=O)Ci-C3alkyl, -C(=O)OH, -C(=O)OCi-C3alkyl, -C(=O)NH2, - C(=O)NHCi-C3alkyl, -C(=O)N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci- C3hydroxyalkyl, Ci-C3aminoalkyl, Ci-C3heteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo.
[0043] In some embodiments of a compound of Formula (I), the compound is of Formula (lb):
Formula (lb).
[0044] In some embodiments of a compound of Formula (I), (la), or (lb), R1 is hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R1 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R1 is hydrogen.
[0045] In some embodiments of a compound of Formula (I), (la), or (lb), R2 is Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R2 is hydrogen.
[0046] In some embodiments of a compound of Formula (I), (la), or (lb), R3 is Ci-Cioalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C-rCioalkyl, Ci-Ciohaloalkyl, Ci-Cwdeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is Ci-Cioalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C4-Cioalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is Ci-Cioalkyl or Ci-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C4-Cioalkyl or C2-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is Ci-Cioalkyl optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C4-Cioalkyl optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C4-Cioalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is Ci-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R3a. In some embodiments of a
compound of Formula (I), (la), or (lb), R3 is C2-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R3a. In some embodiments of a compound of Formula (I), (la), or (lb), R3 is C2-Cgalkylene(aryl); wherein the aryl is optionally and independently substituted with one or more R3a.
[0047] In some embodiments of a compound of Formula (I), (la), or (lb), each R3a is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; or two R3a on the same atom are taken together to form an oxo. In some embodiments of a compound of Formula (I), (la), or (lb), each R3a is independently deuterium, halogen, -OH, -ORa, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; or two R3a on the same atom are taken together to form an oxo. In some embodiments of a compound of Formula (I), (la), or (lb), each R3a is independently halogen, -ORa, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), each R3a is independently Ci-Cghaloalkyl.
[0048] In some embodiments of a compound of Formula (I), (la), or (lb), X is N. In some embodiments of a compound of Formula (I), (la), or (lb), X is CRX.
[0049] In some embodiments of a compound of Formula (I), (la), or (lb), Rx is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), Rx is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), Rx is hydrogen.
[0050] In some embodiments of a compound of Formula (I), (la), or (lb), R5 is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R5 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (I), (la), or (lb), R5 is hydrogen.
[0051] In some embodiments of a compound of Formula (I), (la), or (lb), each R6 is chloro. In some embodiments of a compound of Formula (I), (la), or (lb), each R6 is fluoro. In some embodiments of a compound of Formula (I), (la), or (lb), one R6 is fluoro and the other R6 is chloro.
embodiments of a compound of Formula (I), (la), or (lb),
embodiments of a compound of Formula (I), (la), or (lb),
[0053] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl),
Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a.
[0054] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a.
[0055] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is cycloalkyl optionally substituted with one or more with one or more R4a.
[0056] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is heterocycloalkyl optionally substituted with one or more with one or more R4a.
[0057] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is aryl or heteroaryl; wherein the aryl and heteroaryl is optionally substituted with one or more with one or more R4a.
[0058] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is aryl optionally substituted with one or more with one or more R4a.
[0059] In some embodiments of a compound of Formula (I), (la), or (lb), R4 is heteroaryl optionally substituted with one or more with one or more R4a.
[0060] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently deuterium, halogen, -CN, -OH, -ORa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -C(=O)Ra, - C(=O)ORb, -C(=O)NRcRd, Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6deuteroalkyl, Ci-C6hydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo.
[0061] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently deuterium, halogen, -CN, -OH, -ORa, -S(=O)Ra, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo.
[0062] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently deuterium, halogen, -CN, -S(=O)Ra, or Ci-Cgalkyl optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo.
[0063] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently deuterium, halogen, -CN, -OH, -ORa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -C(=O)Ra, -
C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; or two R4a on the same atom are taken together to form an oxo.
[0064] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently deuterium, halogen, -CN, -OH, -ORa, -S(=O)Ra, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, cycloalkyl, or heterocycloalkyl; or two R4a on the same atom are taken together to form an oxo.
[0065] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently halogen, -CN, -OH, -ORa, -S(=O)Ra, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl; or two R4a on the same atom are taken together to form an oxo.
[0066] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently halogen, -S(=O)Ra, Ci-Cgalkyl, or Ci-Cghaloalkyl; or two R4a on the same atom are taken together to form an oxo.
[0067] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently halogen, -S(=O)Ra, Ci-Cgalkyl, or Ci-Cghaloalkyl.
[0068] In some embodiments of a compound of Formula (I), (la), or (lb), each R4a is independently halogen.
[0069] In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R. In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the same carbon are taken together to form a cycloalkyl optionally substituted with one or more R. In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the same carbon are taken together to form a heterocycloalkyl; each optionally substituted with one or more R.
[0070] In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the different atoms are taken together to form a cycloalkyl optionally substituted with one or more R. In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the different atoms are taken together to form a heterocycloalkyl optionally substituted with one or more R. In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the different atoms are taken together to form a aryl optionally substituted with one or more R. In some embodiments of a compound of Formula (I), (la), or (lb), two R4a on the different atoms are taken together to form a heteroaryl optionally substituted with one or more R.
In some embodiments of a compound of Formula
ome embodiments of a compound of Formula
me embodiments of a compound of Formula
ome embodiments of a compound of Formula
some embodiments of a compound of Formula
ome embodiments of a compound of Formula
me embodiments of a compound of Formula
[0075] Also disclosed herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (II), wherein:
R1 is halogen;
R2 is halogen;
X is N or CRX;
Rx is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
Y is N or CRY;
RY is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R3 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
Ring A is a pyrazole; each R4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; n is 0-2;
R5 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R6 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a; each R6a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2- Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more Rfib: or two R6a on the same atom are taken together to form an oxo;
each Rfib is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2- Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two Rfib on the same atom are taken together to form an oxo; each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently deuterium, halogen, -CN, -OH, -OCi-Cgalkyl, -S(=O)Ci-Cgalkyl, - S(=O)2Ci-C6alkyl, -S(=O)2NH2, -S(=O)2NHCi-C6alkyl, -S(=O)2N(Ci-C6alkyl)2, -NH2, - NHCi-C6alkyl, -N(Ci-C6alkyl)2, -NHC(=O)OCi-C6alkyl, -C(=O)Ci-C6alkyl, -C(=O)OH, - C(=O)OCi-C6alkyl, -C(=O)NH2, -C(=O)N(Ci-C6alkyl)2, -C(=O)NHCi-C6alkyl, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; or two R on the same atom are taken together to form an oxo.
[0076] In some embodiments of a compound of Formula (II), the compound is of Formula (Ila), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (Ila),
wherein:
R4a is hydrogen or R4; and
R4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
[0077] In some embodiments, of a compound of Formula (II), the compound is of Formula (lib), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (lib), wherein:
R4a is hydrogen or R4; and
R4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
[0078] In some embodiments, of a compound of Formula (II), the compound is of Formula (lie), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (lie), wherein:
R4a is hydrogen or R4; and
R4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
[0079] In some embodiments, of a compound of Formula (II), the compound is of Formula (lid), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (lid), wherein:
R4a is hydrogen or R4; and
R4b is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R.
[0080] In some embodiments of a compound of Formula (Ila)-(IId), R4ais hydrogen, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Ila)-(IId), R4ais hydrogen.
[0081] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R1 is fluoro or chloro. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R1 is chloro.
[0082] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R2 is fluoro or chloro. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R2 is chloro.
[0083] In some embodiments of a compound of Formula (II) or (Ila)-(IId), X is CRX. In some embodiments of a compound of Formula (II) or (Ila)-(IId), X is N.
[0084] In some embodiments of a compound of Formula (II) or (Ila)-(IId), Rx is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), Rx is hydrogen or halogen. In some embodiments of a compound of Formula (II) or (Ila)-(IId), Rx is hydrogen. [0085] In some embodiments of a compound of Formula (II) or (Ila)-(IId), Y is CRY. In some embodiments of a compound of Formula (II) or (Ila)-(IId), Y is N.
[0086] In some embodiments of a compound of Formula (II) or (Ila)-(IId), RY is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), RY is hydrogen or halogen. In some embodiments of a compound of Formula (II) or (Ila)-(IId), RY is hydrogen. [0087] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R3 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R3 is hydrogen.
[0088] In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl; wherein each alkyl, cycloalkyl, and aryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently Ci-Cgalkyl or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R4 is independently aryl.
[0089] In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 0 or 1. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 0. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 1. In some embodiments of a compound of Formula (II) or (Ila)-(IId), n is 2.
[0090] In some embodiments of a compound of Formula (Ila)-(IId), R4b is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (Ila)-(IId), R4b is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (Ila)- (Ild), R4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (Ila)-(IId), R4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl; wherein each alkyl, cycloalkyl, and aryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (Ila)- (Ild), R4b is Ci-Cgalkyl, Ci-Cghaloalkyl, cycloalkyl, or aryl. In some embodiments of a compound of Formula (Ila)-(IId), R4b is Ci-Cgalkyl or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (Ila)-(IId), R4b is aryl.
[0091] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R5 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R5 is hydrogen. [0092] In some embodiments of a compound of Formula (II) or (Ila)-(IId), R6 is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R6 is Ci-Cgalkyl optionally substituted with
- 28 -
\
one or more R6a. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R6 is Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R6a. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R6 is Ci-Cgalkylene(aryl) or Ci-Cgalkylene(heteroaryl); wherein the alkylene, aryl, and heteroaryl is optionally substituted with one or more R6a. In some embodiments of a compound of Formula (II) or (Ila)-(IId), R6 is Ci-Cgalkylene(aryl); wherein the alkylene and aryl is optionally substituted with one or more R6a.
[0093] In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R6a is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more Rfib.
[0094] In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R6a is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; wherein each alkyl is optionally and independently substituted with one or more R6b. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R6a is independently -ORa, Ci-Cgalkyl, or Ci-Cghaloalkyl. [0095] In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R6b is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (II) or (Ila)-(IId), each R6b is independently deuterium, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl.
[0096] Also disclosed herein is a compound of Formula (III), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R11 is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2- Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is 1-5;
R12 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
each R13 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; p is 0-3;
R14 is Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R14a; each R14a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2- Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R14b; or two R14a on the same atom are taken together to form an oxo; each R14b is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2- Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R14b on the same atom are taken together to form an oxo; each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl),
- 30 -
\
Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently deuterium, halogen, -CN, -OH, -OCi-Cgalkyl, -S(=O)Ci-Cgalkyl, - S(=O)2Ci-Cgalkyl, -S(=O)2NH2, -S(=O)2NHCi-Cgalkyl, -S(=O)2N(Ci-C6alkyl)2, -NH2, - NHCi-C6alkyl, -N(Ci-C6alkyl)2, -NHC(=O)OCi-C6alkyl, -C(=O)Ci-C6alkyl, -C(=O)OH, - C(=O)OCi-C6alkyl, -C(=O)NH2, -C(=O)N(Ci-C6alkyl)2, -C(=O)NHCi-C6alkyl, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; or two R on the same atom are taken together to form an oxo.
[0097] In some embodiments of a compound of Formula (II), Ring B is aryl or heteroaryl. In some embodiments of a compound of Formula (II), Ring B is aryl. In some embodiments of a compound of Formula (II), Ring B is heteroaryl. In some embodiments of a compound of Formula (II), Ring B is 5- or 6-membered heteroaryl. In some embodiments of a compound of Formula (II), Ring B is phenyl or pyridyl. In some embodiments of a compound of Formula (II), Ring B is phenyl. In some embodiments of a compound of Formula (II), Ring B is pyridyl.
[0098] In some embodiments of a compound of Formula (II), each R11 is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl.
[0099] In some embodiments of a compound of Formula (II), each R11 is independently halogen, -OH, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (II), each R11 is independently halogen or -OH.
[00100] In some embodiments of a compound of Formula (III), m is 1-3. In some embodiments of a compound of Formula (III), m is 2 or 3. In some embodiments of a compound of Formula (III), m is 2. In some embodiments of a compound of Formula (III), m is 3.
[00101] In some embodiments, of a compound of Formula (III), the compound is of Formula (Illa), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (Illa), wherein:
R15 is halogen;
R16 is halogen;
W is N or CRW;
Rw is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
Z is N or CRZ;
Rz is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or
C i-Cgdeuteroalkyl .
[00102] In some embodiments of a compound of Formula (Illa), R15 is fluoro or chloro. In some embodiments of a compound of Formula (Illa), R15 is chloro.
[00103] In some embodiments of a compound of Formula (Illa), R16 is fluoro or chloro. In some embodiments of a compound of Formula (Illa), R16 is chloro.
[00104] In some embodiments of a compound of Formula (Illa), W is CRW. In some embodiments of a compound of Formula (Illa), W is N.
[00105] In some embodiments of a compound of Formula (Illa), Rw is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Illa), Rw is hydrogen or halogen. In some embodiments of a compound of Formula (Illa), Rw is hydrogen.
[00106] In some embodiments of a compound of Formula (Illa), Z is CRZ. In some embodiments of a compound of Formula (Illa), Z is N.
[00107] In some embodiments of a compound of Formula (Illa), Rz is hydrogen, deuterium, halogen, or Ci-Cgalkyl. In some embodiments of a compound of Formula (Illa), Rz is hydrogen or halogen. In some embodiments of a compound of Formula (Illa), Rz is hydrogen.
[00108] In some embodiments of a compound of Formula (III) or (Illa), R12 is hydrogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (III) or (Illa), R12 is hydrogen.
[00109] In some embodiments of a compound of Formula (III) or (Illa), each R13 is independently deuterium, halogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of a compound of Formula (III) or (Illa), each R13 is independently halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R13 is independently halogen or Ci-Cgalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R13 is independently halogen. In some embodiments of a compound of Formula (III) or (Illa), each R13 is independently Ci-Cgalkyl.
[00110] In some embodiments of a compound of Formula (III) or (Illa), p is 0-2. In some embodiments of a compound of Formula (III) or (Illa), p is 0 or 1. In some embodiments of a compound of Formula (III) or (Illa), p is 0. In some embodiments of a compound of Formula (III) or (Illa), p is 1. In some embodiments of a compound of Formula (III) or (Illa), p is 2.
[00111] In some embodiments of a compound of Formula (III) or (Illa), R14 is Ci-Cgalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R14a. In some embodiments of a
- 32 -
\
compound of Formula (III) or (Illa), R14 is Ci-Cgalkyl optionally substituted with one or more R14a. In some embodiments of a compound of Formula (III) or (Illa), R14 is Ci-Cgalkylene(aryl) or Ci-Cgalkylene(heteroaryl); wherein each alkylene, aryl, and heteroaryl is optionally and independently substituted with one or more R14a. In some embodiments of a compound of Formula (III) or (Illa), R14 is Ci-Cgalkylene(aryl); wherein each alkylene and aryl is optionally and independently substituted with one or more R14a.
[00112] In some embodiments of a compound of Formula (III) or (Illa), each R14a is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-C6alkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R14b.
[00113] In some embodiments of a compound of Formula (III) or (Illa), each R14a is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; wherein each alkyl is optionally and independently substituted with one or more R14b.
[00114] In some embodiments of a compound of Formula (III) or (Illa), each R14a is independently - ORa, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R14a is independently Ci-Cghaloalkyl.
[00115] In some embodiments of a compound of Formula (III) or (Illa), each R14b is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound of Formula (III) or (Illa), each R14b is independently deuterium, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl.
[00116] In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl. In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl or Ci-Cghaloalkyl. In some embodiments of a compound disclosed herein, each Ra is independently Ci-Cgalkyl.
[00117] In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein
- 33 -
\
each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen or Ci-Cgalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen. In some embodiments of a compound disclosed herein, each Rb is independently Ci-Cgalkyl.
[00118] In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, heterocycloalkyl, Ci-Cgalkylene(cycloalkyl), or Ci-Cgalkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen or Ci-Cgalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen. In some embodiments of a compound disclosed herein, each Rc and Rd are independently Ci-Cgalkyl.
[00119] In some embodiments of a compound disclosed herein, Rc and Rd are taken together with the atom to which they are attached to form a 5 - or 6-membered heterocycloalkyl optionally substituted with one or more R. In some embodiments of a compound disclosed herein, Rc and Rd are taken together with the atom to which they are attached to form a 5 -membered heterocycloalkyl optionally substituted with one or more R. In some embodiments of a compound disclosed herein, Rc and Rd are taken together with
- 34 -
\
the atom to which they are attached to form a 6-membered heterocycloalkyl optionally substituted with one or more R.
[00120] In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -NH2, -NHCi-C3alkyl, -N(Ci-C3alkyl)2, -C(=O)Ci-C3alkyl, - C(=O)OH, -C(=O)OCi-C3alkyl, -C(=O)NH2, -C(=O)NHCi-C3alkyl, -C(=O)N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci-C3hydroxyalkyl, Ci-C3aminoalkyl, Ci-C3heteroalkyl, or C3- Cgcycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -NH2, -NHCi- C3alkyl, -N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci-C3hydroxyalkyl, Ci- C3aminoalkyl, Ci-C3heteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OCi- C3alkyl, -OCi-C3haloalkyl, -NH2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, Ci-C3alkyl, or Ci-C3haloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, Ci-C3alkyl, or Ci- C3haloalkyl. In some embodiments of a compound disclosed herein, each R is independently halogen or Ci-C3alkyl. In some embodiments of a compound disclosed herein, each R is independently halogen. [00121] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00122] Described herein is a compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from a compound in Table la.
[00123] Described herein is a compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from a compound in Table lb.
TABLE lb.
Further Forms of Compounds Disclosed Herein
Isomers/Stereoisomers
[00124] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
Labeled compounds
[00125] In some embodiments, the compounds described herein exist in their isotopically -labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically -labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically -labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as 2H, 3H, 13C, 14C, 15N, 18O, 170, 31P, 32P, 35S, 18F, and 36C1, respectively. Compounds described herein, and the pharmaceutically acceptable salts, solvates, or stereoisomers thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H and carbon-14, i.e., 14C, isotopes are particularly preferred fortheir ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e., 2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
[00126] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[00127] In some embodiments, the labeled compounds described herein are used for measuring in vitro and in vivo binding of unlabeled HSD17B13 inhibitors.
Pharmaceutically acceptable salts
[00128] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[00129] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or a solvate, or stereoisomer thereof, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- 55 -
\
[00130] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid or inorganic base, such salts including, acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-l,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne- 1,6-dioate, hydroxybenzoate, y-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-napthalene sulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate, undecanoate, and xylenesulfonate.
[00131] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane sulfonic acid, ethane sulfonic acid, 1,2 -ethanedisulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo- [2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4 ’-methylenebis-(3 -hydroxy-2 -ene-1 - carboxylic acid), 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. In some embodiments, other acids, such as oxalic, while not in themselves pharmaceutically acceptable, are employed in the preparation of salts useful as intermediates in obtaining the compounds disclosed herein, solvate, or stereoisomer thereof and their pharmaceutically acceptable acid addition salts.
[00132] In some embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(CI-4 alkyl)4, and the like.
[00133] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. It
- 56 -
\
should be understood that the compounds described herein also include the quatemization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quatemization.
Solvates
[00134] In some embodiments, the compounds described herein exist as solvates. The invention provides for methods of treating diseases by administering such solvates. The invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
[00135] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
Tautomers
[00136] In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
Method of Treatment
[00137] Provided herein are methods of inhibiting HSD17B13 expression or activity, which can be useful for treating, preventing, or ameliorating a disease associated with HSD17B13 in a subject in need thereof, such as NAFLD or NASH, by administration of a compound that targets HSD 17B 13, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[00138] Provided herein are methods of inhibiting expression or activity of HSD17B13 in a cell comprising contacting the cell with a HSD17B13 inhibitor disclosed or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, thereby inhibiting expression or activity of HSD 17B 13 in the cell . In some embodiments, the cell is a hepatocyte cell. In some embodiments, the cell is in the liver. In some embodiments, the cell is in the liver of a subject who has, or is at risk of having a disease, disorder, condition, symptom, or physiological marker associated with a liver disease, metabolic disease, or cardiovascular disease or disorder. In some embodiments, the cells are the adipocytes or monocytes from a subject who has or is at risk of having a disease. In some embodiments, the cells are the lymphocytes from a subject who has or is at risk of having a disease. In some embodiments, the liver disease,
- 57 -
\
metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, nonalcoholic steatohepatitis (NASH), fulminant Wilson’s disease, rapidly fibrosing hepatitis C viral injury, and decompensated portal vein hypertension. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is cholestatic liver disease.
[00139] In some embodiments, the liver disease is primary biliary cirrhosis or primary sclerosing cholangitis,
[00140] Provided herein are methods of treating, preventing, delaying the onset, slowing the progression, or ameliorating one or more diseases, disorders, conditions, symptoms, or physiological markers associated with HSD17B13 comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the subject in need thereof is identified as having, or at risk of having, the disease, disorder, condition, symptom, or physiological marker. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH. [00141] Provided herein are methods of reducing, improving, or regulating hepatic steatosis, liver fibrosis, triglyceride synthesis, lipid levels, hepatic lipids, ALT levels, NAFLD Activity Score (NAS), cholesterol levels, or triglyceride levels, or a combination thereof, in a subject in need thereof comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating hepatic steatosis in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating liver fibrosis in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating triglyceride synthesis in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating lipid levels in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating hepatic lipids in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating ALT levels in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating NAFLD
- 58 -
\
Activity Score in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating cholesterol levels in the individual. In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is provided for use in reducing, improving, or regulating triglyceride levels in the individual. In some embodiments, the subject is identified as having, or at risk of having a disease, disorder, condition, symptom, or physiological marker associated with a liver disease, metabolic disease, or cardiovascular disease or disorder. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, liver cirrhosis, hepatic steatosis, steatohepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH.
[00142] Provided herein are methods for treating, preventing, or delaying onset drug induced liver injury (DILI) in a subject in need thereof, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the liver injury is steatohepatitis. Also provided herein are methods for treating, preventing, or delaying onset drug induced steatohepatitis (DISH) in a subject in need thereof. In some embodiments, the subject in need thereof is receiving chemotherapy for treating cancer. In some embodiments, the subject in need thereof is receiving a treatment for a cardiovascular disease. In some embodiments, the subject in need thereof is receiving treatment for a psychiatric disease/condition. In some embodiments, the subject in need thereof is receiving treatment for pain. In some embodiments, the subject in need thereof is receiving treatment for arthritis. In some embodiments, the chemotherapy is tamoxifen, toremifene, irinotecan, methotrexate, fluorouracil (5-FU), or any combination thereof. In some embodiments, the subject in need thereof is receiving amiodarone, perhexiline, propranolol, or any combination thereof. In some embodiments, the subject in need thereof is receiving amitriptyline, clozapine, or any combination thereof. In some embodiments, the subject in need thereof is receiving methotrexate, pirprofen, or any combinations thereof.
Cholestatic Diseases
[00143] Provided herein is a method of treating a cholestatic disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[00144] In some embodiments, inhibiting HSD17B13 improves bile flow. In some embodiments, inhibition of HSD17B13 is used to treat a cholestatic disease. Cholestatic diseases include primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in cystic fibrosis patients and progressive familial intrahepatic cholestasis (PFIC).
[00145] HSD17B13 protein is very highly expressed in liver and gallbladder. The gallbladder is developmentally downstream of hepatocytes through the biliary tree. Inactive HSD17B13 has been associated with increases in liver and plasma phosphatidylcholine. Phosphatidylcholine is essential for bile flow. Hepatic phosphatidylcholine is secreted into the bile at a rate equivalent to the total liver levels of phosphatidylcholine being secreted within a day along with bile acids (BAs) and cholesterol. In some embodiments, inactive HSD17B13 is associated with increased plasma levels of VLDL-cholesterol. Meaning that there is a greater secretion of cholesterol out of the liver and not catabolized to bile acids for secretion in bile. In some embodiments, inhibition of HSD17B13 improves bile flow through increased phosphatidylcholine. In some embodiments, HSD17B13 is protecting the biliary tree by preventing inflammation. In some embodiments, HSD17B13 is protecting the biliary tree by preventing the cytotoxic bile acids from injuring the biliary tree.
[00146] In some embodiments, the cholestatic disease is primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in a cystic fibrosis patient, progressive familial intrahepatic cholestasis (PFIC), intrahepatic cholestasis of pregnancy; drug-induced cholestasis, AIDS cholangiopathy, IG4-associated cholangitis, biliary stricture, or low phospholipid- associated cholestasis.
[00147] In some embodiments, the cholestatic disease is primary sclerosis cholangitis (PSC), primary biliary cholangitis (PBC), Alagille Syndrome, biliary atresia, liver injury in a cystic fibrosis patient, or progressive familial intrahepatic cholestasis (PFIC).
[00148] In some embodiments, the cholestatic disease is primary sclerosis cholangitis (PSC).
[00149] In some embodiments, the PSC is accompanied by inflammatory bowel disease (IBD). In some embodiments, the PSC is accompanied by elevated levels of lipopolysaccharide (LPS) (endotoxemia). In some embodiments, the elevated levels of LPS is in the blood. In some embodiments, the elevated levels of LPS is in the liver. In some embodiments, the elevated levels of LPS is in the biliary tree. In some embodiments, the cholestatic disease is primary biliary cholangitis (PBC). In some embodiments, the cholestatic disease is Alagille Syndrome. In some embodiments, the cholestatic disease is biliary atresia. In some embodiments, the cholestatic disease is liver injury in a cystic fibrosis patient. In some embodiments, the cholestatic disease is progressive familial intrahepatic cholestasis (PFIC). In some embodiments, the PFIC is PFIC-3 type. In some embodiments, the PFIC-3 type is due to a mutation in ABCB4 which requires phosphatidylcholine for bile acid transport.
[00150] In some embodiments, the cholestatic disease is treated by improving bile flow in the subject in need thereof. In some embodiments, the cholestatic disease is treated by improving cholesterol secretion out of the liver in the subject in need thereof.
[00151] In some embodiments, inactive HSD17B13 is associated to lower cytokines and inflammatory gene expression. In some embodiments, there is an improvement in the hepatocyte response to LPS in hepatocytes with inactive HSD17B13. In some embodiments, inactive HSD17B13 is associated with improved autophagy in response to LPS (see FIG. 1A, FIG. IB, and FIG. 1C). In some embodiment,
- 60 -
\
increases in LC3B-11 combined with increases in p62 indicate accumulation of autophagosomes and defective autophagy.
Liver injury due to protein accumulation
[00152] Disclosed herein is a method of treating liver injury due to protein accumulation in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the protein that accumulates is alpha 1 -antitrypsin.
[00153] Alpha 1 -antitrypsin is encoded by the gene SERPINA1. The normal allele is referred to as M, while common SERPINA1 alleles that have been associated with liver disease have amino acid changes Glu264Val, referred to as S and Glu342Lys, referred to as Z. Individuals that are homozygotes for the Z (designated PiZZ) allele, have pulmonary manifestations of their Al AT deficiency and can be treated by supplementation of the enzyme. However, individuals that are heterozygotes for the Z allele either with the M (designated PiMZ) or with the S allele (designated PiSZ) have liver disease manifestations. The protein resulting from translation of the Z and S alleles is a misfolded protein. This misfolded protein has been found to polymerize and lead to cellular injury due to accumulation of misfolded and polymerized protein. Protection against the injury due to accumulated misfolded protein has been observed by increasing autophagy.
[00154] In some embodiments, HSD17B13 plays a role in autophagy. In some embodiments, autophagy is important for eliminating misfolded proteins and has been implicated in liver injury due to alpha 1 -antitrypsin deficiency. In some embodiments, inhibition of HSD17B13 improves autophagy and thus improve clearance of misfolded proteins and thus, improve liver health. In some embodiments, liver disease associated with alpha 1-antitrypsin deficiency include inflammation and decreases in platelets. In some embodiments, inactive HSD17B13 is associated with lower inflammation, decreased inflammatory genes including NF-kB and TGF-J3 as well as increases in platelets.
[00155] In some embodiments, the protein accumulation is cleared via autophagy. In some embodiments, the protein is a misfolded protein. In some embodiments, the liver injury is due to alpha 1- antitrypsin deficiency. In some embodiments, the alpha 1-antitrypsin deficiency results in a protein that does not get fully processed and accumulates as a mis-folded protein in the liver. In some embodiments, the liver disease associated with alpha 1-antitrypsin deficiency include inflammation. In some embodiments, the liver disease associated with alpha 1-antitrypsin deficiency include decreases in platelets.
Treatment of viral-induced injuries
[00156] Disclosed herein is a method of treating a viral infection-induced liver injury in a subject in need thereof, the method comprising administering a therapeutically effective amount of a
- 61 -
\
hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[00157] Also disclosed herein is a method of decreasing the severity of inflammation in a subject with a viral infection, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor to the subject.
[00158] Also disclosed herein is a method of decreasing the severity of acute immune response in a subject with a viral infection, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[00159] Viral infections are often associated with dysregulated liver inflammatory response. In some embodiments, inactive HSD17B13 is associated with lower levels of genes of activation of immune response including innate immune response, cytokines. Inflammation is a key component of viral-driven injury. In some embodiments, inactive HSD17B13 protects against rapidly progressing fibrosis in HCV patients.
[00160] AAV-driven gene therapies are aided by autophagy for incorporating into liver cells so an HSD17B13 inhibitor that improves autophagy and decreases inflammation can both enhance efficacy and decrease side effects.
[00161] In some embodiments, the viral infection is hepatitis A. In some embodiments, the viral infection is hepatitis B. In some embodiments, the viral infection is hepatitis C.
[00162] In some embodiments, the viral infection is SARS-Cov-2.
SARS-Cov-2
[00163] Liver injury and elevations of liver transaminases are a common feature in patients with severe SARS-Cov-2 infection. There is no apparent increased risk of COVID- 19 associated with liver disease, therefore, 2-11% of patients with COVID-19 have underlying liver comorbidities. In contrast, a much larger portion of patients (14-53%) have elevated liver transaminases. Patients suspected of having COVID-19 that test positive for the SARS-CoV-2 RNA had elevations in ALT, AST and decreases in albumin when compared to patients that tested negative for the viral RNA consistent with liver injury. In patients that died from COVID-19, 58% and 78% of patients had liver transaminase elevations. The liver transaminase elevations have been especially notable in patients in intensive care units at 62% compared to 25% of patients not requiring ICU care. Patients with a CT-scan confirmed diagnosis of COVID-19 in the subclinical stage have a lower incidence of liver transaminase elevations when compared to patients diagnosed after the onset of symptoms. While there may be a role of the virus causing direct liver injury as evidenced by the observation of SARS-CoV-2 RNA in blood and feces and 2-10% of patients that have diarrhea, the liver injury may also arise from secondary inflammatory events or the use of many different drugs during critical care.
[00164] In addition to liver injury in patients with severe COVID- 19, there is an increase in cytokines, or incidence of cytokine storm that is a cause of multiple organ failure and death. To prevent or treat the
- 62 -
\
cytokine storm would therefore be important to treating the patients with the most severe disease. Analysis of COVID- 19 patient’s blood has shown in general decreases in CD4 and CD8 cells but an increase in Thl7 cells. Similarly, in a cohort of patients with severe disease there was an increase in IL-6, IL-10, IL-2 and IFNy. On the whole, liver injury is seen in COVID-19 patients who are experiencing a broader and more severe disease where multiple organs, beyond the lungs, have become involved. Among the possible reasons for this could be that through an oral route that is then taken up through a more permeable intestinal barrier in patients with co -morbidities such as diabetes. The liver then is exposed to the virus and as a critical mediator for inflammatory responses, could thus mediate either a resolving inflammatory process or mediate an accelerating inflammatory process that leads to increased cytokine release and further organ damage.
[00165] The genetic evidence for the gene for the enzyme HSD17B13 association with liver transaminase levels and liver diseases has grown rapidly. At this writing, the genetic evidence includes many studies with genetic and disease information from more than 200,000 individuals. The lack of HSD 17B 13 activity has been shown to be protective against liver disease caused by over nutrition, excess and chronic alcohol intake, toxins such as copper and viruses such as HCV. The highly reproducible association of HSD17B13 with liver disease, liver transaminase elevations and liver injury in multiple forms has inspired efforts to develop inhibitors of this enzyme to protect against and reverse liver damage. The variety of toxicants and injuries against which HSD17B13 loss of function protects is such that it is proposed here to protect against liver injury in severe COVID-19.
[00166] HSD17B13 activity has been shown to be involved in inflammation and inflammatory response. HSD17B13 loss of function has recently been associated with decreased gene expression and protein levels of immune response genes involved in adverse outcomes including IL-6, IL- 10 and IL-1J3. Enzymatically inactive polymorphs of HSD17B13 are associated with lower severity of histopathological endpoints of inflammation in addition to lower ALT levels in patients with nonalcoholic fatty liver disease.
[00167] In some embodiments, HSD17B13 inhibitors prevent and treat liver injury and decrease the severity of inflammation and acute immune response in patients with COVID-19.
[00168] In some embodiments, the viral infection is associated with a dysregulated liver inflammatory response. In some embodiments, the administration results in lowering the levels of immune response activation genes. In some embodiments, the administration results in decreased inflammation. In some embodiments, the subject in need thereof has elevated levels of alanine aminotransferase (ALT). In some embodiments, the subject in need thereof has elevated levels of aspartate aminotransferase (AST). In some embodiments, the subject in need thereof has decreased levels of albumin.
Malignancies
[00169] Disclosed herein is a method of treating a malignancy selected from hepatocellular carcinoma (HCC), cholangioadenoma, cholangiocarcinoma, gallbladder adenocarcinoma, and malignancy of bile duct, in a subject in need thereof, the method comprising administering a therapeutically effective
- 63 -
\
amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[00170] Inactive HSD17B13 is associated with lower rates of HCC. However, HSD17B13 expression is low in tumor tissue but normal in the peritumoral space. High protein levels in the peritumoral space is associated with improved survival and tumor free survival. This apparent contradiction supports the use of small molecules to inhibit HSD17B13 but keep the protein available to support autophagic activity. Autophagy is important to maintaining a killer T cell response and use the body’s own immune system to fight the tumor. By inhibiting HSD17B13, the surrounding tissue will be capable of killer T cell response due to effective autophagy.
[00171] HSD17B13 is highly expressed in normal gallbladder. Inactive HSD17B13 is associated with increased phospotidylcholine which is essential for sequestering cytotoxic bile acids for excretion and bile flow. For these reasons and the additional improved killer T cell response and decreased inflammation and fibrosis are the mechanism by which an inhibitor of HSD17B13 can be used to treat cholangioadenoma and gallbladder adenocarcinoma.
[00172] In some embodiments, the malignancy is hepatocellular carcinoma (HCC). In some embodiments, the malignancy is cholangioadenoma. In some embodiments, the malignancy is cholangiocarcinoma. In some embodiments, the malignancy is gallbladder adenocarcinoma. In some embodiments, the HSD17B13 receptor is expressed in the peritumoral space.
Hemochromatosis
[00173] A method of treating hemochromatosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the hemochromatosis is primary hemochromatosis. In some embodiments, the hemochromatosis is secondary hemochromatosis. In some embodiments, the hemochromatosis is caused by a liver disease. In some embodiments, the hemochromatosis is drug- induced hemochromatosis.
Lysosomal acid lipase deficiency (LAL-D)
[00174] Disclosed herein is a method of treating lysosomal acid lipase deficiency (LAL-D) in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the lysosomal acid lipase deficiency (LAL-D) is caused by mutations in the LIPA gene. In some embodiments, the lysosomal acid lipase deficiency (LAL-D) causes Wolman disease. In some embodiments, the lysosomal acid lipase deficiency (LAL-D) causes Cholesteryl ester storage disease. In some embodiments, the lysosomal acid lipase deficiency (LAL-D) is caused by mutations in the LIPA gene. In some embodiments, the
- 64 -
\
lysosomal acid lipase deficiency (LAL-D) causes a buildup of faty substances in the body's cells and tissues.
Bleeding disorders/coagulation factor disorders
[00175] Disclosed herein is a method of treating a bleeding disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the bleeding disorder is hemophilia A or hemophilia B. [00176] Disclosed herein is a method of treating a coagulation factor disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17- beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the coagulation factor disorder is Von Willebrand disease.
[00177] In some embodiments, the disease to be treated by inhibition of hydroxy steroid 17-beta dehydrogenase 13 (HSD17B13) is listed in the table below.
[00178] Also disclosed herein is a method for selectively inhibiting HSD17B13, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound selectively inhibit HSD17B13 over HSD17B2, HSD17B14, or any combination thereof. In some
embodiments, inhibition of HSD17B2 is associated with disruption of normal endocrine function in multiple tissues. In some embodiments, inhibition of HSD17B2 is associated with weight loss. In some embodiments, inhibition of HSD17B2 is associated with muscle loss. In some embodiments, inhibition of HSD17B14 is associated with disruption of normal endocrine function in multiple tissues.
Dosing
[00179] In certain embodiments, the compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient’s health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation and/or dose ranging clinical trial.
[00180] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder, or condition. Such an amount is defined to be a “prophylactically effective amount or dose.” In this use, the precise amounts also depend on the patient’s state of health, weight, and the like. When used in patients, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient’s health status and response to the drugs, and the judgment of the treating physician. In one aspect, prophylactic treatments include administering to a mammal, who previously experienced at least one symptom of or risk factor for the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent a return of the symptoms of the disease or condition. In one aspect, prophylactic treatments include administering to a mammal having patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism, a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, in order to prevent liver damages. The 148 Isoleucine to Methionine protein variant (I148M) of patatin-like phospholipase domain-containing 3 (PNPLA3), a protein is expressed in the liver and is involved in lipid metabolism, has recently been identified as a major determinant of liver fat content. Several studies confirmed that the I148M variant predisposes towards the full spectrum of liver damage associated with fatty liver: from simple steatosis to steatohepatitis and progressive fibrosis. Furthermore, the I148M variant represents a major determinant of progression of alcohol related steatohepatitis to cirrhosis, and to influence fibrogenesis and related clinical outcomes in chronic hepatitis C virus hepatitis, and possibly chronic hepatitis B virus hepatitis, hereditary hemochromatosis and primary sclerosing cholangitis. In some embodiments, PNPLA3 polymorphism is used to predict liver disease progression.
[00181] In certain embodiments wherein the patient’s condition does not improve, upon the doctor’s discretion the administration of the compounds are administered chronically, that is, for an extended
- 66 -
\
period of time, including throughout the duration of the patient’s life in order to ameliorate or otherwise control or limit the symptoms of the patient’s disease or condition.
[00182] Once improvement of the patient’s conditions has occurred, a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage, or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent or daily treatment on a long-term basis upon any recurrence of symptoms.
[00183] The amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, but nevertheless is determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
[00184] In general, however, doses employed for adult human treatment are typically in the range of 0.01 mg-5000 mg per day. In one aspect, doses employed for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously or at appropriate intervals, for example as two, three, four or more sub-doses per day.
[00185] In one embodiment, the daily dosages appropriate for the compound described herein, or a pharmaceutically acceptable salt thereof, are from about 0.01 to about 50 mg/kg per body weight. In some embodiments, the daily dosage, or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
[00186] Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LDw and the ED<)(I. The dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50. In certain embodiments, the data obtained from cell culture assays and animal studies are used in formulating the therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans. In some embodiments, the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED 50 with minimal toxicity. In certain embodiments, the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
[00187] In any of the aforementioned aspects are further embodiments in which the effective amount of the compound described herein, or a pharmaceutically acceptable salt thereof, is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously
- 67 -
\
administered to the mammal; and/or (d) administered by injection to the mammal; and/or (e) administered topically to the mammal; and/or (f) administered non-systemically or locally to the mammal.
[00188] In any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once a day; or (ii) the compound is administered to the mammal multiple times over the span of one day.
Routes of Administration
[00189] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
[00190] In certain embodiments, a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation. In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically.
Pharmaceutical Compositions/Formulations
[00191] The compounds described herein are administered to a subject in need thereof, either alone or in combination with pharmaceutically acceptable carriers, excipients, or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. In one embodiment, the compounds of this invention may be administered to animals. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal, and topical routes of administration.
[00192] In another aspect, provided herein are pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be
- 68 -
\
found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.
[00193] In some embodiments, the pharmaceutically acceptable excipient is selected from carriers, binders, fdling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, and any combinations thereof.
[00194] The pharmaceutical compositions described herein are administered to a subject by appropriate administration routes, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[00195] Pharmaceutical compositions including compounds described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
[00196] Pharmaceutical compositions for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. In some embodiments, dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[00197] Pharmaceutical compositions that are administered orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The
- 69 -
\
push-fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added.
[00198] Pharmaceutical compositions for parental use are formulated as infusions or injections. In some embodiments, the pharmaceutical composition suitable for injection or infusion includes sterile aqueous solutions, or dispersions, or sterile powders comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the pharmaceutical composition comprises a liquid carrier. In some embodiments, the liquid carrier is a solvent or liquid dispersion medium comprising, for example, water, saline, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and any combinations thereof. In some embodiments, the pharmaceutical compositions further comprise a preservative to prevent growth of microorganisms.
Combination
[00199] Disclosed herein are method of treating a liver disease, metabolic disease, or cardiovascular disease using a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an additional therapeutic agent.
[00200] In some embodiments, the additional therapeutic agent is used for the treatment of diabetes or diabetes related disorder or conditions.
[00201] In some instances, the additional therapeutic agent comprises a statin, an insulin sensitizing drug, an insulin secretagogue, an alpha-glucosidase inhibitor, a GLP agonist, a GIP agonist, a THR beta agonist, a PDE inhibitor, a DPP -4 inhibitor (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, gemigliptin, or dutogliptin), a catecholamine (such as epinephrine, norepinephrine, or dopamine), peroxisome proliferator-activated receptor (PPAR)-gamma agonist (e.g., a thiazolidinedione (TZD) [such as pioglitazone, rosiglitazone, rivoglitazone, or troglitazone], aleglitazar, farglitazar, muraglitazar, or tesaglitazar), peroxisome proliferator-activated receptor (PPAR)-alpha agonist, peroxisome proliferator-activated receptor (PPAR)-delta agonist, a famesoid X receptor (FXR) agonist (e.g., obeticholic acid), or a combination thereof. In some cases, the statin is a HMG-CoA reductase inhibitor. In other instances, additional therapeutic agents include fish oil, fibrate, vitamins such as niacin, retinoic acid (e.g., 9 cis-retinoic acid), nicotinamide ribonucleoside or its analogs thereof, or combinations thereof. In other instances, additional therapeutic agents include ACC inhibitors, FGF19 and FGF21 mimics, CCR2/CCR5 antagonists, or combinations thereof.
[00202] In some embodiments, the additional therapeutic agent is vivitrol.
[00203] In some embodiments, the additional therapeutic agent is a statin such as a HMG-CoA reductase inhibitor, fish oil, fibrate, niacin, or a combination thereof. In other instances, the additional therapeutic agent is a dyslipidemia drug that prevent lipid absorption such as orlistat.
- 70 -
\
[00204] In some embodiments, the additional therapeutic agent is a vitamin such as retinoic acid or tocopheryl acetate for the treatment of diabetes and diabetes related disorder or condition such as lowering elevated body weight and/or lowering elevated blood glucose from food intake.
[00205] In some embodiments, the additional therapeutic agent is a glucose-lowering agent. In some embodiments, the additional therapeutic agent is an anti-obesity agent. In some embodiments, the additional therapeutic agent is selected from among a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon -like peptide- 1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a glucophage, a human amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, and sulfonylurea. In some embodiments, the additional therapeutic agent is metformin, sitagliptin, saxaglitpin, repaglinide, nateglinide, exenatide, liraglutide, insulin lispro, insulin aspart, insulin glargine, insulin detemir, insulin isophane, and glucagon -like peptide 1, or any combination thereof. In some embodiments, the additional therapeutic agent is a lipid-lowering agent.
[00206] In some embodiments, the additional therapeutic agent is an antioxidant, corticosteroid such as budesonide, anti-tumor necrosis factor (TNF), or a combination thereof.
[00207] In some embodiments, the additional therapeutic agent is administered at the same time as the compound disclosed herein. In some embodiments, the additional therapeutic agent and the compound disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered prior than the administration of the compound disclosed herein. In some embodiments, the additional therapeutic agent is administered after the administration of the compound disclosed herein.
EXAMPLE
Example 1: Synthesis of 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl) carbarn oyl)-lH- pyrazol-3-yl)picolinamide
Step 1: Synthesis of 3-amino-N-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide:
[00208] To a stirred solution of methyl 3-amino-lH-pyrazole-4-carboxylate (0.6 g, 4.25 mmol) and 1- [2-(trifluoromethyl)phenyl]methanamine (0.745 g, 4.25 mmol) in Toluene (3 mL) was added 2M trimethylaluminium in toluene (2.04 mL, 21.3 mmol) at 0°C. The resulting reaction mixture was stirred at 100°C for 32 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL) and extracted with Ethyl acetate (15 x 2 mL). The combined organic phase was washed
with brine solution (15 mL) and dried over anhydrous sodium sulphate, filtered, and evaporated in vacuo to obtain crude. The crude was purified through flash column chromatography to afford 3-amino-N-(2- (trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide (0.520 g, 43%) as a brown solid. LCMS (ES): m/z calculated for C12H11F3N4O, 284.24; found, 285.1(M+H).
Step 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl) carbamoyl)-lH- pyrazol-3-yl)picolinamide:
[00209] To a stirred solution of 3-amino-N-{[2-(trifluoromethyl)phenyl]methyl}-lH-pyrazole-4- carboxamide (0.5 g, 1.76 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.439 g, 2.11 mmol) in Acetonitrile (5 mL, 76.6 mmol) was added Phosphorous trichloride (0.164 mL, 1.76 mmol) at ambient temperature. The resulting reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (20 mL). The precipitated solid was filtered and dried under reduced pressure to afford crude solid. The resulting crude product was purified by reverse phase prep-HPLC to afford 4,6-dichloro-5-hydroxy-N-(4-((2- (trifluoromethyl)benzyl)carbamoyl)-lH-pyrazol-3-yl)picolinamide (0.093 g, 11 %) as an off-white solid. LCMS (ES): m/z calculated for C18H12C12F3N5O3; 473.03 found, 472.1 (M-H); 1H NMR (400 MHz, DMSO d6): 5 11.71 (s, 1H), 8.83 (t, J= 5.2 Hz, 1H), 8.21-8.16 (m, 1H), 8.10 (s, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.70-7.66 (m, 1H), 7.55-7.48 (m, 2H), 4.73-4.63 (m, 2H).
Example 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-4-((2-(trifluoromethyl) benzyl)carbamoyl)-lH-pyrazol-3-yl)picolinamide
Step 1: Synthesis of 3-amino-l-methyl-N-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide: [00210] To a stirred solution of methyl 3-amino-l-methyl-lH-pyrazole-4-carboxylate (0.4 g, 2.58 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (0.45 g, 2.58 mmol) in toluene (4 mL) was added 2 M trimethylaluminium in toluene (2.47 mL, 25.8 mmol) at 0 °C. The resulting reaction mixture was stirred at 100°C for 32 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL) and extracted with Ethyl acetate (15 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, filtered, and evaporated in vacuo to obtain crude. The crude was purified through flash column chromatography to afford 3- amino-l-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.5 g, 65.05 %) as a brown solid. LCMS (ES): m/z calculated for C13H13F3N4O, 298.27; found, 299.1(M+H) Step 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-4-((2-(trifluoromethyl)benzyl) carbamoyl)-lH-pyrazol-3-yl)picolinamide [00211] To a stirred solution of 3-amino-l-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-lH- pyrazole-4-carboxamide (0.5 g, 1.68 mmol) and 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (0.42
g, 2.01 mmol) in Acetonitrile (5 mL) was added Phosphorous trichloride (0.157 mL, 1.68 mmol) at ambient temperature. The resulting reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (20 mL). The precipitated solid was fdtered and dried under reduced pressure to afford crude. The resulting crude product was purified by reverse phase prep-HPLC to afford 4,6-dichloro-5-hydroxy-N-[l-methyl-4-({[2- (trifluoromethyl)phenyl]methyl}carbamoyl)-lH-pyrazol-3-yl]pyridine-2-carboxamide (0.073 g, 9 %) as a pale yellow solid. LCMS (ES): m/z calculated for C19H14C12F3N5O3, 487.04; found, 486.1 (M-H); 1H NMR (400 MHz, DMSO-d6): 5 11.47 s, 1H), 8.77 (t, J = 6.0 Hz, 1H), 8.27 (s, 1H), 8.05 (s,lH), 7.75 (d, J=8.0 Hz, 1H), 7.95-7.68 (m, 1H), 7.54-7.47 (m, 2H), 4.68-4.58 (m, 2H), 3.86 (s, 3H).
Example 3: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-N-(2-(trifluoromethyl) benzyl)-lH- pyrazole-4-carboxamide
[00212] To a stirred solution of 3-amino-N-{[2-(trifluoromethyl)phenyl]methyl}-lH-pyrazole-4- carboxamide (0.15 g, 0.528 mmol) and 3,5-dichloro-4-hydroxybenzoic acid (0.12 g, 0.580 mmol) in Acetonitrile (3 mL) was added Phosphorus trichloride (0.013 mL, 0.158 mmol) dropwise at room temperature. The resulting reaction mixture was heated to 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL), obtained solid was collected through fdtration, washed with diethyl ether (5 mL) and dried under reduced vacuum to afford crude as off white solid. The resulting crude product was purified by prep-HPLC (Column: XBridge C18 (250 mm x 4.6 mm x 5pm); Mobile phase (A): 0.1% TFA in Water; Mobile phase (B): Acetonitrile; Flow rate: 1.0 mL/min) to afford 3-(3,5-dichloro-4-hydroxybenzamido)-N-(2-(trifluoromethyl)benzyl)-lH- pyrazole-4-carboxamide (0.058 g, 23 %) as white solid. LCMS (ES) m/z calculated for C19H13C12F3N4O3 is 472.03; found, 473.1 (M+H), 98.63% at 254 nm. ‘H NMR (400 MHz, DMSO 76 at 90 °C) 3 8.4 (bs, 1H), 8.13 (bs, 1H), 7.85 (s, 2H), 7.70 (d, J= 7.6 Hz, 1H), 7.62-7.57 (m, 2H), 7.49- 7.47 (m, 1H), 4.63 (d, J= 24.8 Hz, 2H).
Example 4: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-3-((2-(trifluoromethoxy) benzyl)carbamoyl)-lH-pyrazol-4-yl)picolinamide
Step 1: Synthesis of methyl l-methyl-4-nitro-lH-pyrazole-3-carboxylate
[00213] To a stirred solution of methyl 4-nitro-lH-pyrazole-3-carboxylate (3 g, 17.5 mmol) in anhydrous dimethylformamide (25 mL) was added potassium carbonate (2.91 g, 21 mmol) at 0° C followed by iodomethane (2.99 g, 21 mmol) was added slowly over the period of 15 min. The resulting reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (30 mL) and extracted into ethyl acetate (20 mL x 2 times). The combined organic layer was washed with water (30 mL x 2 times), brine (20 mL x 2 times), dried over sodium sulfate and evaporated under reduced pressure to result in crude. The crude product was purified by flash chromatography to afford methyl l-methyl-4-nitro-lH-pyrazole-3-carboxylate (1.87 g, 58%) as off-white solid and methyl 1- methyl-4-nitro-lH-pyrazole-5-carboxylate (0.92 g, 28%) as yellow viscous solid respectively. LCMS (ES) m/z calculated for C6H7N3O4 is 185.04; found, 186.1 (M+H) .
Step 2: Synthesis of methyl 4-amino-l-methyl-lH-pyrazole-3-carboxylate
[00214] To a stirred solution of methyl l-methyl-4-nitro-lH-pyrazole-3-carboxylate (1.87 g, 10.1 mmol) in methanol (30 mL) was added Pd/C (0.45 g, 2.11 mmol) and then stirred at room temperature under hydrogen atmosphere for 3 h. The reaction mixture was filtered through pad of celite and washed with methanol (10 mL). The filtrate was concentrated under reduced pressure to result in crude compound which was triturated with w-pcntanc (10 mL), diethyl ether (10 ml) to afford methyl 4-amino- l-methyl-lH-pyrazole-3-carboxylate (1.2 g, 77%) as a black color solid.
Step 3: Synthesis of 4-amino-l-methyl-N-(2-(trifluoromethoxy)benzyl)-lH-pyrazole-3-carboxamide [00215] To a stirred solution of methyl 4-amino-l-methyl-lH-pyrazole-3-carboxylate (0.25 g, 1.61 mmol) and l-[2-(trifluoromethoxy)phenyl]methanamine (0.30 g, 1.61 mmol) in Toluene (5 mL) was added 2A7 trimethylaluminium in toluene (0.46 mL, 4.83 mmol) at 0 °C. The resulting reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL) and extracted with Ethyl acetate (15 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, fdtered, and evaporated in vacuo to obtain crude. The crude was purified through flash column chromatography to afford 4- amino-l-methyl-N-(2-(trifluoromethoxy)benzyl)-lH-pyrazole-3-carboxamide (0.17 g, 35 %) as pale yellow liquid. LCMS (ES) m/z calculated for C13H13F3N4O2 is 314.10; found, 315.1(M+H).
Step 4: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-3-((2-(trifluoromethoxy) benzyl)carbamoyl)-lH-pyrazol-4-yl)picolinamide
[00216] To a stirred solution of 4-amino-l-methyl-N-(2-(trifluoromethoxy)benzyl)-lH-pyrazole-3- carboxamide (0.14 g, 0.445 mmol) and 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (0.1 g, 0.490 mmol) in chlorobenzene (0.8 mL) was added Phosphorus trichloride (0.011 mL, 0.134 mmol) dropwise to at room temperature. The resulting reaction mixture was heated to 100 °C for 6 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL), obtained solid was collected through filtration, washed with diethyl ether (5 mL) and dried under reduced vacuum to afford crude as off white solid. The resulting crude product was purified by prep-HPLC to afford 4,6- dichloro-5-hydroxy-N-(l-methyl-3-((2-(trifluoromethoxy)benzyl)carbamoyl)-lH-pyrazol-4- yl)picolinamide (0.067 g, 30%) as off-white solid. LCMS (ES) m/z calculated for C19H14C12F3N5O4 is 503.04; found, 504.1 (M+H). 1H NMR (400 MHz, DMSO d6) 3 11.13 (s, 1H), 8.98 (t, J= 6.0 Hz, 1H), 8.43 (s, 1H), 8.07 (s, 1H), 7.43-7.36 (m, 4H), 4.55 (d, J= 6.0 Hz, 2H), 3.96 (s, 3H).
Example 5: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-5-((2- (trifluoromethoxy)benzyl)carbamoyl)-lH-pyrazol-4-yl)picolinamide
[00217] The title compound was synthesized as described above. LCMS (ES) m/z calculated for C19H14C12F3N5O4 is 503.04; found, 504.1 (M+H). 1H NMR (400 MHz, DMSO d6) 3 11.13 (s, 1H), 8.94 (t, J= 6.0 Hz, 1H), 8.43 (s, 1H), 8.07 (s, 1H), 7.43-7.36 (m, 4H) 4.55 (d, J= 6.0 Hz, 2H), 3.96 (s, 3H).
Example 6: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2- (trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide
Step 1: Synthesis of 3-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
[00218] To a stirred solution of 3,5-dichloro-4-methoxybenzoic acid (0.22 g, 1.01 mmol) in pyridine (2 mL) was added phosphoroyl trichloride (0.094 mL, 1.01 mmol) at 0 °C and allowed to stir at room temperature for 10 minutes. Then added 3-amino-l-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-lH- pyrazole-4-carboxamide (0.3 g, 1.01 mmol) and stirred for 30 minutes. Progress of the reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-cold water, extracted with ethyl acetate (3 mL x 2). The combined organic layer was washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate to afford crude compound which was purified through flash column chromatography to afford 3-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-{[2-
(trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.2 g, 40%) as white solid. LCMS (ES) m/z calcd, For C21H17C12F3N4O3, 500.06; found, 501.1 (M+H)
Step 2: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
[00219] To a stirred solution of 3-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-{[2- (trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.110 g, 0.219 mmol) in dichloromethane (0.5 m ) was added boranetribromide in dichloromethane (0.167 m , 1.76 mmol) was added at 0 °C and the reaction was allowed to stir at room temperature for 1 hour. Progress of the reaction was monitored by TEC and ECMS. After completion of the reaction, reaction mixture was quenched with ice-cold water and then extracted with DCM (3x5 mb). The combined organic layer was washed with water (3 mb x 2), brine (2 mb x 2), dried over sodium sulfate to afford crude compound which was purified flash column chromatography to afford off white solid. The solid material was further purified by reverse phase prep- HPEC to afford pure 3-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-{[2- (trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide as a white solid. (31 mg, 29%). ECMS(ES) m/z calculated for C20H15C12F3N4O3, 486.05; found, 487.1 (M+H), ‘H NMR (400 MHz, DMSO-t/6) 5 10.98 (s, 1H), 10.51 (s, 1H), 8.51 (t, J= 5.6 Hz, 1H), 8.22 (s, 1H), 7.83 (s, 2H), 7.70 (d, J= 7.6 Hz, 1H), 7.61 (t, J= 7.6 Hz, 1H), 7.53 (d, J= 7.6 Hz, 1H), 7.46 (t, J= 7.6 Hz, 1H) 4.58 (d, J= 5.6 Hz, 2H), 3.85 (s, 3H).
Example 7: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2- (trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide
Step 1: Synthesis of 5-amino-l-methyl-N-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide [00220] To a solution of methyl 5-amino-l-methyl-lH-pyrazole-4-carboxylate (0.4 g, 2.58 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (0.358 mb, 2.58 mmol) in toluene (5 mb, 42.3 mmol) was added 2M trimethylaluminium in toluene (0.741 mb, 3 eq., 7.73 mmol) at 0 °C. Then the reaction mixture was allowed to stir at 120 °C for 12 h. The reaction mixture was cooled to ambient temperature and poured into cold water, obtained solid material was fdtered off and fdtrate was extracted with DCM (3mb x 2). The combined organic phase was washed with water (2mb x 2), brine (2 mb x 2), dried over sodium sulfate and evaporated under reduced pressure to afford 5-amino-l-methyl-N-{[2- (trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.77g, quantitative). ECMS (ES) m/z calcd, For C13H13F3N4O, 298.10; found, 299.1 (M+H).
Step 2: Synthesis of 5-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
[00221] To a stirred solution of 3,5-dichloro-4-methoxybenzoic acid (0.0593 g, 0.268 mmol) in pyridine (1 mL) was added phosphoroyl trichloride (0.025 mL, 0.268 mmol) at 0 °C and allowed to stirred at room temperature for 10 minutes. To this stirred solution was added 5 -amino- 1 -methyl -N-{ [2- (trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.08 g, 0.268 mmol) and stirred for another 30 minutes. The reaction mixture was quenched with ice-cold water, extracted with ethyl acetate (3 mL x 2). The combined organic layer was washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate to afford crude compound which was purified through flash column chromatography to afford 5 -(3,5 -dichloro-4-methoxybenzamido)- 1 -methyl -N- { [2-(trifluoromethyl)phenyl]methyl} - 1H- pyrazole-4-carboxamide as a white solid (0.11 g, 82%). LCMS (ES) m/z calcd, For C21H17C12F3N4O3, 500.06; found, 501.0 (M+H).
Step 3: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-l-methyl-N-(2-(trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide
[00222] To a stirred solution of 5-(3,5-dichloro-4-methoxybenzamido)-l-methyl-N-{[2- (trifluoromethyl)phenyl]methyl}-lH-pyrazole-4-carboxamide (0.1 g, 0.199 mmol) in dichloromethane (0.556 mL) was added (0.151 mL, 1.6 mmol) was added at 0 °C and the reaction was allowed to stir at room temperature for 1 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was quenched with ice-cold water, extracted using DCM (3x5 mL). The combined organic layer was washed with water (3 mL x 2), brine (2 mL x 2), dried over sodium sulfate to afford crude compound which was purified through flash column chromatography to give an off white solid, which was further purified by reverse phase prep-HPLC to afford 5-(3,5-dichloro-4- hydroxybenzamido)- 1 -methyl -N- { [2-(trifluoromethyl)phenyl]methyl} - lH-pyrazole-4-carboxamide (5 mg, 5%) as white solid. LCMS(ES) m/z calculated for C20H15C12F3N4O3, 486.05; found, 487.1 (M+H); 1H NMR (400 MHz, DMSO-t/6) 5 11.01 (s, 1H), 10.31 (bs, 1H), 8.55 (t, J= 5.6 Hz, 1H), 8.00 (d, J= 6.4 Hz, 3H), 7.70 (d, J= 8 Hz, 1H), 7.61 (t, J= 7.6 Hz, 1H), 7.52 - 7.43 (m, 2H), 4.57 (d, J= 5.6 Hz, 2H), 3.65 (s, 3H).
Example 8: Synthesis of 4,6-dichloro-5-hydroxy-2V-(l-phenyl-4-((2-(trifluoromethyl) benzyl (carbamoyl)-! //-pyrazol-3-yl)picolinamide
Step 1: Synthesis of methyl 3-amino- l-phenyl- l//-pyrazole-4-carboxylate
[00223] A stirred solution of methyl 3-amino-lH-pyrazole-4-carboxylate (0.3 g, 2.13 mmol) in DMF (10 mL) was added iodobenzene (0.35 mL, 3.19 mmol), cesium carbonate (693 mg, 2.13 mmol) and copper bromide (30.5 mg, 0.213 mmol) and heated the reaction mass to 150°C in MW for 45 min. After completion of reaction, reaction mass was quenched with water (20mL) and extracted with ethyl acetate (20 mL), organic layer was collected and washed with water (20 mL), brine solution (20 mL), organic layer was dried over sodium sulphate and filtered and evaporated to get crude product which was purified by flash column chromatography to get pure methyl 3 -amino- 1 -phenyl- lH-pyrazole-4-carboxylate (0.3 g, 65%) as off-white solid. LCMS (ES) m/z calculated for Cl 1H11N3O2, 217; found, 218 (M+H) .
Step 2: Synthesis of methyl 3-(4,6-dichloro-5-hydroxypicolinamido)-l-phenyl-LH-pyrazole-4- carboxylate
[00224] A stirred solution of methyl 3 -amino- 1 -phenyl- lH-pyrazole-4-carboxylate (250 mg, 1.15 mmol) in chlorobenzene (5 mL) was added 4, 6-dichloro-5 -hydroxypicolinic acid (311 mg, 1.5 mmol), PCL (158 mg, 1.15 mmol) and heated the reaction mass to 130 °C for 4 h. After completion of reaction, reaction mass was cooled to room temperature and quenched with ice water (10 mL) and extract with ethyl acetate (10 mL), organic layer was collected and washed with water (10 mL), brine solution (10 mL). Organic layer was dried over sodium sulphate and filter and dried to get crude product, which was purified by flash column chromatography to get title product methyl 3-(4,6-dichloro-5- hydroxypicolinamido)-l -phenyl- lH-pyrazole-4-carboxylate (250 mg, 53%) as off-white solid. LCMS (ES) m/z calculated for C17H12C12N4O4, 406; found, 407 (M+H).
Step 3: Synthesis of 4,6-dichloro-5-hydroxy-2V-(l-phenyl-4-((2-(trifluoromethyl) benzyl)carbamoyl)-LH-pyrazol-3-yl)picolinamide
[00225] A stirred solution of methyl 3-(4,6-dichloro-5-hydroxypicolinamido)- 1 -phenyl- lH-pyrazole-4- carboxylate (220 mg, 0.540 mmol) in toluene (5 mL) was added (2- (trifluoromethyl)phenyl)methanamine (0.076 mL, 0.540 mmol) and cooled the reaction mass to 0°C and added trimethylaluminium 2.0 M in toluene (0.81 mL, 1.62 mmol) and heated the reaction mass to 100 °C for 2 h. Progress of the reaction was monitored by TLC and LCMS, after completion of reaction, reaction mass was cooled to room temperature and quenched with ice water (10 mL) and extract with ethyl acetate (20 mL) and dried over sodium sulphate to get crude product which was purified by flash column chromatography, fractions were collected and dried to get crude product which was further purified by prep-HPLC. LCMS (ES) m/z calculated for C24H16C12F3N5O3, 549.0; found, 550 (M+H). 1H NMR (400 MHz, DMSO-d6): 5 10.53 (s, 1H), 8.70-8.62 (m, 1H), 8.28 (s, 1H), 7.91 (s, 1H), 7.71 (d, J = 8.0Hz, 1H), 7.63- 7.60 (m, 1H), 7.56-7.53 (m, 3H), 7.49-7.45 (m, 3H), 7.40-7.38 (m, 1H), 4.60 (d, J = 5.2 Hz, 2H).
Example 9: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-l-phenyl-2V-(2- (trifluoromethyl)benzyl)-lH-pyrazole-4-carboxamide
[00226] The title compound was synthesized as described above. LCMS (ES): m/z calculated for C25H17C12F3N4O3, 548.0; found, 549 (M+H). 1H NMR (400 MHz, DMSO- 6): 5 11.00 (bs, 1H), 10.73
- 78 -
\
(s, 1H), 9.01 (s, 1H), 8.66 (t, J=5.6Hz, 1H), 7.94 (s, 2H), 7.87-7.80 (m, 2H), 7.73-7.68 (m, 1H), 7.64-7.62 (m, 2H), 7.61-7.57 (m, 2H), 7.50-7.47 (m, 1H), 7.40-7.37 (m, 1H), 4.63 (d, J=5.2Hz, 2H).
Example 10: Synthesis of 4,6-dichloro-5-hydroxy-JV-(l-methyl-4-((2-(trifluoromethyl) benzyl (carbamoyl)-! //-pyrazol-5-yl)picolinamide
Step 1: Synthesis of 5-amino-l-methyl-JV-(2-(trifluoromethyl)benzyl)-LH-pyrazole-4-carboxamide [00227] To a solution of methyl 5 -amino- 1 -methyl- lH-pyrazole-4-carboxylate (0.4 g, 2.58 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (0.358 mL, 2.58 mmol) in toluene (5 mL, 42.3 mmol), trimethylalumane (0.741 mL, 3 eq., 7.73 mmol) was added dropwise at 0 °C under nitrogen and stirred for some time. Then the reaction mixture was allowed to stir at 120 °C for 12 h. Progress of the reaction was monitored by TLC and LCMS. After reaction completion, the reaction mixture was quenched with ice chunks and the solid formed was filtered off. The aqueous layer was extracted with DCM (3 mL x 2). The combined organic layer was washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate and evaporated under reduced pressure to resulted in 5 -amino- 1 -methyl -A-(2- (trifluoromethyl)benzyl)- lH-pyrazole-4-carboxamide (0.77 g, 2.58 mmol). LCMS (ES) m/z calcd, For C13H13F3N4O, 298.10; found, 299.1 (M+H).
Step 2: Synthesis of 4,6-dichloro-5-hydroxy-JV-(l-methyl-4-((2-(trifluoromethyl)benzyl) carbamoyl)-LH-pyrazol-5-yl)picolinamide
[00228] To a stirred solution of 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.174 g, 0.838 mmol) in pyridine (2 mL) was added PCL (0.157 mL, 1.68 mmol) at 0 °C and allowed to stirred at room temperature for 15 min. After that 5-amino-l-methyl-A-(2-(trifluoromethyl)benzyl)-lH-pyrazole-4- carboxamide (0.25 g, 0.838 mmol) was added to it and stirred for 30 min. Progress of the reaction was monitored by TLC and LCMS. After reaction completion, the reaction mass was quenched with ice-cold water, extracted with ethyl acetate (5 mL x 2). The combined organic layer was washed with water (3 mL x 2), brine (4 mL x 2), dried over sodium sulfate to afford crude compound which was purified by Combi flash chromatography. Pure fractions were collected and concentrated to afford title compound which was further purified by reverse phase prep-HPLC. Pure fractions were collected and concentrated to afford pure 4,6-dichloro-5-hydroxy-A-( 1 -methyl -4-((2-(trifluoromethyl)benzyl) carbamoyl )- 1 H-pyrazol- 5-yl)picolinamide (0.012 g, 0.0246 mmol) as white solid. LCMS(ES) m/z calculated for C19H14C12F3N5O3, 487.04; found, 488.00 (M+H), 99.6% at 254 nm. ’H NMR (400 MHz, DMSO- 6) 5 10.41 (s, 1H), 8.59 - 8.57 (m,lH), 7.99 (d, J= 17.6 Hz, 2H), 7.67 (d, J= 8 Hz, 1H), 7.56 - 7.47 (m,lH), 7.48 - 7.42 (m, 2H), 4.54 (d, J= 4.4 Hz, 2H), 3.66 (s, 3H).
Example 11: Synthesis of 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4-dihydrobenzo[d] [1,2,3] triazin-5-yl)benzamide
Step 1: Synthesis of 2-amino-6-bromo-3-methyl-N-(2-(trifluoromethyl)benzyl)benzamide
[00229] To a stirred solution of 2-amino-6-bromo-3 -methylbenzoic acid (2 g, 8.69 mmol) in N,N- dimethylformamide (10 mL) was added by l-[2-(trifluoromethyl)phenyl]methanamine (1.23 mL, 8.69 mmol), triethylamine (4.24 mL, 30.4 mmol), HATU (3.97 g, 10.4 mmol) and A'. A'-dimcthylpyridin-4- amine (0. 106 g, 0.869 mmol) and allowed to stirred at room temperature for 2 h. The reaction was monitored by TLC. The reaction mixture was poured into water (40 mL) and extracted with ethyl acetate (2 x 75 mL). The combined organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography to afford 2-amino-6-bromo-3-methyl-N-(2-(trifluoromethyl)benzyl)benzamide (2 g, 59 %) as off white solid. LCMS (ES): m/z calculated for C16H14BrF3N2O, 386.02; found, 387.2
Step 2: Synthesis of 5-bromo-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d] [1,2,3] triazin-4(3H)- one
[00230] To a stirred solution of IM hydrogen chloride (72 mL) was added sodium nitrite (2.89 g, 41.8 mmol) portion wise 0°C and stirred for 20 min, then 2-amino-6-bromo-3-mcthyl-A'-(2- (trifluoromethyl)benzyl)benzamide (5.4 g, 13.9 mmol) in N, A'-dimcthylformamidc (4 mL) was added at 0 °C and allowed to stirred for Ih. The reaction was monitored by TLC. After adjusting the pH to about 9 with concentrated ammonia, reaction mixture was stirred for 20 minutes and then adjust the pH to about 2 with concentrated hydrochloric acid, and continued stirring for another 20 min. The precipitated solid was filtered and washed with hexane (25 mL), dried to obtain 5-bromo-8-methyl-3-(2- (trifluoromethyl)benzyl)benzo[d][l,2,3] triazin-4(3H)-one (3.4 g, 61 %) as orange solid. LCMS (ES): m/z calculated for C16Hl lBrF3N3O, 397.18; found, 398.
Step 3: Synthesis of tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[</] [l,2,3]triazin-5-yl)carbamate
[00231] To a suspension of 5-bromo-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[<7][ 1,2,3 ] triazin- 4(327)-one (3.4 g, 8.54 mmol), tert-butyl carbamate (1.10 g, 9.39 mmol) and cesium carbonate (8.35 g, 25.6 mmol) in 1,4-dioxane (80 mL, 1.04 mmol) was degassed with nitrogen and added Xanthphos (0.49
g, 0.854 mmol) and Pd(dba)2 (0.491 g, 0.854 mmol) at room temperature and stirred at 100 °C for 16 h in a sealed tube. The progress of the reaction was monitored by LCMS and TLC. After completion, reaction mixture was quenched with water and compound was extracted with ethyl acetate. Organic layer was washed with brine solution, dried over anhydrous sodium sulphate, filtered, and evaporated under vacuum to obtain crude solid. The crude was purified through flash column chromatography to afford tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][l,2,3]triazin-5- yl)carbamate (2.1 g, 56 %) as off white solid. LCMS (ES): m/z calcd. C21H21F3N4O3, 434.42; found, 435.1
Step 4: Synthesis of 5-amino-8-methyl-3-(2-(trifluoromethyl) benzyl) benzo[d] [1,2,3] triazin-4(3H)- one.
[00232] To a suspension of tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[d][l,2,3]triazin-5-yl)carbamate (2 g, 4.76 mmol) in methanol (3.12 m , 77.1 mmol) was added 4M HC1 in dioxane (0.826 m , 23.8 mmol) at room temperature. The resulting reaction mixture was stirred at ambient temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford 5-amino-8-methyl-3-(2-(trifluoromethyl) benzyl) benzofd] [1,2,3] triazin- 4(3H)-one (1.4 g, 92 %) as a yellow solid. LCMS (ES): m/z calculated for C16H13F3N4O, 334.30; found, 335.1.
Step 5: Synthesis of 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[</] [l,2,3]triazin-5-yl)benzamide
[00233] To a suspension of 5-amino-8-methyl-3-(2-(trifluoromethyl) benzyl) bcnzo|t/|| 1.2.31 triazin- 4(3//)-onc (0.350 g, 1.05 mmol) in Acetonitrile (5 mL) was added 3,5-dichloro-4-hydroxybenzoic acid (0.238 g, 1.15 mmol) and Phosphorus trichloride (0.916 mL, 1.05 mmol) at ambient temperature. The resulting reaction mixture was heated to 130°C for 3 h. The reaction mixture was cooled to ambient temperature and then poured into ice cold water (20mL) and extracted with ethyl acetate (lOmL x 3). The combined organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified through prep-HPLC to afford 3,5-dichloro-4- hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo \d\ [l,2,3]triazin-5- yl)benzamide (0.010 g, 2 %) as white solid. LCMS (ES): m/z calculated for C23H15C12F3N4O3, 522.05; found 521.1 (M-H); 1H NMR (400 MHz, DMSO-d6): 5 12.29 (s, 1H), 11.15 (bs, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.00 (d, J= 8.4 Hz, 1H), 7.84-7.80 (m, 3H), 7.62-7.52 (m, 2H), 7.31 (d, J=8 Hz, 1H), 5.78 (s, 2H), 2.72 (s, 3H).
Example 12: Synthesis of 4,6-dichloro-5-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)- 3,4-dihydrobenzo [d] [1 ,2,3]triazin-5-yl)picolinamide
[00234] To a suspension of 5-amino-8-methyl-3-(2-(trifhioromethyl) benzyl) benzo[d][l,2,3] triazin- 4(3H)-one (0.35 g, 1.05 mmol) in acetonitrile (5 m ) was added 4,6-dichloro-5-hydroxypyridine-2- carboxylic acid (0.240 g, 1.15 mmol) and Phosphorus trichloride (0.09 m , 1.05 mmol) at ambient temperature. The resulting reaction mixture was heated to 130 °C for 3 h. The reaction mixture was cooled to ambient temperature and then poured into ice cold water (20mL) and extracted with ethyl acetate (lOmL x 3). The combined organic phase was washed with water, brine and dried over anhydrous sodium sulfate, fdtered, and concentrated in vacuo. The crude product was purified through prep-HPLC to afford 4,6-dichloro-5-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4-dihydrobenzo [d] [ 1,2,3] triazin-5 -yl)picolinamide (0.006 g, 1.8 %) as white solid. LCMS (ES): m/z calculated for C22H14C12F3N5O3, 523.04; found 524.1 (M+H); 1H NMR (400 MHz, DMSO-d6): 5 13.05 (s, 1H), 9.0 (d, J= 8.4 Hz, 1H), 8.09 (s, 1H), 7.97 (d, J= 8.8 Hz, 1H), 7.82 (t, J=7.6 Hz, 1H), 7.61-7.51 (m, 2H), 7.30 (d, J=8 Hz, 1H), 5.76 (s, 2H), 2.71 (s, 3H).
Example 13: Synthesis of 4,6-dichloro-JV-(8-fluoro-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4- dihydrobenzo[</| [1,2,3] triazin-5-yl)-5-hydroxypicolinamide
Step 1: Synthesis of 2-amino-6-bromo-3-fluoro-JV-(2-(trifluoromethyl)benzyl) benzamide
[00235] To a stirred solution of 2-amino-6-bromo-3 -fluorobenzoic acid (1 g, 4.27 mmol) in DMF (15 mb) was added l-[2-(trifluoromethyl) phenyl]methanamine (0.604 mb, 4.27 mmol), triethylamine (2.08 mb, 15 mmol), HATU (1.95 g, 5.13 mmol), N,N-dimethylpyridin-4-amine (0.052 g, 0.427 mmol) and allowed to stirred at room temperature for 16 h. The reaction was monitored by TLC. The reaction mixture was poured into water (40 mb) and extracted with ethyl acetate (150 mb). The organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered, and concentrated in
vacuo. The crude material was purified by flash column chromatography to afford 2-amino-6-bromo-3- fluoro-A'-(2-(trifliioromcthyl (benzyl (benzamide (1.5 g, 89.74%) as off white solid. LCMS (ES): m/z calculated for C15Hl lBrF4N2O, 390.0; found, 391.0.
Step 2: Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) benzo[d] [1,2,3] triazin-4(3/7)- one
[00236] To a stirred solution of sodium nitrite (1.06 g, 15.3 mmol), add IM solution ofHCL (25 mL) dropwise at 0°C and stir for 20 min, then was added by 2-amino-6-bromo-3-fluoro-JV-{[2-
(trifl uoromcthyl (phenyl | methyl [benzamide (2 g, 5. 11 mmol) dissolved in DMF (10 mL) and allowed to stirred at 0°C for Ih. The reaction was monitored by TLC. Then adjust the pH to about 9 with concentrated ammonia, stir for 20 minutes and then adjust the pH to about 2 with concentrated hydrochloric acid, and continue stirring for 20 minutes. After the reaction is completed, suction filtration is performed, the filter cake is washed with a small amount of Hexane, and dried to obtain 5-bromo-8- fluoro-3-(2-(trifluoromethyl) benzyl) benzo[<7][l,2,3] triazin-4(327)-one (0.6 g, 29 %) as orange solid. LCMS (ES): m/z calculated for C15H8BrF4N3O, 400.98; found, 402.0.
Step 3: Preparation of tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4- dihydrobenzo[<Z] [1,2,3] triazin-5-yl)carbamate
[00237] To a suspension of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) bcnzo|r/|| 1.2.31 triazin- 4(3H)-one (0.2 g, 0.497 mmol), tert-butyl carbamate (0.117g, 0.995 mmol) and cesium carbonate (0.486 g, 1.49 mmol) in 1,4-dioxane (5.15 mL, 60.4 mmol) was degassed with nitrogen and added Xantphos (0.0288 g, 0.0497 mmol), Pd(dba)2 (0.0286 g, 0.0497 mmol) at room temperature and stirred at 100 °C for 16 h in a sealed tube. The progress of the reaction was monitored by LCMS and TLC. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20mL x 3). The organic phase was washed with water (10 mL), brine (3ml) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography to afford tertbutyl (8-fluoro-4-oxo-3-(2-(trifliioromcthyl )bcnzyl)-3.4-dihydrobcnzoft/| 1 1.2.3 |triazin-5-yl (carbamate (0.130 g, 59.6%) as colorless liquid. LCMS (ES): m/z calcd. C20H18F4N4O3, 438.34; found, 439.1.
Step 4: Synthesis of 5-amino-8-fluoro-3-(2-(trifluoromethyl) benzyl) benzo [</] [1,2,3] triazin-4(3/7)- one
[00238] To a suspension of tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[<7][l,2,3]triazin-5-yl)carbamate (0.130 g, 0.297 mmol) in methanol (5 ml) and was added 4M HC1 in dioxane (0.0515 mL, 1 .48 mmol) was allowed to stirred at RT for 16 h. The reaction mixture was poured into water (20mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography to afford 5- amino-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[<7][l,2,3]triazin-4(327)-one (0.095 g, 94%). LCMS (ES): m/z calculated for C15H10F4N40, 338.27; found, 339.1
Step 5: Synthesis of 4,6-dichloro-5-hydroxy-JV-(8-methyl-4-oxo-3-(2-(trifluoromethyl) benzyl)-3,4- dihydrobenzo[</| [1,2,3] triazin-5-yl)picolinamide
- 83 -
\
[00239] To a suspension of 5-amino-8-fluoro-3-(2-(trifluoromethyl) benzyl) bcnzo|t/|| I .2.31 triazin- 4(3//)-onc (0.130 g, 0.384 mmol) in acetonitrile (5 ml) was added 4,6-dichloro-5-hydroxypyridine-2- carboxylic acid (0.0879 g, 0.423 mmol) and phosphorous trichloride (33.6 pL, 0.384 mmol) was allowed to stirred at 120°C for 3 h. The reaction was monitored by TLC. The reaction mixture was poured into water(20mL) and extracted with ethyl acetate (lOmL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by Prep HPLC. Pure fractions were collected and concentrated to afford 4,6- dichloro-/V-(8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[<7][l,2,3]triazin-5-yl)-5- hydroxypicolinamide (0.007 g, 3.45%) as white solid. rH NMR (400 MHz, DMSO-dg): 5 12.90 (s, 1H), 9.14-9.10 (m, 1H), 8.10-8.04 (m, 2H), 7.86 (d, J= 7.6 Hz, 1H), 7.64-7.54 (m, 2H), 7.38 (d, J= 8 Hz, 1H), 5.80 (s, 2H). LCMS (ES) m/z calculated for C21H11C12F4N5O3, 527.02; found 528.1 (M+H).
Example 14: Synthesis of 3,5-dichloro-2V-(8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4- dihydrobenzo[d] [l,2,3]triazin-5-yl)-4-hydroxybenzamide
[00240] The title compound was synthesized as described above. LCMS (ES) m/z calculated for C22H12C12F4N4O3, 526.02; found, 527.0 (M+H); ‘H NMR (400 MHz, DMSO- 6) 5 12.03 (s, 1H), 11.22 (s, 1H), 8.90 (d, J= 9.2 Hz, 1H), 8.07 (t, J= 9.6 Hz, 1H), 7.85-7.81 (m, 3H), 7.61-7.51 (m, 2H), 7.36 (d, J= 8 Hz, 1H), 5.78 (s, 2H).
Example 15: Synthesis of 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)- 3,4-dihydroquinazolin-5-yl)-5-hydroxypicolinamide
Step 1: Synthesis of 2-amino-6-bromo-3-fluoro-N-((lS,2R)-2-phenylcyclobutyl) benzamide
[00241] To a stirred solution of 2-amino-6-bromo-3 -fluorobenzoic acid (0.5 g, 2.14 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.89 mL, 6.41 mmol), HATU (0.75 g, 3.2 mmol) and (lS,2R)-2-phenylcyclobutan-l -amine (315 mg, 2.14 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 2 h. The reaction mixture was poured into water (25 mL) and extracted into ethyl acetate (2 x 50 mL). The combined organics were washed with water (10 mL) and brine solution (10 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced vacuum to afford crude which was purified through flash column chromatography to afford 2-amino-6- bromo-3-fluoro-N-((lS,2R)-2-phenylcyclobutyl)benzamide (0.62 g, 80%) as an off white solid. LCMS (ES) m/z calculated for C17H16BrFN2O, 362.04; found, 363.0 (M+2H).
Step 2: Synthesis of 5-bromo-8-fluoro-2-methyl-3-((lS,2R)-2-phenylcyclobutyl) quinazolin-4(3/7)- one
[00242] To a stirred solution of 2-amino-6-bromo-3-fluoro-N-[(lS,2R)-2-phenylcyclobutyl]benzamide (619 mg, 1.7 mmol) in toluene (6 mL) was added p-TSA (58.7 mg, 0.341 mmol) and pentane-2, 4-dione (0. 192 mL, 1.87 mmol) at room temperature. The resulting reaction mixture was heated to 120 °C for 16 hours in a sealed tube. After completion, the reaction mixture was quenched with water (25 mL) and extracted into ethyl acetate (2 x 50 mL). The combined organics were washed with water (20 mL) and brine solution (20 mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced vacuum to afford the crude 5-bromo-8-fluoro-2-methyl-3-((lS,2R)-2-phenylcyclobutyl)quinazolin- 4(3H)-one (0.62 g, 94%) as a brown solid. LCMS (ES) m/z calculated for C19H16BrFN2O, 387.05; found, 389.1 (M+2H).
Step 3: Synthesis of tert-butyl (8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4- dihydroquinazolin-5-yl)carbamate
[00243] To a stirred solution of 5-bromo-8-fluoro-2-methyl-3-[(lS,2R)-2-phenylcyclobutyl]-3,4- dihydroquinazolin-4-one (0.5 g, 1.29 mmol) in 1,4-dioxane (3 mL) was added tert-butyl carbamate (454 mg, 3.87 mmol) and cesium carbonate (1.26 g, 3.87 mmol). The mixture was purged with N2 for 10 min followed by Xanthphos (0.15 g, 0.258 mmol) and Pd(dba)2 (74.2 mg, 0.129 mmol) was added and heated to 100 °C for 16 hr. The reaction mixture was filtered through celite pad, washed with Ethyl acetate (30 mL), the filtrate was evaporated to give crude which was purified through flash column chromatography to afford tert-butyl (8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5- yl)carbamate (0.33 g, 60%) as an off white solid. LCMS (ES) m/z calculated for C24H26FN3O3,423.20; found, 424.2 (M+H).
Step 4: Synthesis of 5-amino-8-fluoro-2-methyl-3-((lS,2R)-2-phenylcyclobutyl) quinazolin-4(3H)- one
[00244] To a solid tert-butyl N-{8-fluoro-2-methyl-4-oxo-3-[(lS,2R)-2-phenylcyclobutyl]-3,4- dihydroquinazolin-5-yl}carbamate (0.33 g, 0.779 mmol) was added 4M HC1 in Dioxane (1.95 mL) at 0 °C under nitrogen atmosphere. The reaction mixture was heated to 80 °C for 2 hours. After completion, the reaction mixture was evaporated to dryness under reduced pressure to get solid, which was further triturated with n-pentane (20 mL) and dried to afford 5-amino-8-fluoro-2-methyl-3-((lS,2R)-2- phenylcyclobutyl)quinazolin-4(3H)-one (0.2 g, 79%) as a white solid. LCMS (ES) m/z calculated for C19H18FN3O, 323.14; found, 324.1 (M+H).
Step 5: Synthesis of 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4- dihydroquinazolin-5-yl)-5-hydroxypicolinamide
[00245] To a stirred solution of hydroxypyridine 5-amino-8-fluoro-2-methyl-3-[(lS,2R)-2- phenylcyclobutyl]-3,4-dihydroquinazolin-4-one (150 mg, 0.464 mmol) in acetonitrile (2 mL) was added 4,6-dichloro-5- -2-carboxylic acid (0.092 g, 0.18 mmol) and Phosphorus trichloride (0.041 mL, 0.464 mmol). The resulting reaction mixture was heated at 100 °C for 3 hours in a sealed tube. After completion, reaction mixture was quenched with ice cold water (15 mL) and stirred for 5 minutes,
- 85 -
\
obtained solid was collected through filtration. The solid material was washed with n-pentane (10 mL) and Acetonitrile (10 mL), dried under reduced pressure to afford 4,6-dichloro-N-(8-fluoro-2-methyl-4- oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-5-hydroxypicolinamide (0.092 g, 39%) as an off white solid. LCMS (ES) m/z calculated for C25H19C12FN4O3, 512.08; found, 513.1 (M+H).
HNMR (400 MHz, DMSO-t/6) 5 13.54 (s, 1H), 8.72-8.68 (m, 2H), 8.12 (s, 1H), 7.70-7.65 (m, 1H), 7.35- 7.28 (m, 4H), 7.22-7.19 (m, 1H), 4.95-4.90 (m, 1H), 4.81-4.76 (m, 1H), 2.40 (s, 3H), 2.36-2.25 (m, 2H), 2.01-1.96 (m, 2H).
Example 16: Synthesis of 3,5-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)- 3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
12 hrs
[00246] To a stirred solution of 5-amino-8-fluoro-2-methyl-3-[(lS,2R)-2-phenylcyclobutyl]-3,4- dihydroquinazolin-4-one (90 mg, 0.278 mmol) and 3,5-dichloro-4-hydroxybenzoic acid (69.1 mg, 0.334 mmol) in chlorobenzene (3.0 mL) was added Phosphorus trichloride (0.024 mL, 0.278 mmol) at 0 °C under nitrogen atmosphere. The resulting reaction mass was heated to 130 °C for 12 hours. The reaction mixture was quenched with ice cold water (10 mL) and stirred for 5 minutes, obtained solid was collected through filtration. The solid was washed with n-pentane (10 ml) and dried under reduced vacuum to afford crude as a pale yellow solid. The crude material was purified through Prep-HPLC to afford 3,5-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((lS,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin- 5-yl)-4-hydroxybenzamide (0.030 g, 21%) as an off white solid. LCMS (ES) m/z calculated for C26H20C12FN3O3, 511.09; found, 512.1 (M+H). HNMR (400 MHz, DMSO-t/6) 5 12.73 (s, 1H), 11.17 (s, 1H), 8.56-8.53 (m, 1H), 7.93 (s, 2H), 7.70-7.65 (m, 1H), 7.34-7.18 (m, 5H), 4.97-4.93 (m, 1H), 4.76- 4.69 (m, 1H), 3.25-3.15 (m, 2H), 2.42 (s, 3H), 2.38-2.25 (m, 2H), 1.99-1.94 (m, 1H).
Example 17: Preparation 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
Step 1: Preparation of l-(cyclopropylidenemethyl)-2-(trifluoromethyl) benzene
[00247] To a stirred solution of 2-(trifluoromethyl) benzaldehyde (10 g, 57.4 mmol) (1) in tetrahydrofuran (150 mL) was added (3 -bromopropyl) triphenyl phosphonium bromide (29.3 g, 63.2 mmol) followed by Potassium tert-butoxide (19.3 g, 172 mmol) and then stirred at 70 °C for 2 h. The reaction mixture was cooled to ambient temperature and poured into cold water (50 mL), extracted with ethyl acetate (3 x 45 mL). The combined organic layer was dried over sodium sulphate, filtered, and concentrated to afford crude. The crude was purified through flash column chromatography to afford 1- (cyclopropylidenemethyl)-2-(trifluoromethyl) benzene as yellowish oil (2.5 g, 22%). 1H NMR (4OO MHz, CDCh): 3 7.96 (d, J= 8.0 Hz, 1H), 7.63 (d, J= 8.0 Hz, 1H), 7.48 (t, J= 7.6 Hz, 1H), 7.32-7.25 (m, 1H),7.12 (s, 1H), 1.2-1.5 (m, 4H).
Step 2: Synthesis of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one
[00248] To a stirred solution of l-(cyclopropylidenemethyl)-2-(trifluoromethyl) benzene (1.2 g, 6.05 mmol in dichloromethane (10 mL) was added m-CPBA (1.25 g, 7.27 mmol) at 0°C. After completion of addition, the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with cold water (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layer was washed with aqueous saturated sodium bicarbonate solution (25 mL) and dried over sodium sulphate, filtered and concentrated to afford crude. The crude was purified through flash column chromatography to afford 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one as yellowish oil (0.5 g, yield: 39 %). 1H NMR (400 MHz, CDC13): 37.67 (d, J= 8.0 Hz, 1H), 7.43-7.58 (m, 2H), 7.38 (t, J= 7.6 Hz, 1H), 4.90 (t, J= 8.8 Hz, 1H), 3.25-3.4 (m, 1H), 3.12-3.18 (m, 1H), 2.6-2.7 (m, 1H), 2.08-2.2 (m, 1H).
Step 3: Synthesis of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one oxime
[00249] To a stirred solution of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one (4) (0.365 g, 1.7 mmol) in ethanol (10 mL) was added hydroxylamine hydrogen chloride (0.355 g, 5.11 mmol) and potassium carbonate (0.707 g, 5.11 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. the reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), combined organic layer was dried over sodium sulphate, filtered, and concentrated to afford 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one oxime (0.4 g, yield: 102%) as crude yellow solid. LCMS (ES) z calculated for C11H10F3NO, 229.07; found 230.1 (M+H);
Step 4: Synthesis of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-amine
[00250] To a stirred solution of 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-one oxime (0.4 g, 1.75 mmol) in THF: MeOH (4: 1) (12mL) was added nickel chloride hexahydrate (0.083 mg, 0.349 mmol) followed by sodium borohydride (0.330 mg, 8.73 mmol) addition portion wise at 0°C under inert atmosphere, after complete addition the reaction was stirred at ambient temperature for 1 h. the reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), combined organic layer was dried over sodium sulphate, filtered and concentrated to afford 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-amine (6) as a yellow viscous solid (0.215 g, 57%). LCMS (ES)m/z calculated for C11H12F3N, 215.09; found 216.1 (M+H).
Step 5: Synthesis of 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) benzamide
[00251] To a stirred solution of 2-amino-6-bromo-3 -methylbenzoic acid (7) (0.2 g, 0.869 mmol) in N, N-dimethylformamide (5 mL) was added triethylamine (0.422 mL, 3.04 mmol) followed by HATU (0.661 g,1.74 mmol) at 0°C under inert atmosphere and stirred for 5 min, then to this solution was added 2-(2-(trifluoromethyl) phenyl) cyclobutan-l-amine (6) (0.187 g, 0.869 mmol) and then stirred at room temperature for 16 h. the reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), combined organic layer was dried over sodium sulphate, filtered and concentrated to afford crude. The crude was purified through flash column chromatography to afford 2- amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) benzamide as a yellow viscous solid (0.1 g, 26.92%). LCMS (ES)m/z calculated for C19H18BrF3N2O, 426.06; found 427.0 (M+H).
Step 6: Synthesis of 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) quinazolin- 4(3H)-one
[00252] To a stirred solution of 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) benzamide (0.090 g, 0.211 mmol) in toluene (1 mL) was added pentane-2, 4-dione (0.031 g, 0.316 mmol) and p-TSA (0.008 g, 0.042 mmol). The resulting reaction mixture was stirred at 100°C for 1 h. The reaction mixture was concentrated under reduced pressure to get residue. The residue was dissolved in ethyl acetate (25 mL) and washed with sat. sodium bicarbonate solution (15 mL), water (15 mL) and then organic layer was dried over sodium sulphate, filtered, and concentrated to afford crude 5- bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) quinazolin-4(3H)-one (0.090 g, yield:
- 88 -
\
95%) as a yellow viscous solid. LCMS (ES) m/z calculated for C21H18BrF3N2O, 450.06; found 451.1 (M+H).
Step 7: Preparation 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl) phenyl)cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
[00253] To a stirred solution of 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl) quinazolin-4(3H)-one (9) (0.075 g, 0.166 mmol) in 1,4-dioxane (7.5 mL) was added 3,5-dichloro-4- hydroxybenzamide (10) (0.034 mg, 0.166 mmol) and potassium t-butoxide (0.056 g, 0.499 mmol), the reaction mixture was degassed for 10 min using argon gas, then to this solution was added Xantphos (0.0192 g, 0.033 mmol) and Bis(dibenzylideneacetone)palladium(0) (0.0191 g, 0.033 mmol) at room temperature. The resulting reaction mixture was heated to 100 °C for Ih, the reaction mixture was cooled to room temperature and to it was added ice cold water (15 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layer was dried over sodium sulphate, filtered, and concentrated to afford crude. The crude was purified through flash column chromatography to afford 3,5-dichloro-N-(2,8- dimethyl-4-oxo-3-(2-(2-(trifluoromethyl) phenyl) cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4- hydroxybenzamide as off-white solid (0.008 g, 8%). LCMS (ES) m/z calculated for C28H22C12F3N3O3, 575.10; found 576.2 (M+H); 1H NMR (4OO MHz, DMSO-t/6) 3 12.41 (s, IH), 11.1 (s, IH), 8.36 (d, J = 8.4 Hz, IH), 7.65-7.8 (m, 2H), 7.53 (d. J= 8.4 Hz, IH), 7.37 (d, J= 8.0 Hz, 2H), 7.26 (t, J= 7.2 Hz, IH), 7.16 (t, J= 7.6 Hz, IH), 5.41-5.45 (m, IH), 4.60-4.64 (m, IH), 3.0-3.10 (m, IH), 2.65-2.8 (m, IH), 2.57 (s, 3H), 2.37 (s, 3H), 1.2-1.3 (m, IH), 1.15 (t, J=7.2Hz, IH).
Example 18: Synthesis of 4,6-dichloro-2V-(l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l,2,3,4- tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
Stepl: Synthesis of 5-bromo-3-{[2-(trifluoromethyl)phenyl]methyl}-l,2,3,4-tetrahydro quinazoline- 2, 4-dione
[00254] To a solution of 5-bromo-2//-bcnzo|t/|| 1,3 ]oxazine-2,4( l//)-dionc (5 g, 20.7 mmol) in THF
(40 mL) was added (2-(trifluoromethyl)phenyl)methanamine (3.62 g, 20.7 mmol) and triethylamine (6.7 mb, 2.5 eq., 51.6 mmol) at ambient temperature. The resulting reaction mixture was heated to 80 °C for Ih, cooled to room temperature and diluted with ethyl acetate (50 mL) and water (30 mL) and extracted
- 89 -
\
into ethyl acetate. The organic layer was dried over Na2SC>4 and concentrated to obtain a brown oil. The viscous compound was dissolved in THF (10 mL) cooled to 0°C, then Triphosgene (3.07 g, 0.5 eq., 10.3 mmol) was added and stirred at ambient temperature for 30 min, then triethylamine was added to the stirred solution and continued the stirring for another 2 h, the solid material was removed from the reaction mixture by fdtration. The fdtrate was concentrated and dried to give brown solid which was triturated with diethyl ether (10 mL) to get 5-bromo-3-(2-(trifluoromethyl)benzyl)quinazoline- 2,4(lH,327)-dione as off white solid (5 g, 60% yield). LCMS (ES) m/z calculated for C16H10BrF3N2O2 397.99 found, 399.0.
Step 2: Synthesis of 5-bromo-l-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2, 4(1/7, 3/7)-dione [00255] To a solution of 5-bromo-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4( lH,327)-dione (0.5 g, 1.25 mmol) in 5 mL of dimethylformamide was added potassium carbonate (0.26 g, 1.88 mmol), potassium iodide (0.05 g, 0.301 mmol) and bromoethane (0.13 g, 1.25 mmol). The resulting reaction mixture was heated at 120 °C for 16 h, cooled to room temperature and diluted with ethyl acetate (30 mL) and water (20 mL) and extracted into ethyl acetate (2 x 20 mL). The organic layer was dried over Na2SC>4 and concentrated to a obtain residue which was triturated with diethyl ether (20 mL) to afford pure 5-bromo-l-ethyl-3-(2-(trifhioromethyl) benzyl)quinazoline-2,4(lH,327)-dione (0.5 g, 93 %) as an off white solid. LCMS (ES) m/z calculated for C18H14BrF3N2O2 426.0; found, 427.0.
Step 3: Synthesis of tert-butyl (l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate
[00256] To a stirred solution of 5-bromo-l-ethyl-3-(2-(trifluoromethyl) benzyl)quinazoline- 2,4(lH,327)-dione (1 g, 2.34 mmol) and tert-butyl carbamate (0.27g, 2.34 mmol) in 1,4-dioxane (5 mL) and cesium carbonate (1.53 g, 4.68 mmol) was degassed with nitrogen for 10 min, then added Pd(dba)2 (0.067 g, 0.117 mmol) and Xanthphos (0.13 g, 0.234 mmol). The resulting reaction mixture was stirred at 100 °C for 5 h. Progress of the reaction was monitored by LCMS. After the completion of the reaction, reaction mixture was filtered through celite and filtrate was diluted with ethyl acetate (50 mL) and washed with water (30 mL) and the organic layer was dried over Na2SO4 and concentrated to get residue which was triturated with diethyl ether (20 mL) to get pure tert-butyl (l-ethyl-2,4-dioxo-3-(2- (trifluoromethyl)benzyl)-l,2,3,4-tetrahydroquinazolin-5-yl)carbamate (0.6 g, 55 %). LCMS (ES) m/z calculated for C23H24F3N3O4 463.17; found, 364.1(M-Boc).
Step 4: Synthesis of 5-amino-l-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(l//,3//)-dione [00257] To a stirred solution of tert-butyl (l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate (0.6 g, 1.29 mmol) in dichloromethane (5 mL) was cooled to 0 °C and added HC1 in dioxane (5 mL) and the reaction was stirred at ambient temperature for 2 h. Progress of the reaction was monitored by TLC/ LCMS. After completion of reaction, reaction mixture was concentrated and triturated with diethyl ether (10 mL) to get pure 5-amino-l-ethyl-3-(2- (trifluoromethyl)benzyl)quinazoline-2,4( lH,327)-dione (450 mg, 95 % yield) as off white solid. LCMS (ES) m/z calculated for C18H16F3N3O2 363.2; found, 364.1 (M+H).
- 90 -
\
Step 5: Synthesis of 4,6-dichloro-2V-(l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l,2,3,4- tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[00258] To a solution of 5-amino- l-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4( l//.3//)-dionc (0.2 g, 0.55 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.11 g, 0.55 mmol) in chlorobenzene (2 mL) was added PCL (0.075 g, 0.550 mmol). The reaction mixture was heated at 120 °C for 3 h. The progress of the reaction was monitored by TLC/LCMS. After the completion of the reaction, reaction mixture was diluted with ethyl acetate (10 mL) and washed with water (10 mL x 2), aqueous bicarbonate solution (10 mL) and the combined organic layer was concentrated to get residue which was purified by reverse phase prep-HPLC. Pure fractions were collected and concentrated to afford 4,6- dichloro-A-(l-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l,2,3,4-tetrahydroquinazolin -5-yl)-5- hydroxypicolinamide (54 mg, 18 % yield) as white solid. LCMS (ES) m/z calculated for C24H17C12F3N4O4 553.36; found, 553.1 (M+H). 1H NMR (400 MHz, DMSO-d6) 3 13.54 (s, 1H), 8.64 (d, J= 8 Hz, 1H), 8.08 (s, 1H), 7.82-7.7.5 (m, 2H), 7.53 (t, J= 7.6 Hz, 1H), 7.45 (t, J= 8 Hz, 1H), 7.30- 7.22 (m,lH), 7.21 (d, J= 9.2 Hz, 1H), 5.33 (s, 2H), 4.17 (q, J= 6.8 Hz, 2H), 1.23 (t, J= 6.8 Hz, 3H).
Example 19: Synthesis of 4,6-dichloro-2V-(8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl) benzyl)-l,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
Step-6
Step 1: Synthesis of 5-bromo-8-fluoro-2/f-benzo[rZ|[l,3] oxazine-2, 4(1 //(-dione
[00259] A stirred solution of 2-amino-6-bromo-3 -fluorobenzoic acid (0.5 g, 2.14 mmol) in THF (6 mL) was added triphosgene (0.63 g, 2. 14 mmol) at -10°C for 30 min, then it was stirred for 1 h at -10 to -5 °C, followed by 16 hours at room temperature. After completion, the reaction mixture was evaporated under
reduced vacuum to afford the residue to which diethyl ether (3x50 mL) was added and stirred for 5 min, obtained solid was collected through fdtration, the solid was triturated with diethyl ether (25 mL) and evaporated to dryness to afford 5-bromo-8-fhioro-2H-benzo[d][l,3] oxazine-2, 4( 17/)-dionc (0.4 g, 72%) as light yellow colored solid. LCMS (ES) m/z calcd, For C8H3BrFNO3, 258.93; found, 259.9 (M+H). Step 2: Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) quinazoline-2, 4(1/7, 3//)-dione [00260] To a solution of 5-bromo-8-fluoro-2H-benzo[d][l,3] oxazine-2, 4( l//)-dionc (0.4 g, 1.54 mmol) in tetrahydrofuran (10 mL) was added with l-[2-(trifluoromethyl)phenyl]methanamine (0.21 mL, 1.54 mmol) and triethylamine (0.24 mL) dropwise. The reaction mixture was heated at 80 °C for 2 h. After completion, reaction mixture was cooled to room temperature and quenched with water (50 mL) and extracted into ethyl acetate (3x50 mL). The combined organics were washed with water (10 mL) and brine solution (10 mL) dried over Na2SC>4, filtered, and concentrated under reduced vacuum to afford a brown oil. The oil was dissolved in Tetrahydrofuran (10 mL) cooled to 0°C, then Triphosgene (0.22 g, 0.76 mmol) was added. The reaction mixture was stirred at room temperature for 30 min then was added with triethylamine (0.24 mL). The reaction mixture was stirred at room temperature for 2 h and filtered. The filtrate was concentrated and dried to give 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) quinazoline-2, 4( 1/7, 3/7)-dione (0.6 g, 93.5%) as yellow solid. LCMS (ES) m/z calcd, For C16H9BrF4N2O2, 415.98; found, 417.0 (M+H).
Step 3: Synthesis of 5-bromo-8-fluoro-l-methyl-3-(2-(trifluoromethyl) benzyl) quinazoline- 2, 4(1/7, 3/0-dione
[00261] To a stirred solution of 5-bromo-8-fluoro-3-(2-(trifluoromethyl) benzyl) quinazoline- 2,4(l//,377)-dione (0.7 g, 1.68 mmol) in N, A-dimcthylformamidc (7 mL) was added with potassium carbonate (0.69 g, 5.03 mmol) and stirred at room temperature for 15 min. Then iodomethane (0.15 mL, 2.52 mmol) was added to the reaction mixture and was stirred at room temperature for 1 h. After completion, water (25 mL) was added and it was extracted with ethyl acetate (3 x 25 mL). The combined organics were washed with brine solution (15 mL) and dried over anhydrous sodium sulfate, filtered and dried under reduced vacuum to afford 5-bromo-8-fluoro-l-methyl-3-(2-(trifluoromethyl) benzyl) quinazoline-2,4(17/,3/7)-dione 5 (0.5 g, 69.1%) as off white solid. LCMS (ES) m/z calcd, For C17H1 lBrF4N2O2, 431.2; found, 432.0 (M+H).
Step 4: Synthesis of tert-butyl (8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-l, 2,3,4- tetrahydroquinazolin-5-yl)carbamate
[00262] To a stirred solution of 5-bromo-8-fluoro-l-methyl-3-(2-(trifluoromethyl) benzyl) quinazoline- 2,4(l//,3/7)-dione (0.2 g, 0.464 mmol) and tert-butyl carbamate (0.16 g, 1.39 mmol) in 1,4-dioxane (3 mL) was added with cesium carbonate (0.45 g, 1.39 mmol). The reaction mixture was degassed with nitrogen and was added with Xantphos (0.053 g, 0.92 mmol) and Pd(dba)2 (0.026 g, 0.46 mmol). The reaction mixture was heated to 100 °C for 12 h. The reaction mixture was filtered through celite pad, washed with ethyl acetate (2 x 50 mL), the filtrate was evaporated under reduced pressure to afford crude tert-butyl (8 -fluoro- l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)- 1,2,3, 4-tetrahydroquinazolin-5-
- 92 -
\
yl)carbamate (0.5 g, 92 %) as off white solid. LCMS (ES) m/z calcd, For C22H21F4N3O4, 467.15; found, 368.1 (M- Boc H).
Step 5: Synthesis of 5-amino-8-fluoro-l-methyl-3-(2 (trifluoromethyl) benzyl) quinazoline- 2,4(1 //,3//)-dione
[00263] To a stirred solution of tert-butyl (8-fhioro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-
1.2.3.4-tetrahydroquinazolin-5-yl)carbamate (0.5 g, 1.07 mmol) in 1,4-dioxane was added 4M HC1 in
1.4-Dioxane (5 mL) at room temperature and then stirred at same temperature for 16 h. After completion of the reaction, the reaction mixture was evaporated under reduced vacuum to afford yellow colored solid, the solid was triturated with diethyl ether (25 mL) and evaporated to dryness to afford 5-amino-8- fluoro-l-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(lH,327)-dione (0.3 g, 76%) as light yellow colored solid. LCMS (ES) m/z calcd, For C17H13F4N3O2, 367.09; found, 368.1 (M+H).
Step 6: Synthesis of 4,6-dichloro-N-(8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl) benzyl)-
1.2.3.4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[00264] To a stirred solution of 5-amino-8-fluoro-l-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline- 2,4(lH,327)-dione (0.15 g, 0.408 mmol) and 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (0.084 mg, 0.40 mmol) in chlorobenzene (2 mL) was added with trichlorophosphane (0.025 mL, 0.286 mmol) at 0 °C under nitrogen atmosphere and was heated to 130°C for 3 h. After completion, the reaction mass was quenched with ice cold water (15 mL) and stirred for 5 min, obtained solid was collected through filtration, washed with diethyl ether (2x15 mL) and dried under reduced vacuum to afford crude as a yellow colored solid. The crude solid material was purified through prep-purification. Collected fractions were lyophilized to afford 4,6-dichloro-N-(8-fluoro-l-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)- l,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide (0.045 g, 20%) as an off white solid. LCMS (ES) m/z calcd, For C23H14C12F4N4O4, 556.03; found, 555.1 (M-H); 1H NMR (400 MHz, DMSO-t/6) 513.42 (s, 1H), 8.65-8.61 (m, 1H), 8.07 (s, 1H), 7.77-7.72 (m, 2H), 7.56-7.52 (m, 1H), 7.48-7.44 (m,lH), 7.31-7.29 (m, 1H), 5.31 (s, 2H), 3.68 (d, J=9.2 Hz, 3H).
Example 20: Synthesis of 4,6-dichloro-5-hydroxy-N-(l-methyl-2,4-dioxo-3-(2- (trifluoromethyl)benzyl)-l,2,3,4-tetrahydroquinazolin-5-yl)picolinamide
[00265] The title compound was synthesized as described above. LCMS (ES) m/z calculated for C23H15C12F3N4O4 calculated for 538.04; found, 539.1 (M+H). ’H NMR (400 MHz, DMSO-t/6) 5 13.52 (s, 1 H), 8.65 (d, J= 8.4 Hz, 1H), 8.08 (s, 1H), 7.83 - 7.75 (m, 2H), 7.55 - 7.40 (m, 2H), 7.25 - 7.22 (m, 2H), 5.33 (s, 2 H), 3.54 (s, 3H).
Example 21: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide
Step 1: Synthesis of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide [00266] To a stirred solution of 5-amino-2-methylthiazole-4-carboxylic acid (0.5 g, 3.16 mmol) in tetrahydrofuran (5 mL) was added HATU (2.4 g, 6.32 mmol), triethylamine (2.2 mL, 15.8 mmol) and (2- (trifluoromethoxy)phenyl)methanamine (0.6 g, 3.16 mmol) at ambient temperature. The resulting reaction mixture was stirred for 16 h at ambient temperature. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction the reaction mixture was quenched with ice cold water (20 mL) and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to result in crude compound which was purified through flash column chromatography to afford 5-amino-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide as a yellow liquid (0.88 g, 84 %). LCMS (ES) m/z calcd. C13H12F3N3O2S, 331.0; found, 332.1(M+1).
Step 2: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide:
[00267] To a stirred solution of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4- carboxamide (0.4 g, 1.21 mmol) in Chlorobenzene (5 mL) was added phosphorus trichloride (52.8 pL, 0.604 mmol) and 3,5-dichloro-4-hydroxybenzoic acid (275 mg, 1.33 mmol) and allowed to stirred at 130°C for 2 h. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction, the reaction mixture was quenched with ice cold water (20 mL) and filtered to result in crude compound which was purified through Flash column chromatography to get off-white solid. The solid was further triturated with hot methanol (10 mL) to afford 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide as a white solid (0.05 g, 8%). LCMS (ES) m/z calcd.C20H14C12F3N3O4S, 519.0; found, 52O.1(M+1).1H NMR (400 MHz, DMSO t/6) 3 12.31 (s, 1H), 11.32 (s, 1H), 9.11 (t, J= 8.0 Hz, 1H), 7.82 (s, 2H), 7.45-7.35 (m, 4H), 4.59 (d, J= 4.0 Hz, 2H), 2.65 (s, 3H).
Example 22: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-methyl-N-(2- (trifluoromethoxy) benzyl)thiazole-4-carboxamide
[00268] To a stirred solution of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4- carboxamide (0.4 g, 1.21 mmol) in Chlorobenzene (5 mL) was added Phosphorus trichloride (52.8 pL, 0.604 mmol) and 4,6-dichloro-5-hydroxypicolinic acid (0.27 g, 1.33 mmol) at ambient temperature. The resulting reaction mixture was heated to 130 °C for 2 h. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction, the reaction mixture was quenched with ice water (20
mL). Precipitated solid was filtered and dried to get off white solid. The solid material was purified through Plash column chromatography to afford 5-(4,6-dichloro-5-hydroxypicolinamido)-2-methyl-N-(2- (trifluoromethoxy)benzyl)thiazole-4-carboxamide as a white solid (0.051 g, 8 %). LCMS (ES) m/z calcd. C19H13C12F3N4O4S, 520.00; found, 521.1(M+1); 1H NMR (4OO MHz, DMSO t/6) 3 12.64 (s, 1H), 9.0 (t, J= 4 Hz, 1H), 8.09 (s, 1H), 7.40 - 7.32 (m, 4H), 4.55 (d, J= 8.0 Hz, 2H), 2.62 (s, 3H).
Example 23: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-phenyl-N-(2 (trifluoromethyl)benzyl)thiazole-4-carboxamide
Stepl: Synthesis of ethyl 2-amino-2-cyanoacetate
[00269] To a stirred solution of (E)-(ethyl cyano(hydroxyimino)formate) (5 g, 35.2 mmol) in acetic acid (50 mL) was added zinc (11 .5 g, 5 eq., 176 mmol) portion-wise at ambient temperature. The reaction mixture was stirred at ambient temperature for 30 minutes. The reaction progress was monitored by TLC. After completion of the reaction, the mixture was filtered through celite, washed with dichloromethane (200 mL). The filtrate was evaporated under reduced pressure to afford ethyl 2-amino-2-cyanoacetate (4 g) as an orange viscous solid. The crude compound was used for the next step without purification.
Step2: Synthesis of ethyl 2-cyano-2-(phenylformamido)acetate
[00270] To a stirred solution of ethyl 2-amino-2 -cyanoacetate (4 g, 31.2 mmol) in dichloromethane (50 mL) was added benzoyl chloride (4.83 g, 34 mmol) and triethylamine (7.9 g, 78 mmol) at 0 °C. The reaction was allowed to stir for 2 h at ambient temperature. The reaction progress was monitored by TLC. After completion of the reaction, the mixture was diluted with dichloromethane (50 mL), washed with water (100 mL) and brine solution (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to get crude product. Purification by flash chromatography afforded ethyl 2-cyano-2-(phenylformamido) acetate as yellow solid (1 g, 13% yield). LCMS (ES) m/z calculated for C12H12N2O3 232.08; found, 233.1.
Step3: Synthesis of ethyl 5-amino-2-phenyl-l,3-thiazole-4-carboxylate
[00271] To a stirred solution of ethyl 2-cyano-2-(phenylformamido)acetate (1 g, 4.31 mmol)in toluene (20 mL) was added Lawesson's reagent (5.22 g, 3 eq., 12.9 mmol). The resulting reaction mixture was heated to reflux for 18 hr. The reaction progress was monitored by TLC and LCMS. After completion,
reaction mixture was diluted with Ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (3 x 50 mL). The organic phase was dried over anhydrous sodium sulfate, fdtered, and evaporated to get a residue. Which was purified by flash chromatography to afford as ethyl 5-amino-2- phenyl-l,3-thiazole-4-carboxylate as a yellow solid (400 mg, 37%). LCMS (ES) m/z calculated for C12H12N2O2S 248.06; found, 249.1.
Step 5: Synthesis of 5-amino-2-phenyl-N-{[2-(trifluoromethyl)phenyl]methyl}-l,3-thiazole-4- carboxamide
[00272] To a stirred solution of ethyl 5-amino-2-phenyl-l,3-thiazole-4-carboxylate (0.25 g, 1.01 mmol) and l-[2-(trifhioromethyl)phenyl]methanamine (0.21 g, 1.21 mmol) in Toluene (1 mL) was added 2 M trimethylaluminium in toluene (2 mL, 4 mmol). The reaction mixture was heated at 100 °C for 1 h. The reaction mixture was cooled to ambient temperature and quenched with ice cold water (15 mL) and extracted with Ethyl acetate (25 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, fdtered, and evaporated in vacuo to obtain crude brown solid which was triturated with diethyl ether (10 mL) to afford 5-amino-2-phenyl-N-{[2- (trifhroromethyl)phenyl]methyl}-l,3-thiazole-4-carboxamide (0.2 g, 52% yield). LCMS (ES) m/z calculated for C18H14E3N3OS 377.3; found, 378.1
Step 6: Synthesis of Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-phenyl-N-(2 (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00273] To a stirred solution of 5-amino-2-phenyl-N-{[2-(trifluoromethyl)phenyl]methyl}-l,3-thiazole- 4-carboxamide (0.2 g, 0.53 mmol)and 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (110 mg, 0.53 mmol) in Chlorobenzene (2 mL) was added Phosphorous trichloride (72.8 mg, 0.53 mmol) at ambient temperature. The resulting reaction mixture was heated at 120 °C for 3 h. The progress of reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL) and washed with water (10 mLx2), aqueous bicarbonate solution (10 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure to get crude residue which was purified by reverse phase prep-HPLC to afford 4,6-dichloro-5-hydroxy-N-[2-phenyl-4-({[2- (trifluoromethyl)phenyl]methyl}carbamoyl)-l,3-thiazol-5-yl]pyridine-2-carboxamide as a pale yellow solid (0.07 g, 22% yield). LCMS (ES) m/z calculated for C24H15C12L3N4O3S 566.02 found, 565.1 (M- H). 1H NMR (400 MHz, DMSO d6) 5 12.73 (s, 1H), 9.25 (d, J= 6 Hz, 1H), 8.13 (s, 1H), 8.04 (d, J=7.2 Hz, 2H), 7.74 (d, J= 8 Hz, 1H), 7.66 - 6.63 (m, 1H), 7.54-7.47 (m, 5H), 4.75 (d, J= 4.8 Hz, 2H).
Example 24 : 5-(4,6-dichloro-5-hydroxypicolinamido)-N-(l-(2-(trifluoromethyl)phenyl) cyclopropyl)thiazole-4-carboxamide
Step 1: Synthesis of l-(2-(trifluoromethyl)phenyl)cyclopropan-l-amine
[00274] To as stirred solution of 2-(trifluoromethyl)benzonitrile (5 g, 29.2 mmol) and titanium tetraisopropoxide (13.3 mL, 43.8 mmol) in diethyl ether (50 mL, 481 mmol) was added IM ethylmagnesium bromide in diethyl ether (73 mL, 73 mmol) at -78 °C under nitrogen atmosphere and then reaction mixture was slowly rise to 0 °C for Ih. To this was added boron trifluoride diethyl etherate (9.02 mL, 73 mmol) dropwise at 0 °C. The reaction mixture was allowed to stir at ambient temperature for 1 hr. Then the reaction mixture was cooled to 0 °C, added with 4N HC1 (50 mL) and to stirred at ambient temperature for another 1 hr. Then the reaction mixture cooled to 0 °C, diluted with diethyl ether (100 mL) and was added 20% Aq NaOH (80 mL). The reaction mixture was stirred at ambient temperature for 1 hr. The layers were separated, organic layer was washed with cold 4N HC1 (2X25 mL). The aqueous layer was basified by using cold 20% Aq NaOH (pH =10) and extracted with diethyl ether (2X100 mL). The organic layer was dried over anhydrous sodium sulfate, fdtered, and concentrated under reduced pressure at ambient temperature to afford l-[2-(trifluoromethyl)phenyl]cyclopropan-l- amine (3 g, 14.9 mmol) as yellow liquid.. LCMS (ES) m/z calcd, For C10H10F3N, 201.08; found, 202.1 (M+H).
Step 2: Synthesis of 5-amino-N-(l-(2-(trifluoromethyl)phenyl)cyclopropyl)thiazole-4-carboxamide [00275] To a stirred solution of 5-amino-l,3-thiazole-4-carboxylic acid (0.2 g, 1.39 mmol) and l-[2- (trifluoromethyl)phenyl]cyclopropan-l-amine (279 mg, 1.39 mmol) and triethylamine (0.5 mL 4.16 mmol) in tetrahydrofuran (4 mL) was added HATU (633 mg, 1.66 mmol). The reaction mixture was stirred at ambient temperature for 3 h. After completion, reaction mixture was diluted with Ethyl acetate (50 mL), washed with water (2x20 mL) and brine solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, fdtered, and evaporated to get crude product. Which was purified through flash column chromatography, collected fractions were judged by TLC, pure fractions were combined and evaporated under reduced pressure to afford 5-amino-N-{ l-[2-(trifluoromethyl)phenyl]cyclopropyl}-
l,3-thiazole-4-carboxamide (0.3 g) as off-white solid. LCMS (ES) m/z calcd, Lor C14H12L3N3OS, 327.07; found, 328.1 (M+H).
Step 3: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-(l-(2-(trifluoromethyl) phenyl)cyclopropyl)thiazole-4-carboxamide
[00276] To a stirred suspension 5-amino-N-{ l-[2-(trifluoromethyl)phenyl]cyclopropyl}-l,3-thiazole-4- carboxamide (0.1 g, 0.306 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (95.3 mg, 1.5 eq., 0.458 mmol) in acetonitrile (5 mL) at 0 °C under nitrogen atmosphere was added Phosphorus trichloride (42 mg, 0.306 mmol). The reaction mixture was heated to 100 °C for 16 hr. After completion, reaction mixture was diluted with Ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (20 mL), water (20 mL) and brine solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to get crude product. Purification by prep HPLC afforded 4,6-dichloro-5-hydroxy-N-[4-({ l-[2-(trifluoromethyl) phenyl] cyclopropyl (carbamoyl) -1,3- thiazol-5-yl]pyridine-2-carboxamide (0.05 g, 31%) as white solid. LCMS (ES) m/z calcd, Lor
C20H13C12L3N4O3S, 516.00; found, 515.1 (M-H); 1H NMR (4OO MHz, DMSO-t/6) 5 12.49 (s, 1H),
8.67 (s, 1H), 8.34 (s, 1H), 8.12 (s, 1H), 8.05 (d, J= 7.6 Hz, 1H), 7.71-7.67 (m, 2H), 7.53-7.49 (m, 1H),
1.45 (m, 2H), 1.33 (m, 2H).
Example 25: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2-
Step-4
Step 1: Synthesis of tert-butyl (2-(trifluoromethyl)benzyl)carbamate
[00277] To a stirred solution of 2-(trifluoromethyl)benzaldehyde (1 g, 5.74 mmol) in methanol (10 mL, 247 mmol) was added methanamine (3.19 mL, 28.7 mmol) and allowed to stir at room temperature for 30 min. After 30 minutes, reaction mass was cooled to 0°C and added Sodium borohydride (0.43 g, 11.5 mmol) portion-wise and stirred at room temperature for 2 hours. To the reaction mixture was added triethylamine (2.4 mL, 17.2 mmol), A. A-dimcthylpyridin-4-aminc (0.14 g, 1.15 mmol) and di-tert-butyl dicarbonate (1.98 mL, 8.61 mmol) and allowed to stir at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure to remove methanol. The residue was quenched with water (50 mL) and extracted into Ethyl acetate (20 mL x 2). The combined organic layer was washed
with brine (20 mL ), dried over sodium sulfate and evaporated under reduced pressure to result in crude tert-butyl (2-(trifluoromethyl)benzyl)carbamate (0.8 g, 48%) as a gummy solid. LCMS (ES) m/z calculated for C13H16F3NO2 is 275.11; found, 275.1 (M+H) .
Step 2: Synthesis of N-methyl-l-(2-(trifluoromethyl)phenyl)methanamine
[00278] To a stirred solution of tert-butyl (2-(trifluoromethyl)benzyl)carbamate (0.8 g, 2.77 mmol) in 4 M HC1 in 1, 4 Dioxane (1.01 g, 10 eq., 27.7 mmol) was allowed to stir at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the residue was washed with di-ethyl ether (10 mL) to afford '-mcthyl- 1 -(2-(trifluoromethyl)phenyl)methanamine (0.6 g, 92%) as an off- white solid. LCMS (ES) m/z calculated for C9H11C1F3N is 225.05; found, 190. 1 (M+H) .
Step 3: Synthesis of 5-amino-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide [00279] To a stirred solution of methyl 5-amino-l,3-thiazole-4-carboxylate (0.25 g, 1.58 mmol), methyl({[2-(trifluoromethyl)phenyl]methyl})amine hydrochloride (0.428 g, 1.9 mmol) and triethylamine (0.22 mL, 1.58 mmol) in toluene (2 mL, 16.9 mmol). The mixture was cooled to 0 °C and added trimethylalumane (0.455 mL, 4.74 mmol). The resulting reaction mixture was heated to 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with water (15 mL) and extracted into ethyl acetate (2 x 30 mL). The combined organics were washed with brine solution (2 x 10 mL), dried over sodium sulfate, fdtered, and evaporated under reduced pressure to afford crude. The crude product was purified by Combi flash chromatography to afford 5-amino- '-mcthyl- '-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide (0.24 g, 48 %) as off-white solid. LCMS (ES) m/z calculated for C13H12F3N3OS is 315.07; found, 316.1 (M+H) .
Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00280] To a stirred solution of 5-amino-JV-methyl-JV-{[2-(trifluoromethyl)phenyl ]methyl } -1,3- thiazole-4-carboxamide (0.220 g, 0.698 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.16 g, 0.767 mmol) in chlorobenzene (4 mL) were added trichlorophosphane (0.018 mL, 0.209 mmol) dropwise to the reaction mixture at room temperature. Then the reaction was stirred at 130 °C for 2 hours. The reaction mixture was cooled to ambient temperature and quenched into ice-cold water (10 mL) and resulting mixture was extracted into ethyl acetate (5 mL x 2). The combined organic layer was washed with brine (3 mL x 2), dried over sodium sulfate, and evaporated under reduced pressure to result in crude. The resulting crude product was purified by prep-HPLC to afford 5-(4,6-dichloro-5- hydroxypicolinamido)-JV-methyl-JV-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.048 g, 13 %) as white solid. LCMS (ES) m/z calculated for C19H13C12F3N4O3S is 504.00; found, 505.1 (M+H). ’H NMR (400 MHz, DMSO 76 at 90 °C) 3 12.78 (bs, 1H), 8.61 (s, 1H), 8.09 (s, 1H), 7.76 (d, J= 7.6 Hz, 1H), 7.66 (t, J= 7.6 Hz, 1H), 7.52-7.46 (m, 3H), 5.34 (bs, 2H), 3.05 (s, 3H).
Example 59: Synthesis of 2-cyclopropyl-5-(4,6-dichloro-5-hydroxypicolinamido)-JV-(2-
Step 1: Synthesis of methyl 5-((/e/7-butoxycarbonyl)amino)-2-cyclopropylthiazole-4-carboxylate [00282] To a stirred solution of methyl 5-bromo-2-cyclopropylthiazole-4-carboxylate (0.5 g, 1.91 mmol) and tert-butyl carbamate (0.223 g, 1.91 mmol) in 1,4-dioxane (10 mL) was added cesium carbonate (1.24 g, 3.82 mmol) and degassed with nitrogen for 10 min, followed by Pd(dba)2 (0.054 g, 0.095 mmol), Xanthphos (0.11 g, 0.19 mmol) were added and stirred at 100°C for 16 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered, and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography to afford methyl 5-((tert- butoxycarbonyl)amino)-2-cyclopropylthiazole-4-carboxylate (0.3 g, 52% yield). LCMS (ES) m/z calcd. for; C13H18N2O4S 298.10; found, 243.1. (M-‘bu).
Step 2: Synthesis of tert-butyl (2-cyclopropyl-4-((2-(trifluoromethyl)benzyl)carbamoyl) thiazol-5- yl)carbamate
[00283] To a solution of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-cyclopropyl-l,3-thiazole-4- carboxylate (0.2 g, 0.670 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (0.141 g, 0.804 mmol) in toluene (4 mL) was added 2 M trimethylaluminium in toluene (2 mL, 2 mmol) at 0°C. The reaction mixture was heated at 100°C for 1 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with Ethyl acetate (25 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, fdtered, and evaporated in vacuo to obtain crude brown solid which was triturated with diethyl ether (10 mL) to afford tert-butyl (2-cyclopropyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.120 g, 40% yield). LCMS (ES) m/z calcd. for C20H22E3N3O3S 441.13; found, 342.1 (M-Boc).
Step 3: Synthesis of 5-amino-2-cyclopropyl-2V-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide [00284] To a stirred solution of tert-butyl N-[2-cyclopropyl-4-({[2- (trifluoromethyl)phenyl]methyl}carbamoyl)-l,3-thiazol-5-yl]carbamate (0.120 g, 0.272 mmol) in dichloromethane (2 mL) was cooled to 0°C and then added 4 M HC1 in 1,4 dioxane (2 mL). The resulting reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was concentrated under reduced pressure and the residue obtained was triturated with diethyl ether (10 mL) to afford 5-amino-2- cyclopropyl-N-{[2-(trifluoromethyl)phenyl] methyl}-l,3-thiazole-4-carboxamide (0.090 g, 97% yield). LCMS (ES) m/z calcd. for; C15H14E3N3OS 341.08; found, 342.1 (M+H).
Step 4: Synthesis of 2-cyclopropyl-5-(4,6-dichloro-5-hydroxypicolinamido)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00285] To a solution of 5-amino-2-cyclopropyl-N-{[2-(trifluoromethyl)phenyl]methyl}-l,3-thiazole- 4-carboxamide (0.080 g, 0.234 mmol) and 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (0.048 g, 0.234 mmol) in chlorobenzene (1 mL) was added phosphorous trichloride (0.032 g, 0.234 mmol). The resulting reaction mixture was heated at 120°C for 1 h. The progress of reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL) and washed with water (10 mLx2), brine solution (10 mL). The organic phase was dried over Na2SC>4, concentrated under reduced pressure to get crude residue which was purified by flash column chromatography to afford 4,6-dichloro-N-[2-cyclopropyl-4-({[2-(trifluoromethyl)phenyl] methyl}carbamoyl)-l,3-thiazol-5-yl]-5-hydroxypyridine-2-carboxamide (0.032 g, 25 % yield) as off white solid. LCMS (ES): m/z C21H15C12E3N4O3S calcd. for 530.0; found, 531.1 (M+H); 1H NMR (400 MHz, DMSO- tf): 3 12.60 (s, 1H), 8.95 (t, J= 6 Hz, 1H), 8.10 (s, 1H), 7.75 (d, J=7.6 1H), 7.66 (t, J =12 Hz, 1H) 7.50-7.46 (m, 2H), 4.71 (d, J= 6Hz, 2H), 2.38-2.33 (m, 1H), 1.20-1.14 (m, 4 H).
Example 60: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-A-(2- (trifluoromethyl) benzyl) thiazole-4-carboxamide
Step 1: Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate [00286] To a stirred solution of methyl 5-amino-2-bromothiazole-4-carboxylate (1 g, 4.22 mmol) in tetrahydrofuran (20 mL, 246 mmol) was added di-tert-butyldicarbonate (1.45 mL, 6.33 mmol), DIPEA (2.2 mL, 12.7 mmol) and DMAP (0.520 g, 4.22 mmol) at ambient temperature and then stirred at same temperature for another 2 h. The reaction mixture was poured into water (40mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with water, brine and dried over anhydrous sodium sulfate, fdtered, and concentrated in vacuo to get crude. The crude material was purified by flash column chromatography to afford methyl 2-bromo-5-((tert- butoxycarbonyl)amino)thiazole-4-carboxylate (0.9 g, 63%) as white solid. LCMS (ES): m/z calcd. for C10H13BrN2O4S, 335.98; found, 337.0.
Step 2: Preparation of methyl 5-((ter/-butoxycarbonyl) amino)-2-(2-fluorophenyl) thiazole-4- carboxylate
[00287] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (0.460 g, 1.36 mmol) and (2-fluorophenyl)boronic acid (0.382 g, 2.73 mmol) in 1,4 -dioxane: water 8:2 (6 mL) was added and potassium carbonate (0.566 g, 4.09 mmol) and degassed with nitrogen for 10 min, followed by bis(tri-tert-butylphosphane) palladium (0.0697 g, 0.136 mmol) was added and stirred at 100°C for 16 h. Progress of the reaction was monitored by TLC/ LCMS. After completion of the reaction, the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered, and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4- carboxylate (0.350 g, 73%) as brown solid. LCMS (ES): m/z calcd. for C16H17FN2O4S, 352.09; found, 353.1.
Step 3: Preparation of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl) benzyl) carbamoyl) thiazol-5-yl) carbamate
[00288] To a stirred solution of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4- carboxylate (0.3 g, 0.851 mmol) in toluene (5 mL) was added l-[2-(trifluoromethyl)phenyl]methanamine (0.119 mL, 0.851 mmol) and 2 M trimethylaluminium in toluene (0.245 mL, 2.55 mmol) at 0°C. The resulting reaction mixture was stirred at 100°C for 16 hours. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (25 mL) and extracted with Ethyl acetate (25 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, fdtered, and evaporated in vacuo to obtain crude. The crude material was purified by flash column chromatography to afford tert-butyl (2-(2-fluorophenyl)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.3 g, 71%) as off white solid. LCMS (ES): z calcd. C23H21F4N3O3S, 495.1; found, 496.1.
Step 4: Preparation of 5-amino-2-(2-fluorophenyl)-2V-(2-(trifluoromethyl) benzyl) thiazole-4- carboxamide
[00289] To a suspension of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl) carbamoyl)thiazol-5-yl)carbamate (0.250 g, 0.505 mmol) in methanol (1 mL) was added 4M HC1 in dioxane (5 mL, 144 mmol) at 0°C and then allowed to stirred at RT for 2 h. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 5-amino-2-(2-fluorophenyl)-JV-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.170 mg, 85%) as a white solid. LCMS (ES): m/z calcd. for C18H13F4N3OS, 395.07; found, 396.1.
Step 5: Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-2V-(2- (trifluoromethyl) benzyl) thiazole-4-carboxamide
[00290] To a suspension of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4- carboxamide (0.175 g, 0.443 mmol) in chlorobenzene (5 mL) was added 4,6-dichloro-5- hydroxypyridine-2-carboxylic acid (0.101 g, 0.487 mmol) and phosphorous trichloride (0.0387 mL, 0.443 mmol). The resulting reaction mixture was heated at 120°C for 3 h. The progress of reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL) and washed with water (10 mL x 2), brine solution (10 mL). The organic phase was dried over Na2SC>4, concentrated under reduced pressure to get crude residue which was purified by flash column chromatography Na2SC>4 to afford 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)- N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.015 g, 6%) as a white solid. LCMS (ES): m/z C24H14C12F4N4O3S calcd. for 584.0; found, 585.1 (M-H); 1H NMR (400 MHz, DMSO-t/tf): 5 12.74 (s, 1H), 9.37 (t, J= 6 Hz, 1H), 8.51-8.47 (m, 1H), 8.15 (s, 1H), 7.78 (d, J= 7.6 Hz, 1H), 7.68 (t, J=7.6 Hz, 1H), 7.58-7.39 (m, 5H), 4.81 (d, J= 6 Hz, 2H).
Example 78: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l,l-dioxidothiomorpholino)-
Step 1: Synthesis of methyl 5-amino-2-bromothiazole-4-carboxylate
[00292] To a stirred solution of methyl 5-aminothiazole-4-carboxylate (0.7 g, 4.43 mmol) in tetrahydrofuran (7 mL, 86 mmol) was added N-bromosuccinimide (0.86 g, 4.87 mmol) at 0°C and then reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with ice water (30 ml) and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over sodium sulfate and evaporated under reduced pressure to result in crude which was purified by flash chromatography to afford methyl 5-amino-2-bromothiazole-4- carboxylate as a brown solid (0.960 g, 92 %). LCMS (ES) m/z calcd. for C5H5BrN2O2S, 235.93; found, 237.0 (M+H).
Step 2: Synthesis of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
[00293] To a stirred solution of methyl 5-amino-2-bromothiazole-4-carboxylate (0.96 g, 4.05 mmol) in tetrahydrofuran (15 mL, 184 mmol) was added di-tert-butyldicarbonate (1.4 mL, 6.07 mmol), N,N- diisopropylethylamine (2.12 mL, 12.1 mmol) and 4-(dimethylamino)pyridine (0.5 g, 4.05 mmol) at ambient temperature. The resulting reaction mixture was stirred at same temperature for another 2 h. The progress of the reaction monitored by TLC. The reaction mixture was quenched with ice water (50 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to result in crude which was purified by flash column chromatography to afford methyl 2-bromo-5-((tert- butoxycarbonyl)amino)thiazole-4-carboxylate as a white solid (1.1 g, 81 %). LCMS (ES) m/z calcd. C10H13BrN2O4S, 335.98; found, 337.0 (M+H).
Step 3: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(l,l-dioxidothiomorpholino)thiazole- 4-carboxylate
[00294] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (0.7 g, 2.08 mmol) and thiomorpholine 1,1-dioxide (421 mg, 3.11 mmol) in 1,4-dioxane (8 mL) was added cesium carbonate (2.03 g, 6.23 mmol) and degassed with nitrogen for 10 min, followed by Pd(dba)2 (0.095 g, 0.155 mmol), Xanthphos (0.18 g, 0.311 mmol) were added and stirred at 100°C for 12 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered, and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(l,l-dioxidothiomorpholino)thiazole-4-carboxylate as an off-white solid (0.70 g, 87 %). LCMS (ES) m/z calcd. C14H21N3O6S2, 391.09; found, 392.0 (M+H).
Step 4: Synthesis of tert-butyl (2-(l,l-dioxidothiomorpholino)-4-((2-(trifluoromethyl) benzyl)carbamoyl)thiazol-5-yl)carbamate
[00295] To a suspension of methyl 5-((tert-butoxycarbonyl)amino)-2-(l,l- dioxidothiomorpholino)thiazole-4-carboxylate (0.7 g, 1.79 mmol) and (2- (trifluoromethyl)phenyl)methanamine (345 mg, 1.97 mmol) in toluene (7 mL) was added 2 M trimethylaluminium in toluene (1.32 mL, 2.68 mmol) at 0°C. The reaction mixture was heated at 100°C for 16 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with ethyl acetate (25 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, filtered, and evaporated in vacuo to obtain crude. The crude material was purified by flash column chromatography to afford / -butyl (2-( 1, 1 - dioxidothiomorpholino)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate as a yellow solid (0.680 g, 71 %). LCMS (ES) m/z calcd. C21H25F3N4O5S2, 534.1; found, 535.1 (M+H).
Step 5: Synthesis of 5-amino-2-(l,l-dioxidothiomorpholino)-N-(2-(trifluoromethyl) benzyl)thiazole- 4-carboxamide
[00296] To a stirred solution of tert-butyl (2-(l,l-dioxidothiomorpholino)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (680 mg, 1.27 mmol) in methanol (2 mL) was added 4M HC1 in dioxane (15 mL, 60 mmol) at 0°C and allowed to stirred at RT for 2 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was evaporated under reduced pressure and obtained residue was triturated with diethyl ether to afford 5- amino-2-(l, l-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide as a brown solid (0.68 g, 58 %). LCMS (ES) m/z calcd.C16H17F3N4O3S2, 434.07; found, 435.0 (M+H).
Step 6: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l,l-dioxidothiomorpholino)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00297] To a suspension of 5-amino-2-(l,l-dioxidothiomorpholino)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide (630 mg, 1.45 mmol) and 4,6-dichloro-5- hydroxypicolinic acid (332 mg, 1.6 mmol) in chlorobenzene (5 mL) was added phosphorus trichloride (0.063 mL, 0.725 mmol) dropwise under nitrogen atmosphere. The resulting reaction mixture was heated to 130°C for 2 h. Progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water (20 ml), precipitated solid was filtered and purified by flash column chromatography to afford brown color solid, which was further purified by Prep-HPLC to afford 5 -(4,6- dichloro-5-hydroxypicolinamido)-2-(l,l-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole- 4-carboxamide as a yellow solid (0.153 g, 17 %). LCMS (ES) m/z calcd.C22H18C12F3N5O5S2, 623.01; found, 622.1 (M-l); 1H NMR (400 MHz, DMSO-t/tf) 3 12.45 (s, 1H), 8.93 (t, J= 6.0 Hz, 1H), 8.09 (s, 1H), 7.80 (d, J= 4.0 Hz, 1H), 7.67 (t, J= 4.0 Hz, 1H), 7.51 - 7.42 (m, 2H), 4.7 (d, J= 8.0 Hz, 2H), 4.02 (br s, 4H), 3.31 (br s, 4H).
Example 79: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-(l,l-dioxidothiomorpholino)-N- (2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[00298] To a suspension of 5-amino-2-(l,l-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl) thiazole-4-carboxamide (0.5 g, 1.15 mmol) and 3,5-dichloro-4-hydroxybenzoic acid (262 mg, 1.27 mmol) in chlorobenzene (5 mL) was added phosphorus trichloride (0.050 mL, 0.575 mmol) dropwise under nitrogen atmosphere. The reaction mass was heated to 130°C for 2 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction the reaction mixture was quenched with ice water (20 mL) and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was washed
with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to result in crude which was purified by flash chromatography. The column purified compound was further purified by Prep-HPLC to afford 5-(3,5-dichloro-4-hydroxybenzamido)-2-(l,l-dioxidothiomorpholino)- N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide as a yellow solid (0.057 g, 8 %). LCMS (ES) m/z calcd. C23H19C12F3N4O5S2, 622.0; found, 621.1(M-H); ’H NMR (400 MHz, DMSO-t/tf) 3 12.0 (s, 1H), 11.28 (br s, 1H), 9.01 (t, J= 8.0 Hz, 1H), 7.79 (s, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.67 (t, J= 8.0 Hz, 1H), 7.48 (t, J= 8.0 Hz, 2H), 4.70 (d, J= 4.0 Hz, 2H), 4.02 (br s, 4H), 3.28 (br s, 4H).
Example 80: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate [00299] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (1.65 g, 4.89 mmol) and Morpholine (0.633 mL, 7.34 mmol) in 1,4-dioxane (8 mL) was added cesium carbonate (4.78 g, 14.7 mmol) and degassed with nitrogen for 10 min, followed by Pd(dba)2 (0.14 g, 0.244 mmol), Xanthphos (0.27 g, 0.48 mmol) were added and stirred at 100°C for 12 h. Progress of the reaction was monitored by TLC/ LCMS. After completion of the reaction, the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered, and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography to afford methyl 5-((tert- butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate as a yellow solid (740 mg, 44 %). LCMS (ES) m/z calcd. C14H21N3O5S, 343.12; found, 344.2 (M+H).
Step 2: Synthesis of tert-butyl (2-morpholino-4-((2-(trifluoromethyl)benzyl)carbamoyl) thiazol-5- yl)carbamate
[00300] To a suspension of methyl 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate (0.7 g, 2.04 mmol) and (2-(trifluoromethyl)phenyl)methanamine (428 mg, 2.45 mmol) in toluene (7 mL) was added 2 M trimethylaluminium in toluene (1.53 mL, 3.06 mmol) at 0°C. The reaction mixture was heated at 100°C for 16 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with ethyl acetate (25 x 2 mL). The combined organic phase was
- I l l -
washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, filtered, and evaporated in vacuo to obtain crude. The crude material was purified by flash column chromatography using 50 % ethyl acetate in n-hexane to afford tert-butyl (2-morpholino-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate as a yellow solid (430 mg, 43 %). LCMS (ES) z calcd. C21H25F3N4O4S, 486.1; found, 487.1 (M+l).
Step 3: Synthesis of 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide [00301] To a stirred solution of tert-butyl (2-morpholino-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (430 mg, 0.884 mmol) in methanol (2 mL) was added HC1 in dioxane (15 mL, 60 mmol) at 0°C and allowed to stirred at RT for 4 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction the reaction mixture was evaporated under reduced pressure and washed with diethyl ether to afford 5-amino-2-morpholino-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide as a brown solid (300 mg, 26 %). LCMS (ES) m/z calcd.C16H17F3N4O2S, 386.10; found, 387.0 (M+l).
Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00302] To a suspension of 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4- carboxamide (0.3 g, 0.776 mmol) and 4,6-dichloro-5-hydroxypicolinic acid (178 mg, 0.854 mmol) in chlorobenzene (4 mL) was added phosphorus trichloride (0.034 mL, 0.388 mmol) dropwise under nitrogen atmosphere. The reaction mass was heated to 130°C for 2 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with ice water (20 mL) and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to get crude which was purified by flash column chromatography to afford 5-(4,6-dichloro-5- hydroxypicolinamido)-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide as a yellow solid (14 mg, 3%). LCMS (ES) m/z calcd. C22H18C12F3N5O4S, 575.04; found, 576.1(M+1); ‘H NMR (400 MHz, DMSO-dtf) 3 12.25 (s, 1H), 8.69 (t, J= 8.0 Hz, 1H), 7.94 (s, 1H), 7.75 (d, J= 8.0 Hz, 1H), 7.67 (t, J= 8.0 Hz, 1H), 7.49-7.48 (m, 2H), 4.7 (d, J= 8.0 Hz, 2H), 3.73 (t, J= 4.0 Hz, 4H), 3.45 (t, J = 4.0 Hz, 4H).
Example 81: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2/7-pyran-4-yl)-A- (2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(3,6-dihydro-2H-pyran-4-yl)thiazole- 4-carboxylate
[00303] To a stirred solution of methyl 2-bromo-5-{[(tert-butoxy)carbonyl]amino}-l,3-thiazole-4- carboxylate (1 g, 2.97 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (0.93 g, 4.45 mmol) in l,4-dioxane:water (10 mL: 1 mL) was added potassium carbonate (1.23 g, 8.9 mmol) and degassed with nitrogen for 10 min, followed by l,l'-bis(diphenylphosphino)ferrocene dichloropalladium (II). DCM complex (110 mg, 0. 148 mmol) was added and stirred at 100°C for 2 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered, and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography to afford methyl 5 - { | (/crt-biitoxy (carbonyl | amino } -2-(3 ,6-dihydro-2//-py ran-4-yl )- 1 ,3 -thiazole-4-carboxylate (0.9 g, 89%) as white solid. LCMS (ES) m/z calcd. C15H20N2O5S 340.11; found, 341.2 (M+l).
Step 2: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(tetrahydro-2/7-pyran-4-yl)thiazole- 4-carboxylate
[00304] To a stirred solution of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-(3,6-dihydro-2H-pyran-4- yl)-l,3-thiazole-4-carboxylate (0.9 g, 2.64 mmol) in methanol (5 mL) and tetrahydrofiiran (5 mL) was added palladium on carbon 10%w/w (0.1 g). The resulting reaction mixture was stirred under hydrogen atmosphere for 16 h at ambient temperature. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was filtered through pad of celite, and filtrate was concentrated under reduced pressure to afford methyl 5-{[(tert-butoxy)carbonyl]amino}-2-(oxan-4-yl)-l,3-thiazole-4- carboxylate (0.9 g, 99% yield) as white solid which was taken to the next step without any column purification. LCMS (ES) m/z calcd. C15H22N2O5S 342.12; found, 343.0 (M+l).
Step 3: Synthesis of tert-butyl (2-(tetrahydro-2H-pyran-4-yl)-4-((2-(trifluoromethyl) benzyl)carbamoyl)thiazol-5-yl)carbamate
[00305] To a suspension of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-(oxan-4-yl)-l,3-thiazole-4- carboxylate (0.9 g, 2.63 mmol) and l-[2-(trifluoromethyl)phenyl]methanamine (5) (0.691g, 3.94 mmol) in toluene (10 mL) was added 2 M trimethylaluminium in toluene (1.97 mL 3.94 mmol) dropwise under
nitrogen atmosphere at 0°C. The resulting reaction mixture was heated to 100°C for 1 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with ice water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over sodium sulfate and evaporated under reduced pressure to get crude which was purified by flash column chromatography to afford tert-butyl (2- (tetrahydro-2H-pyran-4-yl)-4-((2-(trifluoromethyl)benzyl) carbamoyl)thiazol-5-yl)carbamate (0.65 g, 51%) as a white solid. LCMS (ES) m/z calcd. C22H26F3N3O4S 485.16.; found, 486.0 (M+l).
Step 4: Synthesis of 5-amino-2-(tetrahydro-2/f-pyran-4-yl)-JV-(2-(trifluoromethyl) benzyl)thiazole- 4-carboxamide
[00306] To a suspension of tert-butyl N-[-(oxan-4-yl)-4-({[2-(trifluoromethyl)phenyl] methyl}carbamoyl)-l,3-thiazol-5-yl]carbamate (0.650 g, 1.34 mmol) in dichloromethane (5 mL) was added 4M HC1 in dioxane (5 mL) at 0°C and then stirred at ambient temperature for 16 h. the reaction mixture was concentrated under reduced pressure to get 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide (0.4 g, 77%) as off-white solid. LCMS (ES) m/z calcd. C17H18F3N3O2S 385.1; found, 386.0 (M+l).
Step 5: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00307] To a suspension of 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl) thiazole-4-carboxamide (0.2 g, 0.519 mmol) and 4,6-dichloro-5-hydroxypicolinic acid (0.108 g, 0.519 mmol) in chlorobenzene (4 mL) was added phosphorus trichloride (0.071 g, 0.519 mmol) dropwise under nitrogen atmosphere. The reaction mixture was heated to 120°C for 3 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with ice water (20 ml) and extracted with ethyl acetate (3 x 20 ml). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to get crude residue which was triturated with diethyl ether (10 mL) and filtered, the solid was dried under vacuo to afford 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2- (trifluoromethyl) benzyl)thiazole-4-carboxamide (0.101 g, 33%) as pale brown solid. LCMS (ES) m/z calcd. C23H19C12F3N4O4S 574.05; found, 575.2 (M+l); 1H NMR (400 MHz, DMSO- 3 12.23 (s, 1H), 8.81 (t, J= 6.4 Hz, 1H), 7.81-7.74 (m, 2H), 7.71-7.65 (m, 1H), 7.51-7.46 (m, 2H) 4.72 (d, J= 5.6 Hz, 2H), 4.00-3.93 (m, 2H), 3.49-3.44 (m, 2H), 3.25-3.17 (m, 1 H), 2.09-1.99 (m, 2H), 1.85-1.75 (m, 2H).
Example 82: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-(tetrahydro-2H-pyran-4-yl)-N- (2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[00308] To a suspension of 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl) thiazole-4-carboxamide (0.2 g, 0.519 mmol) and 3,5-dichloro-4-hydroxybenzoic acid (0.107 g, 0.519 mmol) in chlorobenzene (4 mb) was added phosphorus trichloride (71.3 mg, 0.519 mmol) dropwise under nitrogen atmosphere. The reaction mixture was heated to 120°C for 3 h. Progress of the reaction was monitored by TLC and LCMS. After completion of the reaction, the reaction mixture was quenched with ice water (20 mL) and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to get crude which was purified by flash column chromatography to afford 5-(3,5-dichloro-4- hydroxybenzamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl) benzyl)thiazole-4-carboxamide as white solid (0.104 g, 34% yield). LCMS (ES) m/z calcd. C24H20C12F3N3O4S 573.05; found, 572.2 (M-l). ’H NMR (400 MHz. DMSO-t/tf) 3 12.24 (s, 1H), 11.32 (br s, 1H), 9.12 (t, J= 6.4 Hz, 1H), 7.82 (s, 2H), 7.77-7.74 (m, 1H), 7.67 (t, J= 7.6 Hz, 1H), 7.52-7.47(m, 2H), 4.72 (d, J= 6 Hz, 2H), 3.97-3.94 (m, 2H), 3.50-3.41 (m, 2H), 3.28-3.23 (m, 1H), 2.03-1.99 (m, 2H), 1.86-1.76 (m, 2H).
Example 85: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl)-2V-(2-(trifluoromethyl) benzyl) thiazole-4-carboxamide
ep
Step 1: Preparation of methyl 5-((tert-butoxycarbonyl) amino)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl) thiazole-4-carboxylate
[00310] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (0.730 g, 2.16 mmol) in 1,4-dioxane (10 ml), water (1.5 ml) was added l-methyl-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine (0.483 g, 2.16 mmol) and potassium carbonate (0.898 g, 6.49 mmol). The reaction mixture was purged with nitrogen for 15 minutes followed by [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.177 g, 0.216 mmol) was added and stirred at 100°C for 16 h. The reaction mixture was monitored by TLC. The reaction mixture was poured into water (40 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with water (10 ml), brine (5mL) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(l-methyl- 1,2,3, 6-tetrahydropyridin-4-yl)thiazole-4- carboxylate (0.7 g, 91%) as brown solid. LCMS (ES): m/z calcd. for C16H23N3O4S 353.14; found, 354.1.
Step 2: Preparation of tert-butyl (2-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-4-((2- (trifluoromethyl) benzyl) carbamoyl) thiazol-5-yl) carbamate
[00311] To a stirred solution of methyl 5-((tert-butoxycarbonyl)amino)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl)thiazole-4-carboxylate (0.3 g, 0.849 mmol) in toluene (5 mL) was added l-[2- (trifluoromethyl)phenyl]methanamine (0.149 g, 0.849 mmol) and 2M trimethylaluminium in toluene (0.229 mL, 2.55 mmol) drop-wise under nitrogen atmosphere at 0°C . The resulting reaction mixture was heated to 100°C for 16 h. Progress of the reaction was monitored by TLC and LCMS. After completion
of the reaction, the reaction mixture was quenched with ice-cold water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over sodium sulfate and evaporated under reduced pressure to get crude which was purified by flash column chromatography to afford tert-butyl (2-(l -methyl- 1,2, 3, 6-tetrahydropyridin-4-yl)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.3 g, 71%) as off-white solid. LCMS (ES): m/z calcd. C23H27F3N4O3S 496.18; found, 497.2.
Step 3: Preparation of 5-amino-2-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4-carboxamide
[00312] To a suspension of tert-butyl JV-[2-( 1 -methyl- 1 ,2,3,6-tetrahydropyridin-4-yl)-4-( { [2- (trifluoromethyl) phenyl] methyl} carbamoyl)-l,3-thiazol-5-yl] carbamate (0.280 g, 0.564 mmol) in methanol (5 mL) was added 4M HC1 in dioxane (7 mL) at ambient temperature. And allowed to stir for another 1 h. The reaction mixture was concentrated under reduced pressure to give 5 -amino-2-(l -methyl - 1 ,2,3.6-tctrahydropyridi n -4-yl )-A- { [2-(trifluoromethyl)phenyl] methyl } - 1 ,3 -thiazole-4-carboxamide (0.18 g, 80%) as white solid. LCMS (ES): m/z calcd. for C18H19F3N4OS 396.16; found, 397.1.
Step 4: Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4-carboxamide [00313] To a suspension of 5-amino-2-( 1 -methyl- 1,2,3, 6-tctrahydropyridin-4-yl)-A- {[ 2- (trifluoromethyl) phenyl] methyl}-l,3-thiazole-4-carboxamide (0.150 mg, 0.378 mmol) in chlorobenzene (5 mL) was added 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.0866 g, 0.416 mmol) and phosphorus trichloride (0.0331 mL, 0.378 mmol) at ambient temperature, the resulting reaction mixture was stirred at 130°C for 3 h. The reaction was monitored by TLC. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 mL), brine (3 mL) and dried over anhydrous sodium sulfate, fdtered, and concentrated in vacuo. The crude material was purified by Prep HPLC to afford 4.6-dichloro-5-hydroxy-A-|2-( I -methyl- 1 .2.3.6- tetrahydropyridin-4-yl)-4-({[2-(trifluoromethyl) phenyl] methyl} carbamoyl)-l,3-thiazol-5-yl] pyridine- 2-carboxamide.TFA salt (0.006 g, 3%) as a white solid. LCMS (ES) m/z calcd. For C24H20C12F3N5O3S 585.06; found 584.2 (M-H); 1H NMR (400 MHz, DMSO-t/tf): 5 12.63 (s, 1H), 9.80 (br s, 1H), 9.04 (t, J= 6 Hz, 1H), 8.04 (s, 1H), 7.78 (d, J= 7.6 Hz, 1H), 7.67 (t, J= 8 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 6.63 (s, 1H), 4.75 (br s, 2H), 4.05-3.88 (m, 1H), 3.76-3.64 (m, 1H), 3.36 (br s, 2H), 2.92 (s, 3H), 2.68-2.67-2.87 (m, 2H).
Example 86: 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methylpiperidin-4-yl)-N-(2-
Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(l-methylpiperidin-4-yl)thiazole-4- carboxylate
[00314] To a stirred solution of 5-{[(tert-butoxy)carbonyl]amino}-2-(l-methyl-l, 2,3,6- tetrahydropyridin-4-yl)-l,3-thiazole-4-carboxylate (0.250 g, 0.707 mmol) in MeOH:THF (4: 1) (6 mL) was added Pd on carbon 10% (0.150 g) and stirred at room temperature for 3 h under H2 atmosphere. The progress of the reaction was monitored by LCMS. Reaction mixture was filtered through pad of celite, filtrate was concentrated under reduced pressure to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(l- methylpiperidin-4-yl)thiazole-4-carboxylate (0.250 g, 99%) as brown solid. LCMS (ES) m/z calcd. C16H25N3O4S for, 355.16; found, 356.2 (M+H)
Step 2: Synthesis of tert-butyl (2-(l-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl) carbamoyl)thiazol-5-yl)carbamate.
[00315] To a stirred solution of methyl 5-((tert-butoxycarbonyl)amino)-2-(l-methylpiperidin-4- yl)thiazole-4-carboxylate (0.250 g, 0.703 mmol) in toluene (10.0 mL) was added l-[2- (trifluoromethyl)phenyl]methanamine (0.123 g, 0.703 mmol) and trimethylaluminium (2.0 M in toluene) (0.101 g, 1.41 mmol) drop-wise at 0°C. the resulting reaction mixture was stirred at 100°C for 3 h. reaction mixture was cooled to ambient temperature and poured into ice-cold water (25 mL), extracted with ethyl acetate (3 x 25 mL). the combined organic layer was dried over sodium sulphate, filtered, and concentrated to afford crude. Crude was purified using flash chromatography to afford tert-butyl (2-(l- methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.150 g, 43%) as an off-white solid. LCMS (ES) z calcd. for. C23H29F3N4O3S, 498.19; found 499.2 (M+H).
Step 3: Synthesis of 5-amino-2-(l-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl) thiazole-4- carboxamide.
[00316] To a stirred solution of tert-butyl (2-(l-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl) carbamoyl)thiazol-5-yl)carbamate (0.150 g, 0.301 mmol) in DCM (3.0 mL) was added hydrogen chloride (4M in 1,4-Dioxane) (0.054 g, 1.5 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated under reduce pressure to get crude residue which was triturated with diethylether (15 mL) and n-pentane (15mL) to afford 5-amino-2-(l-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl) thiazole-4-carboxamide (0.1 g, 83%) as brown solid. LCMS (ES) m/z calcd. for. C18H21F3N4OS, 398.14; found 399.2 (M+H).
Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methylpiperidin-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide.
[00317] To a stirred solution of 5-amino-2-(l-methylpiperidin-4-yl)-N-{[2- (trifluoromethyl)phenyl]methyl}-l,3-thiazole-4-carboxamide (0.1 g, 0.251 mmol) in acetonitrile (10 mL, 191 mmol) was added 4, 6-dichloro-5-hydroxypyridine-2 -carboxylic acid (0.052 g, 0.251 mmol) and phosphorous trichloride (0.027 g, 0.201 mmol) at ambient temperature. The resulting reaction mixture was heated to 130°C for 1 h. Reaction was cooled to room temperature and then to it was added ice-cold water (15 mL), precipitated solid was filtered to obtain crude solid. The crude compound was purified by Prep HPLC to afford 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(l-methylpiperidin-4-yl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide. Formic acid salt (0.0227 g, 15.3%) as off-white solid. LCMS (ES) z calcd. for. C24H22C12F3N5O3S, 587.08; found 588.2 (M+H); ‘HNMR (400 MHz, DMSO- tf): 3 12.25 (s, 1H), 9.30 (s, 1H), 8.77 (s, 1H), 7.75-7.77 (m, 1H), 7.6-7.70 (m, 1H), 7.47-7.52 (m, 2H), 4.73 (d, J = 5.6 Hz, 2H), 3.46 (br s, 4H), 3.08 (br s, 2H), 2.8 (s, 3H), 2.3-2.4 (br s, 1H), 1.8-2.1 (br s, 2H).
[00318] The following compounds has been synthesized as described above.
Example 105: Synthesis of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
Stepl: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-formylphenyl)thiazole- 4-carboxylate
[00319] To a solution of methyl 2-bromo-5-{[(tert-butoxy)carbonyl]amino}-l,3-thiazole-4-carboxylate (0.9 g, 2.67 mmol) and (2-fluoro-5-formylphenyl)boronic acid (0.538g, 3.2 mmol) dissolved in 1,4- dioxane (10 mL) was added potassium carbonate (1.11g, 8.01 mmol) and water (1 mL). The reaction mixture was purged with nitrogen gas for 15 minutes and then added Pd(dppf)C12.DCM complex (0.218 g, 0.26 mmol) at room temperature. The resulting reaction mixture was heated to 100 °C for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through pad of celite, the celite pad was washed with Ethyl acetate (25 mL), filtrate was washed with water (2 x 50 ml), brine solution (25 mL) and dried over Na2SC>4, concentrated and dried to afford crude (0.85 g, 83.7 % yield) as a brown solid. LCMS (ES): m/z calcd. for C17H17FN2O5S 380.08; found, 381.0 (M+H).
Step 2: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)thiazole-4-carboxylate
[00320] To a stirred solution of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-(2-fluoro-5-formylphenyl)- l,3-thiazole-4-carboxylate (0.6 g, 1.58 mmol) in methanol (6 mL, 148 mmol) was added pyrrolidine (1.12 g, 15.8 mmol) and Titanium isopropoxide (4.78 mL, 15.8 mmol) at room temperature and stirred for 12 h under argon atmosphere. To this was added NaBfL (298 mg, 7.89 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for another 2 h. Progress of the reaction was monitored by TLC. After completion, the reaction mixture was quenched with water (20 mL) and resulting residue was filtered through celite pad and washed with DCM (25 mL x 2). The combined organic phase was washed with water (15), dried over sodium sulfate and evaporated under reduced pressure to result in crude compound, the crude material was triturated with 10% Ethyl acetate: Hexane (10 ml x 2) and diethyl ether (10 mL x 2) to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5- (pyrrolidin-l-ylmethyl)phenyl)thiazole-4-carboxylate (0.205 g, 29.84%) as an off-white solid. LCMS (ES): m/z calcd. for C21H26FN3O4S, 435.16; found, 436.1 (M+H).
Step 3: Preparation of tert-butyl (2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[00321] To a stirred solution of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-{2-fluoro-4-[(pyrrolidin-l- yl)methyl]phenyl}-l,3-thiazole-4-carboxylate (0.205 g, 0.471 mmol) in Toluene (2 mb, 16.9 mmol) was added l-[2-(trifluoromethyl)phenyl]methanamine (0.066 mb, 0.471 mmol) and cooled to 0°C. To this was added IM trimethylaluminium in Toluene (0.136 mb, 1.41 mmol). The resulting reaction mixture was heated to 100 °C for 16 h. The Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with cold water (25 mb) and extracted into EtOAc (25 mb x 3). The combined organic layer was dried over sodium sulfate and evaporated under reduced pressure to give crude. The crude was purified by Combiflash chromatography using 3% Methanol: Dichloromethane as an eluent to afford tert-butyl (2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-4-((2- (trifhioromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.4 g, 77%) as off white solid. LCMS (ES): m/z calcd. for C28H30F4N4O3S, 578.20; found, 579.0 (M+H).
Step 4: Preparation of 5-amino-2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00322] To a solution of tert-butyl N-(2-{2-fluoro-4-[(pyrrolidin-l-yl)methyl]phenyl}-4-({[2- (trifluoromethyl)phenyl]methyl}carbamoyl)-l,3-thiazol-5-yl)carbamate (0.4 g, 0.691 mmol) in methanol (4 mL) was added with 4M HC1 in dioxane (0.86 mL) at 0°C and stirred at room temperature for 16 h under argon atmosphere. Progress of the reaction was monitored by TLC. After completion, the reaction mixture was basified with sodium bicarbonate (10 mL) and extracted into Ethyl acetate (25 mL x 2). The combined organic layer was washed with water (10 mL), brine solution (10 ml) dried over sodium sulfate and evaporated under reduced pressure to get 5-amino-2-(2-fluoro-5-(pyrrolidin-l-ylmethyl)phenyl)-N- (2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (95 mg, 29%) as a light yellow solid.
LCMS (ES): m/z calcd. for C23H22F4N4OS, 478.15; found, 479.0 (M+H).
Step-5: Preparation of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-l- ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[00323] To a suspension of 5-amino-2-{2-fluoro-5-[(pyrrolidin-l-yl)methyl]phenyl}-N-{[2- (trifluoromethyl)phenyl]methyl}-l,3-thiazole-4-carboxamide (0.095 g, 0.199 mmol) in acetonitrile (1 mL) was added with 3-chloro-5-fluoro-4-hydroxybenzoic acid (41.6 mg, 0.218 mmol) and Phosphorus trichloride (0.017 mL, 0.199 mmol) at room temperature and then stirred at 130 °C for 2 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into ice cold water (20mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (lOmL), brine solution (5mL) and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by Prep HPLC, using 0.1% TFA in Water: Acetonitrile gradient. Collected pure fractions were lyophilized to get 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro- 5-(pyrrolidin-l-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.012 g, 9.28%). LCMS (ES): m/z calcd. for C30H24C1F5N4O3S, 650.12; found, 651.4 (M+H). 1H NMR (4OO MHz, DMSO-t/e) 5 12.31 (s, 1H), 10.87 (bs, 1H), 9.27 (bs, 1H), 8.45 (d, J= 6.8 Hz, 1H), 7.77 (d, J= 1.6Hz, 1H), 7.71-7.63 (m, 4H), 7.57 (d, J= 6.8 Hz, 2H), 7.52-7.50 (m, 1H), 4.82 (d, J= 6 Hz, 2H), 4.30 (s, 2H), 3.16 (m, 4H), 1.92 (m, 4H). LC-Purity: 99.62 % at 240 nm.
- 122 -
\
Example 106: Synthesis of N-(bicyclo[l.l.l]pentan-l-ylmethyl)-5-(3-chloro-5-fluoro-4- hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide
Stepl: Preparation of methyl 2-(2-fluorophenyl)thiazole-4-carboxylate
[00324] To a stirred solution of methyl 2-bromo-l,3-thiazole-4-carboxylate (50 g, 225 mmol) in 1,4- dioxane (750 mL), water (125 mL) was added (2-fluorophenyl)boronic acid (47.25 g, 337.5 mmol) and Potassium carbonate (93.5 g, 67.5 mmol) . The reaction mixture was purged with nitrogen gas for 15 minutes and then Pd(dppf)C12.DCM complex (9.2 g, 0.05 eq., 2.25 mmol) was added at room temperature. The resulting reaction mixture was heated to 100 °C for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through pad of celite, the celite pad was washed with EtOAc (2 L), filtrate was washed with water (2 x 1000 ml), brine Solution (500 mL) and dried over Na2SC>4, concentrated and dried to afford crude. The crude material was purified by column chromatography by using 5% EtOAc: Hexane as an eluent to afford methyl 2-(2-fluorophenyl)-l,3- thiazole-4-carboxylate (41 g, 77 % yield) as a white solid. LCMS (ES): m/z calcd. for C5H5BrN2O2S 237.03; found, 237.9 (M+H).
Step 2: Preparation of methyl 5-bromo-2-(2-fluorophenyl)thiazole-4-carboxylate
[00325] To a stirred solution of methyl 2-(2-fluorophenyl)-l,3-thiazole-4-carboxylate (20 g, 84.3 mmol) in Acetonitrile was added NBS (45 g, 253 mmol) at room temperature. The resulting reaction mixture was refluxed for 24 h and then added another portion of NBS (30 g) and continued the stirring at reflux temperature for another 24 h. Progress of the reaction was monitored by TLC. After completion of the reaction. The reaction mixture was poured into ice cold water (2 L), precipitated solid was filtered and washed with water (1 L), dried to afford methyl 5-bromo-2-(2-fluorophenyl)thiazole-4-carboxylate (20 g, 75% yield) as a white fluffy solid. LCMS (ES): m/z calcd. for Cl lH7BrFNO2S, 314.94; found, 316.0 (M+H)
Step 3: Preparation of 5-bromo-2-(2-fluorophenyl)thiazole-4-carboxylic acid
[00326] To a stirred solution of methyl 5-bromo-2-(2-fluorophenyl)-l,3-thiazole-4-carboxylate (16 g, 50.6 mmol) in tetrahydrofuran (200 mL), methanol (75 mL) and water (30 mL) was added LiOH.H2O
(3.64 g, 152 mmol) at room temperature. The resulting reaction mixture was stirred at 60 °C for 16 hours. Progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into cold water and acidified to pH~2 by dil. HC1 solution. Precipitated solid was filtered and washed with water (1 L), dried to afford 5-bromo-2-(2-fluorophenyl)-l,3-thiazole-4-carboxylic acid (14 g, 96%) as a white solid. LCMS (ES): m/z calcd. for C10H5BrFNO2S, 300.92; found, 301.9 (M+H)
Step 4: Preparation of JV-(bicyclo[l.l.l]pentan-l-ylmethyl)-5-bromo-2-(2-fluorophenyl)thiazole-4- carboxamide.
[00327] To a stirred solution of 5-bromo-2-(2-fluorophenyl)-l,3-thiazole-4-carboxylic acid (0.2 g, 0.66 mmol) in A'. A'-Dimcthylformamidc (5 ml) was added bicyclo[l . 1. l]pentan-l-yhnethanamine (0.064 g, 0.66 mmol), HATU (0.3 g, 0.794 mmol) and triethylamine (0.37 m , 2.65 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice cold water (10 mL) and extracted with ethyl acetate (2 x 20 mL), the combined organic layer was washed with water, brine solution, dried over Na2SC>4, concentrated and dried to afford crude. The crude material was purified by flash column chromatography using 5% ethyl acetate in Hexane as an eluent to afford A'- (bicyclo[L Ll]pentan-l-yhnethyl)-5-bromo-2-(2-fluorophenyl)thiazole-4-carboxamide (0.075 g, 30%) as a white solid. LCMS (ES): m/z calcd. for C16H14BrFN2OS, 380.00; found, 380.9 (M+H) Step-5: Preparation of JV-(bicyclo[l.l.l]pentan-l-ylmethyl)-5-(3-chloro-5-fluoro-4- hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide
[00328] To a stirred solution of JV-(bicyclo[l. l.l]pentan-l-ylmethyl)-5-bromo-2-(2- fluorophenyl)thiazole-4-carboxamide (0.07 g, 0.184 mmol)and 3-chloro-5-fluoro-4-hydroxybenzamide (0.052 g, 0.275 mmol) in t-butanol (2 mL) was added cesium carbonate (0.18 g, 0.55 mmol). Then reaction mixture degassed under nitrogen gas for 10 min. Then followed by the addition of Xanthphos (11 mg, 0.018 mmol) and Pd2(dba)s (15 mg, 0.018 mmol) at room temperature, the reaction mixture was heated to 100 °C for 16 hours. The progress of the reaction was monitored by LCMS and TLC. The reaction mixture was poured into water (100 ml) and extracted with ethyl acetate (3x 100 ml), the combined organic layer was washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure to get the crude product. The crude solid was stirred with diethyl ether (10 ml) for 30 min and then fdtered the solid. The solid was further triturated with methanol, fdtered, and dried to afford /V-(bicyclo 1 1 . 1. l]pentan-l-yhnethyl)-5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2- fluorophenyl)thiazole-4-carboxamide (0.012 g, 12%). LCMS (ES): m/z calcd. for C23H18C1F2N3O3S, 489.07; found, 490.2 (M+H); 1H NMR (4OO MHz, DMSO-d6): 5 12.53 (s, 1H), 11.65 (bs, 1H), 8.79 (t, J =6.0 Hz, 1H), 7.73 (s, 1H), 7.69-7.66 (m, 1H), 7.58-7.39 (m, 3H), 3.43 (d, J =6.4 Hz, 2H), 1.69 (s, 6H); LC-Purity: 99.84 % at 240 nm.
Example 107: Synthesis of 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
Step-1: Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate [00329] To a stirred solution of methyl 5-amino-2-bromothiazole-4-carboxylate (1 g, 4.22 mmol) in Tetrahydrofuran (20 mL, 246 mmol) was added di-tert-butyl dicarbonate (1.45 mL, 6.33 mmol), DIPEA (2.2 mL, 12.7 mmol) and DMAP (0.520 g, 4.22 mmol) at ambient temperature and then stirred at same temperature for another 2 h. The reaction mixture was poured into water (40mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to get crude. The crude material was purified by flash column chromatography using 30% Ethyl acetate in Hexane as an eluent to afford methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (0.9 g, 63%) as white solid. LCMS (ES): m/z calcd. for C10H13BrN2O4S, 335.98; found, 337.0
Step-2: Preparation of methyl 5-((ter/-butoxycarbonyl) amino)-2-(2-fluorophenyl) thiazole-4- carboxylate
[00330] To a stirred solution of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate (0.460 g, 1.36 mmol) and (2-fluorophenyl)boronic acid (0.382 g, 2.73 mmol) in 1,4 -dioxane: water 8:2 (6 mL) was added and potassium carbonate (0.566 g, 4.09 mmol) and degassed with nitrogen for 10 min, followed by bis(tri-tert-butylphosphane) palladium (0.0697 g, 0.136 mmol) was added and stirred at 100 °C for 16 h. Progress of the reaction was monitored by TLC/ LCMS. After completion of the reaction,
the reaction mixture was filtered through a pad of celite, filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulphate, filtered and concentrated under vacuo to give crude. The crude product was purified by flash column chromatography using 20% ethyl acetate in hexane as an eluent to afford methyl 5-((tert-butoxycarbonyl)amino)-2-(2- fluorophenyl)thiazole-4-carboxylate (0.350 g, 73%) as brown solid. LCMS (ES): m/z calcd. for C16H17FN2O4S, 352.09; found, 353.1
Step-3: Preparation of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl) benzyl) carbamoyl) thiazol-5-yl) carbamate
[00331] To a stirred solution of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4- carboxylate (0.3 g, 0.851 mmol) in Toluene (5 mL) was added l-[2- (trifluoromethyl)phenyl]methanamine (0.119 mL, 0.851 mmol) and 2 M trimethylaluminium in toluene (0.245 mL, 2.55 mmol) at 0 °C. The resulting reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was cooled to ambient temperature and quenched with ice cold water (25 mL) and extracted with Ethyl acetate (25 x 2 mL). The combined organic phase was washed with brine solution (15 mL) and dried over anhydrous sodium sulphate, filtered, and evaporated in vacuo to obtain crude. The crude material was purified by flash column chromatography using 30% EtOAc: Hexane as the eluent to afford tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5- yl)carbamate (0.3 g, 71%) as off white solid. LCMS (ES): m/z calcd. C23H21F4N3O3S, 495.12; found, 496.1
Step-4: Preparation of 5-amino-2-(2-fluorophenyl)-JV-(2-(trifluoromethyl) benzyl) thiazole-4- carboxamide
[00332] To a suspension of tert-butyl (2-(2-fluorophenyl)-4-((2- (trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.250 g, 0.505 mmol) in methanol (1 mL) was added 4M HC1 in dioxane (5 mL, 144 mmol) at 0 °C and then allowed to stirred at RT for 1 h. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 5-amino-2-(2-fluorophenyl)-JV-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide (0.170 mg, 85%) as a white solid. LCMS (ES): m/z calcd. for C18H13F4N3OS, 395.07; found, 396.1
Step-5: Preparation of 5-(4-chloro-6-fluoro-5-methoxypicolinamido)-2-(2-fluorophenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00333] To a suspension of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4- carboxamide (0.1 g, 0.25 mmol) in Chlorobenzene (0.5 mL) was added 4-chloro-6-fluoro-5- methoxypyridine-2-carboxylic acid (0.065 g, 0.30 mmol) and Phosphorous trichloride (0.03 mL, 0.25 mmol). The resulting reaction mixture was heated to 120 °C for 3 h. The progress of reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and reaction mixture was quenched with ice-cold water (10 mL), solid was collected by filtration to get crude residue which was purified by flash column chromatography using 30% Ethyl acetate in Hexane as an eluent to afford 5-(4-
- 126 -
\
chloro-6-fluoro-5-methoxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4- carboxamide (0.08 g, 54%) as an off-white solid. LCMS (ES): m/z C25H16C1F5N4O3S calcd. for 582.06; found, 583.1 (M+H); 1H NMR (400 MHz, DMSO-d6): 5 12.78 (s, 1H), 9.37 (t, J= 5.6 Hz, 1H), 8.48-8.45 (m, 1H), 8.18 (s, 1H), 7.74 (d, J= 8.0 Hz, 1H), 7.66-7.63 (m, 1H), 7.54-7.45 (m, 2H), 7.42- 7.37 (m, 3H), 4.76 (d, J= 5.6 Hz, 2H), 19F NMR (400 MHz, DMSO-d6): 5 -50.05 (m, 3F), -77.37 (IF), - 112.88 (IF). LC Purity: 99.1 % at 254 nm.
Step-6: Preparation of 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2- (trifluoromethyl)benzyl)thiazole-4-carboxamide
[00334] To a stirred solution of 4-chloro-6-fluoro-N-[2-(2-fluorophenyl)-4-({[2- (trifluoromethyl)phenyl]methyl}carbamoyl)-l,3-thiazol-5-yl]-5-methoxypyridine-2-carboxamide (80 mg, 0.137 mmol) in NMP (1 mL) was added lithium chloride (17.5 mg, 0.412 mmol) and p-TSA (78.3 mg, 0.412 mmol). The reaction mixture was heated at 100 °C for 3 h. After completion, reaction mixture was quenched with water (5 mL), solid was collected by filtration to get crude. Which was purified through flash chromatography by using 0-10% MeOH/DCM as eluent to afford 5-(4-chloro-6-fluoro-5- hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (30 mg, 38%). LCMS (ES): m/z C24H14C1F5N4O3S calcd. for 568.04; found, 569.2 (M+H); ‘H NMR (400 MHz, DMSO-d6): 5 12.68 (s, 1H), 9.39 (t, J= 6.4 Hz, 1H), 8.50-8.46 (m, 1H), 8.14 (S, 1H), 7.77 (d, J= 7.6 Hz, 1H), 7.69-7.65 (m, 1H), 7.58-7.38 (m, 5H), 4.78 (d, J = 6.4 Hz, 2H). 19F NMR (400 MHz, DMSO-d6): 5 -59.10 (3F, -CF3), -81.55 (IF, -ArF), -112.92 (IF, -ArF). LC Purity: 99.5 % at 240 nm.
Example A: Estrone detection assay for evaluation of HSD17B13 activity and identification of inhibitors
[00335] The liquid chromatography/mass spectrometry (LC/MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B13. This assay was undertaken in a 96wp format (Eppendorf deep well Plate 96/500) in an 80pl reaction volume containing: 4pM of Estradiol (E2; Cayman; #10006315), 6mM NAD+ (Sigma; #N0623) and 30 nM HSD17B13 enzyme (in-house; E. coli expressed His-tagged, purified, soluble protein) in a reaction containing IM potassium phosphate buffer pH 7.4, with 0.5% vehicle (DMSO). Reactions were incubated for 2 hours at 26.5°C, and estradiol (E2) conversion to estrone (El) was quantitated by LC-MS/MS based analyte detection for both E2 and El using LCMS grade reagents.
[00336] Reactions were terminated by the addition of two volumes of acetonitrile (MeCN; LCMS grade; CAS# 75/05/8) containing deuterated (D4)-E1 used as internal standard (Clear Synth; #CS-T- 54273; 500 ng/mL final concentration). Samples were applied to pre-prepared Bond Elut-C18 extraction cartridges (3 mL; Agilent; #12102028), washed and eluted in MeCN. Eluates were dried under nitrogen and re-suspended in 60% methanol (LCMS grade methanol; CAS# 67/56/1) before submission for analysis. Aqueous linearity for E2 and El were included for quantification.
[00337] Analysis of samples was undertaken on a XBridge BEH C18 column (Waters; #186003033) using 0.1% Diethyl Amine in MeCN (mobile phase A; DEA CAS# 109-89-7) and 0.1% Diethyl Amine
- 127 -
\
in milli-Q water (mobile phase B) in a 3min gradient allowing 25%B. Analytes were detected in negative mode using MRM analysis, with E2 having a RT of 1 ,85min and El having a RT of 2min. Activity of the enzyme, in the absence of NAD+, was used to evaluate specificity of conversion. Enzyme activity in the presence of test samples was expressed as a percentage of the uninhibited enzyme activity, and plotted versus inhibitor concentration. Non-linear regression was performed using a four-parameter logistic model and GraphPad Prism software (GraphPad Software, La Jolla, CA). All assessments were undertaken in duplicate evaluations and pooled during extraction process and subsequently injected as duplicates for LC-MS/MS analysis.
Example B: Estrone detection assay for Evaluation of HSD17B14 activity and identification of inhibitors via detection of estrone product
[00338] The liquid chromatography/mass spectrometry (LC/MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B14. This assay was undertaken in a 96 well plates (Eppendorf deep well), in an 80 pl reaction volume containing: 8 pM of estradiol (E2; Cayman); 4 mM NAD+ (Sigma); 120 nM HSD17B14 enzyme (in-house E. coli expressed His-tagged, purified, soluble protein); IM potassium phosphate buffer pH 7.4, and 1.2% vehicle (DMSO). Reactions were incubated for 2 hours at 37° C. Estradiol (E2) conversion to estrone (El) was quantitated by LC-MS/MS based analyte detection for El using LCMS grade reagents.
[00339] Reactions were terminated by the addition of two volumes of acetonitrile (MeCN; LCMS grade) containing deuterated (D4)-E1 used as internal standard (Clear Synth; 500 ng/mL final concentration). Samples were applied to pre-prepared Bond Elut-C18 extraction cartridges (3 mb; Agilent). The cartridges were washed with 1.5 mb water followed by 1.5 mb 5% aqueous methanol, and dried for 5 minutes under vacuum. They were then eluted with 4.5 mb MeCN. The eluates were dried under nitrogen and re-suspended in 200 pL of 60% methanol (LCMS grade) before submission for analysis. Standard curves of E2 and El in 4% DMSO were included for quantification.
[00340] Analysis of samples was performed on a XBridge BEH C18 column (Waters) using 0.1% Diethyl Amine in MeCN (mobile phase A) and 0.1% Diethyl Amine in milli-Q water (mobile phase B) in a 3 min gradient from 0-25% B. Analytes were detected in negative mode using MRM analysis, with E2 having a RT of 1.89 min and El having a RT of 2.07 min. Activity of the enzyme in the absence of NAD+ was used to evaluate specificity of conversion. Enzyme activity in the presence of test samples was expressed as a percentage of the uninhibited enzyme in the presence of 1.2% DMSO vehicle only, and plotted versus inhibitor concentration. Non-linear regression was performed using a four-parameter logistic model and GraphPad Prism software. All assessments were undertaken in duplicate evaluations, which were pooled during the extraction process and subsequently injected as duplicates for LC-MS/MS analysis.
Example C: Evaluation of HSD17B2 activity and identification of inhibitors via detection of reduced nicotinamide adenine dinucleotide (NADH) product
[00341] The fluorescence based detection assay monitors the conversion of the co-factor NAD+ to NADH, which occurs coincident with the conversion of estradiol to estrone by HSD17B2. These assays were performed in 384 well plates (Greiner V-shape PP -microplate). The 20 pl reaction volume contained: 0.7 pM estradiol (E2); 6 mM NAD+(Sigma); 250 nM HSD17B2 enzyme (Origene; Cat# TP303293); 0.25 M potassium phosphate buffer pH 7.4, 0.75% vehicle (DMSO). Reactions were incubated for 2 hours at 37° C, and the reaction was stopped by freezing the reaction plates at -80° C. Zero time samples were frozen immediately.
[00342] The conversion of NAD+ to NADH was quantitated using NAD-Glo kits (Promega; Cat#G9062) according to the manufacturers’ instructions. A volume of 15 pL of enzyme reaction mixture was added to 15 pL of reconstituted Gio reagent, and the plates were incubated for 30 minutes at room temperature. Luminescence was quantitated on a Tecan Spark Reader®. A standard curve of NADH (0.1- 50 pL) in potassium phosphate buffer pH 7.4/1% DMSO was run on each plate.
[00343] Activity of the enzyme in the absence of E2 was used to evaluate specificity of conversion. Enzyme activity in the presence of test samples was expressed as a percentage of the uninhibited enzyme in the presence of 1% DMSO vehicle only, and was plotted versus inhibitor concentration. Non-linear regression was performed using a four-parameter logistic model and GraphPad Prism software. All assessments were undertaken in duplicate evaluations.
[00344] The data from examples A, B, and C is shown in table 2 and 3 below:
ICso with Estradiol
A is less than or equal to 0.1 pM;
B is more than 0.1 pM and less than or equal to 0.5 pM;
C is more than 0.5 pM and less than or equal to 1.0 pM;
D is more than 1.0 pM and less than or equal to 10 pM;
E is more than 10 pM;
HSD17B13 Inhibition Estradiol Substrate LCMS: Ki
A is less than or equal to 50 nM;
B is more than 50 nM and less than or equal to 100 nM;
C is more than 100 nM and less than or equal to 500 nM;
Claims
1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
Formula (I), wherein:
Ring A is thiazolyl;
R1 is hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, or Ci-Cgaminoalkyl; R2 is hydrogen or Ci-Cgalkyl;
R3 is Ci-Cwalkyl, Ci-Ciohaloalkyl, Ci-Ciodeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, C2-Cioalkenyl, C2-Cioalkynyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a; each R3a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R3a on the same atom are taken together to form an oxo;
R4 is deuterium, halogen, Ci-Cgalkyl, C2-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a; each R4a is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NHS(=O)2Ra, -C(=O)Ra, -C(=O)C(=O)Ra, -C(=O)ORb, - C(=O)NRcRd, -C(=O)C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo; or two R4a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R; or two R4a on the different atoms are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R;
X is N or CRX;
Rx is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl;
R5 is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; each R6 is independently a halogen; each Ra is independently Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more with one or more R; and each Rc and Rd are independently hydrogen, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, C2-Cgalkenyl, C2-Cgalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OCi-C3alkyl, -OCi-C3haloalkyl, -SCi-C3alkyl, -S(=O)Ci- C3alkyl, -S(=O)2Ci-C3alkyl, -S(=O)2NH2, -S(=O)2NHCi-C3alkyl, -S(=O)2N(Ci-C3alkyl)2, -NH2, - NHCi-C3alkyl, -N(Ci-C3alkyl)2, -C(=O)Ci-C3alkyl, -C(=O)OH, -C(=O)OCi-C3alkyl, -C(=O)NH2, -
- 133 -
\
C(=O)NHCi-C3alkyl, -C(=O)N(Ci-C3alkyl)2, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3deuteroalkyl, Ci- C3hydroxyalkyl, Ci-C3aminoalkyl, Ci-C3heteroalkyl, or C3-Cgcycloalkyl; or two R on the same atom form an oxo.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R1 is hydrogen.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is hydrogen.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is Ci-Cioalkyl, Ci-Ciohaloalkyl, Ci-Cwdeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a.
7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C4-Cioalkyl, Ci-Ciohaloalkyl, Ci-Cwdeuteroalkyl, Ci-Ciohydroxyalkyl, Ci-Cioaminoalkyl, Ci-Cioheteroalkyl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a.
The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is Ci-Cioalkyl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C4-Cioalkyl, Ci-C6alkylene(cycloalkyl), Ci-C6alkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is Ci-Cioalkyl or Ci-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C4-Cioalkyl or C2-Cgalkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is Ci-Cioalkyl optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C4-Cioalkyl optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C4-Cioalkyl. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is Ci-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is C2-Cgalkylene(aryl); wherein the alkylene and aryl is optionally and independently substituted with one or more R3a. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R3a is independently deuterium, halogen, -CN, -OH, -ORa, - NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, or Ci-Cgheteroalkyl; or two R3a on the same atom are taken together to form an oxo. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R3a is independently deuterium, halogen, -OH, -ORa,
- 135 -
\
Ci-Cgalkyl, Ci-Cghaloalkyl, or Ci-Cgdeuteroalkyl; or two R3a on the same atom are taken together to form an oxo. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R3a is independently halogen, -ORa, or Ci-Cghaloalkyl. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R3a is independently Ci-Cghaloalkyl. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is N. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is CRX. The compound of any one of claims 1-20 or 22, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Rx is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. The compound of any one of claims 1-20 or 22 or 23, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Rx is hydrogen or Ci-Cgalkyl. The compound of any one of claims 1-20 or 22-24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Rx is hydrogen. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R5 is hydrogen, halogen, Ci-Cgalkyl, or Ci-Cghaloalkyl. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R5 is hydrogen or Ci-Cgalkyl. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R5 is hydrogen. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R6 is chloro. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R6 is fluoro. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, Ci-Cgalkylene(cycloalkyl), Ci-Cgalkylene(heterocycloalkyl), Ci-Cgalkylene(aryl), or Ci-Cgalkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is cycloalkyl optionally substituted with one or more with one or more R4a.
- 136 -
\
The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is heterocycloalkyl optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is aryl or heteroaryl; wherein the aryl and heteroaryl is optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is aryl optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R4 is heteroaryl optionally substituted with one or more with one or more R4a. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4a is independently deuterium, halogen, -CN, -OH, -ORa, - S(=O)Ra, -NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R4a on the same atom are taken together to form an oxo. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4a is independently deuterium, halogen, -CN, -OH, -ORa, - S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, Ci-Cghydroxyalkyl, Ci-Cgaminoalkyl, Ci-Cgheteroalkyl, cycloalkyl, or heterocycloalkyl; or two R4a on the same atom are taken together to form an oxo. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4a is independently deuterium, halogen, -CN, -OH, -ORa, - S(=O)Ra, -NRcRd, Ci-Cgalkyl, Ci-Cghaloalkyl, Ci-Cgdeuteroalkyl, cycloalkyl, or heterocycloalkyl; or two R4a on the same atom are taken together to form an oxo. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4a is independently halogen, -CN, -OH, -ORa, -S(=O)Ra, - NRcRd, Ci-Cgalkyl, or Ci-Cghaloalkyl; or two R4a on the same atom are taken together to form an oxo. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4a is independently halogen, -S(=O)Ra, Ci-Cgalkyl, or Ci-Cghaloalkyl; or two R4a on the same atom are taken together to form an oxo. A compound selected from a compound found in table 1 a or table lb, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. A pharmaceutical composition comprising a compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
- 137 -
\
A method of treating a disease in a subject in need thereof, the method comprising administering a pharmaceutically effective amount of a compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a pharmaceutical composition of claim 44. The method of claim 45, wherein the disease is a liver disease, a metabolic disease, or a cardiovascular disease. The method of claim 45 or 46, wherein the disease is NAFLD. The method of claim 45 or 46, wherein the disease is NASH. The method of claim 45 or 46, wherein the disease is drug induced liver injury (DILI). The method of claim 45 or 46, wherein the disease is associated with HSD17B13. The method of claim 45 or 46, wherein the diseases is alcoholic liver disease. The method of claim 45 or 46, wherein the disease is cirrhosis. The method of claim 45 or 46, wherein the disease is decompensated portal hypertension. The method of claim 45 or 46, wherein the disease is cholestatic liver disease. A method for selectively inhibiting HSD 17B 13 , the method comprising administering a pharmaceutically effective amount of a compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. The method of claim 55, wherein the compound selectively inhibit HSD17B13 over HSD17B2, HSD17B14, or any combination thereof.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202211004338 | 2022-01-26 | ||
IN202211004338 | 2022-01-26 | ||
US202263342786P | 2022-05-17 | 2022-05-17 | |
US63/342,786 | 2022-05-17 | ||
US202263377421P | 2022-09-28 | 2022-09-28 | |
US63/377,421 | 2022-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023146897A1 true WO2023146897A1 (en) | 2023-08-03 |
Family
ID=87472401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/011520 WO2023146897A1 (en) | 2022-01-26 | 2023-01-25 | 2-substituted thiazole hsd17b13 inhibitors and uses thereof |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202337449A (en) |
WO (1) | WO2023146897A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11827619B2 (en) | 2020-11-13 | 2023-11-28 | Inipharm, Inc. | Dichlorophenol HSD17B13 inhibitors and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003934A2 (en) * | 2005-07-04 | 2007-01-11 | Sterix Limited | 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors |
WO2022103960A1 (en) * | 2020-11-13 | 2022-05-19 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
WO2022216627A1 (en) * | 2021-04-05 | 2022-10-13 | Inipharm, Inc. | Thiazole/isothiazole hsd17b13 inhibitors and uses thereof |
-
2023
- 2023-01-25 WO PCT/US2023/011520 patent/WO2023146897A1/en unknown
- 2023-01-30 TW TW112103142A patent/TW202337449A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003934A2 (en) * | 2005-07-04 | 2007-01-11 | Sterix Limited | 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors |
WO2022103960A1 (en) * | 2020-11-13 | 2022-05-19 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
WO2022216627A1 (en) * | 2021-04-05 | 2022-10-13 | Inipharm, Inc. | Thiazole/isothiazole hsd17b13 inhibitors and uses thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11827619B2 (en) | 2020-11-13 | 2023-11-28 | Inipharm, Inc. | Dichlorophenol HSD17B13 inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
TW202337449A (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10392379B2 (en) | Hepatitis B core protein modulators | |
EP3010917B1 (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
US11827619B2 (en) | Dichlorophenol HSD17B13 inhibitors and uses thereof | |
WO2022020730A1 (en) | Quinazolinone hsd17b13 inhibitors and uses thereof | |
EP4185381A1 (en) | Thiophene hsd17b13 inhibitors and uses thereof | |
WO2022216627A1 (en) | Thiazole/isothiazole hsd17b13 inhibitors and uses thereof | |
WO2023146897A1 (en) | 2-substituted thiazole hsd17b13 inhibitors and uses thereof | |
US9242998B2 (en) | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | |
US20230150940A1 (en) | Hsd17b13 inhibitors and uses thereof | |
US20230127898A1 (en) | Hepatitis b capsid assembly modulators | |
EP4320111A1 (en) | Hydroxypyridine hsd17b13 inhibitors and uses thereof | |
US20200338084A1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof | |
CN116670118A (en) | Dichlorophenol HSD17B13 inhibitor and application thereof | |
WO2023224981A1 (en) | Hsd17b13 inhibitors and uses thereof | |
EP2272844A1 (en) | Five-membered ring compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23747551 Country of ref document: EP Kind code of ref document: A1 |